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ABSTRACT 
             Glyoxalase 1 (Glo1) overexpression is found in refractory tumours and this 
project aims to characterise the resistance to clinical anticancer drugs by Glo1 
overexpression in the human HEK-293 tumour cell line in vitro and investigate drug-
induced increased methylglyoxal and related cytotoxicity as a likely cause. 
             HEK-293 cells had high Glo1 expression and activity that was increased up to 
5-fold when stably transfected with a pIRES2-EGFP-GLO1 plasmid with respect to 
empty vector control using G-418. Dose-response studies determined the median 
growth inhibitory concentration and showed that Doxorubicin, Mitomycin C, Taxol, 
Methotrexate and Mechlorethamine had the highest Glo1-linked multi-drug 
resistance. There was drug-induced increased glycolysis and flux of methylgloxal 
formation in vitro. Transient transfection of GLO1 siRNA, the cell-permeable Glo1 
inhibitor S-p-bromobenzylglutathione cyclopentyl diester, exogenous methylglyoxal 
and hypoxia potentiated the cytotoxicity of anti-tumour drugs and increased 
dicarbonyl stress. Stable isotopic LC-MS/MS analysis revealed that Mitomycin C 
enhanced glutathione (GSH) depletion whereas Mechlorethamine increased GSH 
levels. There were increased methylglyoxal levels in drug-treated HEK-293 cells in 
vitro.
               Overall, decreasing Glo1 expression and activity increased MG toxicity and 
sensitivity to anti-tumour drugs. Anti-tumours drugs are not direct Glo1 inhibitors and 
may be influenced by unrecognised downstream signalling mechanisms on glycolysis 
and MG metabolism. 
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1.1.1 The hallmarks of Cancer
             Cancer is an assembly of diseases characterized by uncontrolled cell 
growth and the distribution of cells from the primary site of origin to other parts 
of the body (metastasis) through the blood or lymph (Knox, 2010). Many types of 
human cells may potentially become cancerous whereby they acquire abnormal 
proliferative and invasive characteristics of malignant transformation (Pecorino, 
2016). Hanahan and Weinberg (2011) have defined the hallmarks of cancer that 
consists of six biological abilities required for the multi-step development of 
tumours – Figure 1. This comprises of self-sufficiency to growth signals, evading 
anti-growth signalling mechanisms to proliferate, inhibiting apoptosis, inducing 
angiogenesis, invasion, and metastasis (Hanahan and Weinberg, 2011). This 
framework guides researchers on how to understand the molecular mechanisms 
and develop treatments for tumours.  
          However, they have identified additional characteristics that increase cancer 
progression: evading the immune system, promoting inflammation, 
reprogramming of energy metabolism and genomic instability. Cancer genomes 
are highly unstable where some genetic alterations are intragenic whereas the 
majority of the genetic mutations of the clonal origin have a functional loss 
(aneuploidy) which creates genetic diversity causing multifactorial functions 
(Cahill et al., 1999; Marx, 2002, Hanahan and Wienberg, 2011; Moses et al.,
2018). Moreover, there are non-immortalised stromal cells besides tumour cells 
that form part of the tumour microenvironment that contributes to tumour 
development and progression (Moses et al., 2018). 
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Figure 1: The hallmarks of cancer (Adapted from: Hanahan and Weinberg, 2011)  
The ten hallmarks of cancer that characterise the tumour phenotype.
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            The morphological appearance of several forms of pre-malignant lesions, 
hyperplasia and dysplasia is caused by genetic, epigenetic and chromosomal 
alterations where some are inherited and can also be acquired in response to errors 
in cell division or environmental exposure to ultraviolet radiation and the tobacco 
smoke that damage deoxyribonucleic acid (DNA) (Esteller, 2000; Yokota, 2000). 
This disrupts the signalling mechanisms that control cellular functions and 
proliferation (Sadikovic et al., 2008). An accumulation of these genetic mutations 
induces the formation of primary tumours – Figure 2. The cellular phenotype 
changes as mutations accumulate further progresses to expand and invade to form 
metastatic tumours maintaining the malignant phenotype of tumour cells (Yokota, 
2000).  
             The two antithetical genetic types in oncogenesis are tumour suppressor 
proteins and proto-oncogenes (Shen et al., 2018; Botezatu et al. 2016; Schwab 
and Amler, 1990; Varkondi et al., 2005). Proto-oncogenes during genetic 
diversity can cause tumours cells to proliferate uncontrollably whereas tumour 
suppressor proteins prevent cells from degenerating into tumour cells (Shen et al, 
2018; Croce, 2008; Klein and Klein, 1986). Other genes exhibit both functions 
(Shen et al., 2018). 
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Figure 2 The key stages in cancer progression (Adapted from: Yokota, 2000) 
Genetic alterations and environment stress can cause the normal cells to produce pre-malignant lesions. Additional genetic mutations form the 
primary tumours which undergoes expansion and invasion leading to metastasis. 
 Key: Normal cells , pre-malignant cells , tumour cells with no metastatic ability and tumour cells with metastatic ability . 
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1.1.1.1 Dysregulation of cellular metabolism
            This project focuses on one of the major hallmarks of cancer, 
reprogramming of metabolic activity in cells which facilitates other hallmarks of 
cancer such as self-sufficiency in growth signals and evading apoptosis which is a 
major element in chemotherapeutic resistance and was discovered by Dr Otto 
Warburg (Phan et al., 2014; Ward and Thompson, 2012, Warburg, 1923). 
Overexpression of the cytosolic enzyme, glyoxalase 1 (Glo1) is found in clinical 
refractory tumours and is a negative survival factor in cancer therapy (Rabbani et 
al., 2018). Glo1 is the first line of defence that catalyses the detoxification and 
metabolism of reactive α-aldehydes or dicarbonyl metabolites such as 
methylglyoxal (MG) to the relatively non-toxic metabolic product, D-lactate to 
protect host systems from cell dysfunction and disease  (Rabbani and Thornalley, 
2014a, Thornalley, 2003a; Rabbani et al., 2014b, Xue et al., 2012). 
           Reprogramming of cellular metabolic activity is characterized by the 
following tumour cellular bioenergetic mechanisms: elevated glycolysis, pentose 
phosphate pathway (PPP), lipid metabolism, glutaminolysis and other metabolic 
mechanisms that provide tumour cells energy and metabolites for progression 
(Phan et al., 2014; Ward and Thompson, 2013; Kalyanaraman, 2017). Metabolites 
can also be oncogenic by influencing cell signalling and differentiation (Phan et 
al., 2014; Cazzaniga and Bonanni, 2015). Thus, as illustrated in Figure 3, 
molecular pathways have an impact on metabolic programming. For instance, the 
phosphatidylinositol 3-kinase/ protein kinase B (PI3K/Akt) signalling pathway 
increases glucose consumption through the glucose transporter GLUT-1 (Buzzai 
et al., 2005; Vasseur et al., 2009). This, in turn, increases glycolytic flux. GLUT-1 
expression is increased on the plasma membrane stimulating hexokinase and can 
associate with glucose via phosphorylation (Deprez et al. 1997; Suls et al., 2009; 
Kalyanaraman, 2017). Other mechanisms of increasing glycolytic metabolism are 
the activation of phosphofructokinase-1 and biosynthetic pathways such as the 
synthesis of fatty acids and cholesterol that need acetyl-coA (Kohn et al., 1996; 
Wakil et al., 1957). 
           In normal cells, glucose undergoes a catabolic reaction to pyruvate which 
is converted to acetyl coenzyme A (acetyl-CoA) to facilitate in the tricarboxylic 
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acid (TCA) cycle. This generates the electron carriers, nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH) for energy 
production. Each glucose molecule can produce a maximum of 36 adenosine 
triphosphate (ATP) in response to the mitochondrial respiratory chain. Glycolysis 
is utilized when the supply of oxygen is restricted (Dumas et al., 2017; Phan et 
al., 2014). On the other hand, glycolysis is utilized in cancer cells even when there 
are high amounts of oxygen present (DeBerardinis et al. 2008). Cancer cells 
upregulate glucose transporters to increase glucose uptake predominantly GLUT-
1, GLUT-2, GLUT-3 and GLUT-4 (Phan et al., 2014). However, glucose 
consumption can be suppressed by p53 by halting the transcription and expression 
of Glut1, Glut3 and Glut4 (Schwartzenberg-Bar-Yoseph et al., 2004). 
           Another difference between normal and tumour cells is how the end-
product of glycolysis, pyruvate, is processed. Majority of pyruvate is converted to 
acetyl-CoA for the TCA cycle whereas some are utilized to produce lactate or 
alanine (Phan et al., 2014). In tumour cells, lactate is produced predominantly 
because of the upregulation of the enzyme lactate dehydrogenase (LDH). This 
allows tumour cells to facilitate the oxidation of NADH to nicotinamide adenine 
dinucleotide - oxidised form, (NAD+) and thereby maintain a high glycolytic rate 
(DeBerardinis et al., 2008; Dang, 1999; Kalyanaraman, 2017). Tumours may also 
access nutrients from the blood via monocarboxylate transporters (Phan et al., 
2014). 
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Figure 3: Metabolic reprogramming in cancer (Adapted from: Ward and Thompson, 2012) 
Dysregulated metabolism caused by tumours are characterized by elevated glycolysis, increased oxidative phosphorylation, PPP, glutaminolysis, 
increased nucleic and amino acid production to provide energy and metabolites required for tumours to develop. 
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          The pentose phosphate pathway (PPP) comprises of two mechanisms: 
oxidative and non-oxidative. In the oxidative pathway, the glycolytic intermediate 
glucose-6-phosphate is converted to ribulose-5-phosphate to generate the cofactor 
nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is crucial for 
detoxification, protection from oxidative stress induced by the cytotoxicity of the 
anti-cancer drugs, biosynthetic reactions and the production of glutathione 
(Kalyanaraman, 2017; Phan et al., 2014). Ribose-5-phosphate is required for 
nucleotide synthesis. The non-oxidative PPP pathway produced glyceraldehyde-3-
phosphate and fructose-6-phosphate (Jonas et al., 1992). PPP has a significant 
impact on tumour progression predominantly chemotherapeutic resistance, 
proliferation, invasion, apoptosis and metastasis which aligns it as a therapeutic 
target by effectively inhibiting the metabolic enzymes to eliminate tumour cells 
with minimal cellular damage to the normal cells (Cazzaniga and Bonanni, 2015; 
Phan et al., 2014). 
            Moreover, oxygen plays a significant role in regulating energy metabolism 
and the glyoxalase system where hypoxia is a phenomenon that occurs in most 
malignant tumours. Hypoxia is defined as the non-physiological level of oxygen 
caused by an imbalance between the supply and consumption of oxygen. There 
are three states of oxygen: normoxia (also known as physoxia), physiological 
hypoxia and pathological hypoxia (Aoife et al., 2003; Muz et al., 2015). 
Normoxia is defined as the normal oxygen concentration in healthy tissues, which 
varies widely between the organs due to diversified blood vessel network and 
metabolic activity. It ranges in human tissues between ca. 9.5 % O2 in the renal 
cortex (partial pressure of oxygen pO2 72 mmHg) to 4.6% O2 in the brain (pO2 35 
mmHg). Pathological hypoxia is defined as 1% (8 mmHg) and the homeostatic 
mechanisms do not respond effectively to the oxygen levels that decline. For 
instance, ischaemia and related hypoxia can occur acutely (e.g. stroke) or 
chronically – for examples, as occurs in some tissues in (diabetes). In tumours, 
pathological hypoxia is a microenvironment factor that increases the propagation 
and survival of the tumour (Durand, 1991; Giaccia, 1996; Muz et al., 2015).
               It has been hypothesised that hypoxia increases tumour growth by 
elevating the flux of MG formation via anaerobic glycolysis (Eales et al, 2016; Hu 
et al., 2003; Muz et al. 2015; Rabbani et al., 2017; Shafie et al., 2016; Kumagai et 
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al., 2008). The glycolytic response is enhanced by the overexpression of GLUT-1 
and hexokinase that increases glucose uptake (Semenza et al., 1994; Semenza et 
al., 1996a; Semenza et al., 1996b). This enhances the ability of tumour cells to 
catabolize glucose, increase cell growth via the synthesis of their precursors and 
maintain the production of ATP and induce chemotherapy resistance under low 
oxygen tension conditions (Semenza et al., 1994; Semenza et al., 1996a; Semenza 
et al., 1996b).  
             Other features of hypoxia include the ability to switch to glycolysis for 
energy supply by altering cell metabolism identified by Warburg, preventing 
apoptosis and upregulation of growth factors and proteins associated with 
invasion such as urokinase-type plasminogen activator (Aiofe et al., 2003; Czekay 
et al., 2003; Krishnamachary et al., 2003; Warburg, 1956). The growth factors 
that are stimulated by hypoxia are epidermal grow factor (EGF), insulin-like 
growth factor-2 (IGF-2); platelet-derived growth factor-B (PDGF-B) and 
transforming growth factor-beta (TGF-β) (Koong et al., 2000). Moreover, hypoxia 
downregulates adhesion molecules to facilitate tumour cell attachment and can 
cause other hallmarks of cancer such as metastasis where there is attainment of 
epithelial-to-mesenchymal transition (EMT) phenotype causing cell mobility and 
metastasis (Azad et al., 2008; Mimeault et al., 2012; Muz et al., 2014; Muz et al., 
2015). 
            Tumour hypoxia is a characteristic feature that occurs in solid tumours due 
to an insufficient supply of oxygen caused by exponential cellular proliferation 
and inadequate vascular supply (Aoife et al., 2003; Vaupel and Mayer 2007). 
Thus, it is an adverse prognostic indicator and deleterious factor associated with 
tumour malignant progression, aggressive phenotype and resistance to therapy by 
inducing cell quiescence (Aoife et al., 2003; McKeown, 2014; Vaupel and Mayer, 
2007). Tumour hypoxia may impair disease-free survival for patients with 
cervical cancer, soft tissue sarcomas whereas in head and neck cancer it is a 
prognostic indicator for survival (Vaupel and Mayer, 2007). This has improved 
the use of endogenous markers such as hypoxia-related proteins HIF-1 alpha, 
GLUT-1 and exogenous bio-reductive drugs had significance for the patient 
outcome (Vaupel and Mayer, 2007). It also increases the risk of metastasis and 
mortality rate in breast cancer (Semenza, 2016) 
42 
1.1.2 Epidemiology of cancers
          The prevalence of cancer increases every year and there was an incidence of 
303,135 cases in 2016 where lung (12.7%), breast (15.2%), prostate (13.4%) and 
bowel cancers (15.3%) account for more than 50% of the cases of all ages in total 
(Office for National Statistics, 2018). This excludes the number of patients with 
non-melanoma skin cancers (Office for National Statistics, 2018). It is projected 
that the number of cancer cases is ca. 243,690 and 270,261 for females and males 
respectively in 2035 where breast and prostate cancer will be the most prevalent 
(Smittenaar et al., 2016). In addition, it is projected that ca. 95,961 females and 
116,585 males will die in 2035 (Smittenaar et al., 2016). The increased burden of 
cancer cases and mortality rates stresses the importance of identifying risk factors. 
1.1.3 Risk factors of cancers
            Current epidemiological evidence suggests that lifestyle factors play a 
pivotal role in increasing the risk of cancer and can also significantly decrease its 
burden (Curry et al., 2003). Fifty percent of patients with the most prevalent 
tumours: lung, breast, colorectal and prostate cancers can be treated for 
modifiable risk factors (Ezzati et al, 2002). Table 1 presents a summary of 
modifiable risk factors tumours. People who are overweight are at risk of several 
tumours of the glands, gastrointestinal tract, brain, gynaecological, endocrine and 
the blood. For instance, breast (post-menopausal, liver, meningioma, ovary, 
thyroid and multiple myeloma (Calle et al., 2003; Fedewa et al. 2017). It has been 
reported that obesity accounts for 14% and 20% of the mortality rates caused by 
tumours in men and women respectively (Calle et al. 2003).  
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Table 1: Preventative measures of modifiable risk factors for various cancers (Adapted from: Stein and Colditz, 2004).  


















Maintain a healthy 
weight 
Bladder X X 
Breast X X X X X 
Cervical X X X 
Colorectal X X X X X X 
Throat X X X X 
Kidney X X 
Lung X X 
Oral X X X X 
Pancreatic X X 
Prostate X X 
Skin X 
Stomach X X 
Uterus X 
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             Another modifiable risk factor is physical activity, it reduces the risk of 
many types of tumours: liver, colorectal, breast, lung, prostate, oesophageal and 
kidneys by performing a moderate exercise for 30 minutes for most days of the 
week (Stein and Colditz, 2004; Pate et al., 1995; Fedewa et al., 2017; 
Giovannucci et al., 1996; World Cancer Research Fund and American Institute 
for Cancer Research, 2007). It is estimated that physical activity decreases the risk 
of colon cancer by 50% due to the modification of the bile acid metabolism, 
decreasing the gastrointestinal transit time and less contact with potential 
carcinogens (Colditz et al, 1997; Martinez et al., 1999; McTiernan et al., 1998). 
Increased physical activity also decreases the circulating concentrations of growth 
factors and hormones such as insulin and prostaglandins reducing the risk of 
diabetes and improving immunity respectively (McKeown-Eyssen, 1994; 
Martinez et al., 1999).  
             Other strategies of cancer prevention include reducing tobacco use which 
includes cigarettes, cigars, electric and avoiding smoking environment (second-
hand smoke) that accounts for 5 million deaths annually (Ezzati et al., 2002; Doll 
et al., 1994). It contributes to 30% of all tumours and is the major cause of 90% of 
cases related to lung cancer (Ezzati et al., 2002). The pivotal role of tobacco in 
developing carcinogenesis and cancer progression demonstrates its significance in 
developing preventative measures. For instance, it delivers carcinogens to the site, 
causing inflammation and it affects the physical protective barriers to the human 
body (Ezzati et al., 2002). Hecht (1999) reported that carcinogens, nitrosamines 
and polycyclic aromatic hydrocarbons that reside in the tobacco smoke were 
metabolized by secretion and/or linking with the DNA to form adducts. DNA 
adducts lead to apoptosis and the miscoding mutations of vital genes such as p53 
caused genetic stability (Minna et al., 2002). This consequently causes further 
damage and induces tumour development.  
                   A number of studies focused on identifying the interconnection 
between diet and cancer (Feskanich et al., 2000). Eating a balanced diet composed 
of fruits, vegetables, fish, poultry and whole grain reduces the risk of cancers of 
the mouth, oesophageal, stomach, larynx and the oestrogen receptor-negative 
breast tumours (Colditz et al., 1996; Curry et al., 1993; World Cancer Research 
Fund and American Institute for Cancer Research, 2007; Fedewa et al. 2017). 
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They contain minerals, vitamins and fibre. Ezzati et al. (2002) reported 2.7 
million deaths annually are associated with inadequate dietary intake causing a 
global burden. In addition, consuming less red meat such as veal, beef and lamb 
increases the intake of dietary fibres and this decreases the risk of pancreatic and 
colorectal cancer (Fedewa et al., 2017). This is due to the production of 
carcinogens whilst cooking of animal proteins at elevated temperatures. Other 
studies reported it is due to the elevated concentration of animal fat. Giovannucci 
(1999) conducted a study where he investigated the connection between prostate 
cancer and tomatoes. He discovered tomatoes reduced the risk of prostate cancers 
by 40-50% in men and it has been reported that carotenoid lycopene is the 
causative effect of this protection. 
                   The association of alcohol with tumour development can be initially 
described by the mortality rates where there are more than 1.8 million deaths 
(Ezzati et al., 2002). Thun et al., reported that despite alcohol being a risk factor 
for the increase in mortality rates associated with cancer, moderate consumption 
of alcohol reduces the risk of diabetes and cardiovascular disease (Thun et al., 
1997). It is the primary cause of oral, oesophageal, colorectal and breast cancer 
(Fedewa et al., 2017; Stein and Colditz, 2004). There is also evidence of its 
association with liver and pancreatic cancer (Fedewa et al., 2017). Alcohol 
increases the risk of cancer due to three major respects: transports carcinogens to 
the basal layer of the mucosa, it acts as a solvent permitting carcinogen to 
penetrate the mucosa and increases cell turnover (Stein and Colditz, 2004).  
        Moreover, the enzyme alcohol dehydrogenase (ADH) metabolises alcohol to 
acetaldehyde (Sapkota and Wyatt, 2015). After when cytochrome p450 2E1 
(CYP2E1) is stimulated, it produces reactive oxygen species (ROS), for instance, 
hydrogen peroxide, superoxide and hydrogen radicals (Sapkota and Wyatt, 2015). 
This predominantly occurs during chronic alcohol consumption. This facilitates 
the peroxidation of lipids and the production of 4-hydroxynonenal (4-HNE) and 
malondialdehyde (MDA) forms hybrid, DNA and protein adducts (Sapkota and 
Wyatt, 2015). Heavy consumption of alcohol has also been associated with liver 
and other conditions such as hypertension, complications during pregnancies and 
addiction (Stein and Colditz, 2004). A combination of tobacco smoking and 
alcohol increases the risk of cancer significantly (Fedewa et al., 2017). 
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Preventative measures include educating the public about the benefits and risks of 
alcohol use. 
          Another behavioural factor is ultraviolet radiation that increases the risk of 
tumours of the lip and different forms of skin cancers (Stein and Colditz, 2004). 
This includes malignant melanoma, basal cell carcinoma and squamous cell 
carcinoma. However, these are highly curable (Fedewa et al., 2017). Majority of 
skin cancer-related deaths are linked to invasive melanoma and a recent study 
estimated that ca. 230,000 cases will be prevented between the year periods 2020 
- 2030 if an inclusive cancer prevention programme will be applied (Fedewa et 
al., 2017). Current preventative measures include limited sun exposure, sunscreen, 
protective clothing such as hats and sunglasses decreases risk (Fedewa et al.,
2017). The use of fair skin colour and family history is insufficient data to identify 
those that are at risk of disease (English and Armstrong, 1988).  
          Several infectious agents have been associated with causing tumorigenesis. 
For instance, Helicobacter pylori cause gastric lymphoma and cancer. More than 
half of the global population is infected with this bacterium but are unaware 
(Fedewa et al., 2017). Human immunodeficiency virus (HIV) increases the risk of 
cancers of the cervix, Kaposi sarcoma and non-Hodgkin lymphoma (Fedewa et 
al., 2017). It is estimated 2.9 million deaths annually are caused by unsafe sexual 
acts due to the transmission of the virus and other oncogenic viruses (Ezzati et al, 
2002). There is evidence that a combination of causes increases the rate of cancer. 
For instance, people who smoke and have HIV have a higher rate of 
immunosuppression and lung cancer (Fedewa et al., 2017; Schiffman et al., 
2007).  
          Infection with human papillomavirus (HPV) accounts for cervix, anal, 
vulvar, vaginal and penile tumours (Fedewa et al., 2017; Morrison et al. 1997). 
There is also a risk of other cancers: Chronic infections with Hepatitis B virus 
(HBV) and Hepatitis C (HCV) causes liver cancer and increases the risk for non-
Hodgkin lymphoma (Fedewa et al. 2017). Preventative measures to lower the risk 
of infectious agents being transmitted include the use of vaccines, needle 
exchange programmes for drug users, educating the public on safer sexual 
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practices, the use of treatment for prophylactic infections and screening for blood 
donors (Koutsky et al., 2002).
           Screening for breast, colorectal and cervical cancer and in some cases of 
prostate cancer reduce the burden of cancer due to early detection and effective 
treatment of pre-malignancy and malignancy cases reducing mortality rates 
(Fedewa et al., 2016); Hoffmann et al., 2009; Levin et al., 2008; Paci, 2012; 
Schiffman et al., 2007; Schröder et al., 2009; Stein and Colditz, 2004; Taplin et 
al., 2004). Some medications have protective effects of cancers, for instance, oral 
contraceptive pills and non-steroidal anti-inflammatory drugs such as aspirin 
decreases the risk of ovarian cancers and colorectal cancer. Conversely, the use 
of oestrogen and postmenopausal hormone therapy increases the incidence of 
endometrial and breast cancer respectively (Stein and Colditz, 2004). 
1.1.4 Treatment of cancer using chemotherapy
           Chemotherapy is one of the four types of cancer therapy, other treatments 
being surgery, radiotherapy, and immunotherapy (Luqmani, 2005; Kartal-Yandim 
et al., 2016). This project focuses on the resistance to chemotherapy but in order 
to understand the various mechanisms, an overview of the main types of 
chemotherapeutic treatments is required. The dual role of chemotherapy is to kill 
cancer cells and have systemic effects (Huang et al., 2017). Chemotherapeutic 
agents can be utilized in several ways: alone, with other agents, concurrent with 
radiotherapy and as targeted therapy (Lundqvist et al., 2015).  
          The use of chemotherapy was initiated in the 20th century with attempts to 
develop chemicals that may affect the disease (De Vita and Chu, 2008). In 1955, 
the Cancer Chemotherapy National Service Centre was established in the USA to 
oversee an anticancer drug development programme. The benefits of having a 
combinatorial approach in chemotherapy were recognised after treating acute 
child leukaemia in the 1960s and 1970s to maximise potency and efficacy (De 
Vita and Chu, 2008). During this period, chemotherapy improved markedly to 
provide effective treatment for some solid tumours such as germ cell, childhood 
malignancy and haematological malignancies (Tsuruo, 2003). For instance, the 
capacity for chemotherapeutic drugs to treat advanced Hodgkin’s disease was 
discovered (De Vita and Chu, 2008). Despite this success, the effectiveness of 
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chemotherapy is limited by MDR and adverse side effects (Tsuruo, 2003; Tsuruo 
et al., 2003). Chemotherapy has a small therapeutic window in comparison to 
drugs of other forms. There is the possibility of serious clinical adverse effects 
and hence the optimum and safe dose of an anti-cancer drug for a patient is 
difficult to achieve (Lundqvist et al., 2015).  
          There are several types of goals for chemotherapeutic treatment that need to 
be considered. For a curative intention, adverse effects are accepted if the 
probability rate for the patient to be cured is high. However, if the aim of the 
treatment is to increase the timespan for survival, the balance between the 
advantages of treatment and its adverse effects are carefully considered and 
optimised (Lundqvist et al., 2015). If treatment has a dominant palliative aim to 
alleviate symptoms, there is a small likelihood of adverse effects. Tumour cells 
pass through various phases of the cell cycle and are chemosensitive apart from 
the G0 phase; resting state (Lundqvist et al., 2015). There is a prolonged survival 
in patients who progress slowly and live for a long period of time, their tumours 
become less chemosensitive because most cells are in the resting phase at each 
treatment cycle. 
           There are several classes of chemotherapy, based on modes of action. Anti-
cancer drugs typically target proliferating cells that are more responsive to classes 
of drugs such as DNA alkylating and intercalating agents, topoisomerase 
inhibitors, mitotic inhibitors, and anti-metabolites (Luqmani, 2005). 
1.1.4.1 DNA alkylating agents 
          DNA alkylating agents have been utilized for cancer treatment for over 60 
years (Ralhan and Kaur, 2007). They directly act on DNA forming crosslinks with 
the N-7-guanine residues. This causes interstrand and intrastand DNA strand 
breaks (DSB) leading to irregular base pairing that prevents cell division and cell 
apoptosis (Ralhan and Kaur, 2007; Thirumaran et al., 2007). Figure 4 illustrates 
the mechanism of action of alkylating agents. Methyl-guanine-DNA 
methyltransferase (MGMT) repairs genetic changes and decreases the activity of 
the anti-cancer drug (Martinez-Cardus et al., 2015). Their clinical efficacy is 
limited due to drug resistance and systemic toxicity. There is evidence that the 
potency of alkylating agents increases in combination with other anti-cancer 
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agents. For instance, inhibitors of topoisomerase, phosphatases and other DNA 
repair enzymes (Ralhan and Kaur, 2007). Anti-vascular agents and multi-drug 
resistance proteins also improve efficacy. Novel developments are in progress to 
enhance the sensitivity of cancer cells to DNA alkylating agents. For instance, 
naphthalamides and selective androgen receptor are amongst the examples of 
novel modulators (Ralhan and Kaur, 2007). 
Figure 4: Mechanism of action of DNA alkylating agents (Adapted from: Martinez-
Cardus et al., 2015). 
DNA alkylating agents cause DNA strand breaks leading to irregular base pairing that 
prevents proliferation and increase cell apoptosis. 
           The DNA alkylating agents employed in this study are Mechlorethamine 
Hydrochloride, Mitomycin C, and cisplatin. Mechlorethamine is a nitrogen 
mustard derivative that is utilized in palliative treatment for some tumours 
(Dobson et al., 2008; Newton, 2012; Thirumaran et al., 2007). It has a wide 
clinical anti-tumour spectrum with efficacy in various types of tumours. For 
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instance, Hodgkin lymphoma, chronic lymphocytic leukaemia, bronchogenic 
carcinoma and chronic myelogenous leukaemia and other lymphomas (Newton, 
2006; Thirumaran et al., 2007). It has also been used for the treatment of 
neurological tumours: for instance, gliomas, however, it is associated with causing 
seizures and cerebral edema (Newton, 2006; Newton, 2012). At high doses, it is 
utilized for the preparation of bone marrow transplantation (Newton, 2012). 
Additionally, mechlorethamine is used in combination therapy with vincristine 
and prednisone for the treatment of Hodgkin’s lymphoma (Kwok et al., 2017). It 
is administered intravenously and has limited stability and short half-life (Kwok et 
al., 2017). 
           Mitomycin C is a bio-reductive alkylating agent and anti-tumour antibiotic 
that is predominantly stimulated under anaerobic conditions (Verweij and Pinedo, 
1990). It is utilized for gastric cancer and pancreatic adenocarcinoma. It has been 
utilized for the treatment of advanced breast cancer where there was a 20-30% 
response rate (Godfrey, 1988). However, an adverse effect of utilizing mitomycin 
C is an increase in haematological toxicity but this has been reduced when low 
doses are utilized (Godfrey, 1988).  
            The most effective chemotherapeutic agent for solid tumours is cis-
diamminedichloroplatinum (cisplatin) (Cohen and Lippard, 2001). It is a 
crystalline powder whose colour varies between white, yellow, and orange. The 
metal compound is soluble in N, N-dimethylformamide (DMF) and is slightly 
water-soluble (Dasari and Tchounwou, 2014). It is utilized for a variety of 
neoplasms, for instance, sarcomas, carcinomas breast, lung, kidney, cancers of the 
ovaries and bladder (Dasari and Tchounwou, 2014). 
          Cisplatin is composed of a double-charged platinum ion bordered by four 
ligands (Goodsell, 2006). There are two types of ligands: amine ligands on the left 
create a stronger interaction with the platinum ion (Dasari and Tchounwou, 2014). 
The chloride ions form a bond with DNA bases (Goodsell, 2006). The platinum-
based compound that induces cell cycle arrest and apoptosis by producing DNA 
adducts - Figure 21 (Cohen and Lippard, 2001). The two predominant adducts 
formed are 1,2-intrastrand d(GpG) adducts 1,2-intrastrand d(ApG) adducts in a 
90% to 10% proportion. Other adducts such as 1,3-intrastrand d(GpXpG) adducts 
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are formed increasing the toxicity of cisplatin. It also influences the DNA repair 
mechanisms, crosslinks with purine bases on DNA and stimulates the intrinsic and 
extrinsic apoptotic mechanisms, down-regulating anti-apoptotic proteins and 
proto-oncogenes (Rosenberg and Van Camp, 1970; Roberts and Fraval, 1978; 
Dasari and Tchounwou, 2014; Kelland, 2007; Ozben, 2007).  
          Cisplatin produces ROS and lipid peroxidation which induces oxidative 
stress damaging cellular proteins, DNA, and lipids (Saad et al., 2004). The 
extrinsic apoptotic pathway produces ROS via the activated Fas ligand, a type 2 
transmembrane protein that stimulates the downstream signalling events leading 
to apoptosis (Gupta et al. 2012). On the other hand, in the intrinsic apoptotic 
pathway, ROS aids in the release of cytochrome c by stimulating B-cell 
lymphoma 2 (Bcl-2) and Bcl-xL proteins and preventing the activation of Bcl-2-
associated X protein (Martindale and Holbrook, 2002).   
             There are also several kinases involved in cell signalling pathways 
influenced by cisplatin. Protein kinase C (PKC) plays a pivotal role in inducing 
signal transduction and the regulation of cells (Basu and Sivaprasad, 2007; Dasari 
and Tchounwou, 2014).  Cisplatin stimulates extracellular signal-regulated kinase 
(ERK) via the mitogen-activated protein kinases (MAPK) causing cell cycle arrest 
and DNA repair via p53 (Chang and Karin, 2001). The stereoisomers of cisplatin, 
cis and trans, activates c-Jun N-terminal kinase or stress-activated protein kinase 
(JNK) in response to DNA damage and apoptosis (Johns et al., 2007). The p38 
MAPK pathway also regulates cisplatin-induced apoptosis (Cuadrado et al., 
2007). 
            The cofactor reduced glutathione (GSH) plays a significant role in 
monitoring the inner mitochondrial permeability and enzymatic function in order 
to maintain the sulfhydryl (SH) groups in the reduced state. When the SH group 
cannot be maintained, they become deactivated. Amongst the toxicities stimulated 
by cisplatin is nephrotoxicity where there is a reduced intracellular concentration 
of GSH and SH-groups. NADH helps to maintain the reduced state of the SH 
groups. The depletion of NADH and GSH prevents the enzymatic activity of 
several dehydrogenases (Aggarwal, 1998). This induces oxidative 
phosphorylation, increases the synthesis of hydroxyl radicals and in turn oxidative 
52 
stress that degrades the integrity of the membranes (Dasari and Tchounwou, 
2014). 
            Resistance to cisplatin develops intrinsically and after administration 
(Kartalou and Essigmann, 2001; Rabik and Dolan, 2007). This has been observed 
in lung, colorectal and ovarian cancers. Another form of resistance is the 
association of cisplatin to GSH which inactivates the platinum compound and 
prevents the formation of cisplatin-adducts (Huang et al., 2017). The increased 
expression of glutathione S-transferase (GST-π) isoenzyme has been linked with 
intrinsic resistance to cisplatin (Rowinsky et al. 1993).  
In response to resistance and relapse from cisplatin treatment, other 
platinum compounds have been developed such as bile acid derivatives where it 
increases cytotoxicity and overcame cisplatin resistance (Rodriguez-Fernandez et 
al., 2009). Carboplatin is another platinum compound that is utilized for the 
treatment of the lung, head, and ovaries. In comparison to cisplatin, it has slow 
DNA-binding kinetics and low reactivity that reduces side effects such as 
nephrotoxicity (Go and Adjei, 1999; Natarajan et al., 1999). However, its 
limitation is suppressing the blood cells and platelets (Canetta et al., 1985). 
Adjuvant therapy is another mechanism in overcoming resistance. There is 
evidence that a combination of paclitaxel and cisplatin was effective against 
ovarian cancer (McGuire et al., 1989; Einzig et al., 1992). Doxorubicin and 
cisplatin have also been effective against carcinomas of the salivary gland 
(Dreyfuss et al., 1987). 
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   1.1.4.2 Topoisomerase inhibitors
          Topoisomerases are ubiquitous enzymes found in archaebacteria, eubacteria 
and eukaryotes. Mammalian cells encode six topoisomerases whereas prokaryotes 
comprise of 4 topoisomerases whose function is to regulate DNA supercoiling 
(torsional tension) which is vital for the processes of transcription and replication 
(Pommier, 2013). Positive supercoiling causes DNA tightening and inhibits strand 
separation evading the polymerases from performing its function. On the other 
hand, negative supercoiling extends the DNA strand separation facilitating the 
synthesis of irregular nucleic acid structures such as guanosine quartets, z-DNA 
and intramolecular hairpins and causing dysfunction of the RNA polymerases by 
stalling R-loops (Pommier, 2013; Ewesuedo and Retain 1997). This leads to the 
formation of DNA double-strand breaks (Gellert et al., 1976). 
            There are two types of topoisomerases. Topoisomerase I is a monomeric 
and highly conserved enzyme whose catalytic function is to cleave one strand of 
DNA. Topoisomerase II has two forms: heterotetrameric (bacteria) and 
homodimeric (humans) whose function is to cleave the duplex DNA strands and 
rest the supercoiled DNA preventing helical constraints (Denny and Baguley, 
2003; Gellert et al., 1976; Lodish, 2000; Pommier, 2013; Thakur, 2011).  
              Topoisomerases eliminate supercoiling by various mechanisms, Type 1A 
enzyme transits one strand from the same DNA molecule through a transient 
break in the single or double strand formed by the topoisomerase in another 
duplex (Ewesuedo and Retain, 1997; Thakur 2011). Type 2A enzyme utilizes a 
duplex from the same DNA molecule using the same method that enters breakage 
of both strands. Both Type 1A and IIA undergo DNA cleavage by attaching their 
tyrosine residue to the 5’ end of the DNA whereas the 3’ end are bound tightly 
allowing the DNA to pass through. Type 1B generates 3’ phosphotyrosine bonds 
and allows the strand that is broken to rotate that is regulated around the 5’ end of 
the other strand (Ewesuedo and Retain, 1997; Husain et al., 1994). Through the 
process of transesterification, topoisomerases share a common characteristic 
where the non-homologous families they cleave DNA utilizing the tyrosine as a 
nucleophile attacking the phosphodiester bond and re-ligate the backbone of the 
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double-stranded DNA molecule (Pommier, 2013; Wang 1971; Wang 1996). 
However, they differ in the form of DNA adduct produced.  
             Poly (ADP-ribose) polymerases (PARP) are activated by topoisomerase 1 in 
response to DNA damage but this is dependent on the processes of replication and 
transcription (Pommier, 2013). There is high synergism between the inhibitors of 
PARP and topoisomerase 1 and low synergism with topoisomerase 2. There is much 
interest directed to using small molecule inhibitors of DNA repair enzymes. It has 
been reported that PARP inhibitors increase sensitivity to camptothecin delaying 
DNA repair (Smith et al, 2005; Zhang et al., 2014). Several trials have been 
conducted for determining the combined therapeutic effect of radiotherapy and 
cytotoxic drugs (El-Khamisy et al., 2003).  
           Topoisomerase 1 play a significant role in human tumours especially in 
colorectal cancer where their increased expression of topoisomerase 1 mRNA and 
protein was observed (Husain et al., 1994). It significantly contributes to 
tumorigenesis, (Li and Liu, 2016). Paradoxically, the accumulation of 
topoisomerases induces cell death and is the mechanism of toxicity. However, Liu 
(1990) revealed that human cells naturally suppress the enzymatic activity of 
topoisomerases through small ubiquitin-related modifier (SUMO) modifications 
at the residues of lysine: K436 and K391. This decreases DNA damage induced 
by topoisomerase 1. These SUMOylations cause genetic instability, mutagenesis, 
and cancer development. In addition, mismatch repair proteins (MMR) account 
for 5% of colorectal cancers caused by a germline mutation of MMR. It has been 
hypothesised that MMR modulates response to topoisomerase 1 (Jacob et al, 
2001). The topoisomerase I inhibitor utilized in this PhD project is camptothecin. 
          Camptothecin is a quinoline alkaloid that is utilized to treat various cancers 
(Venditto and Simanek, 2010). It was discovered by Wall and Wani (1996) who 
extracted it from the bark ‘Camptotheca acuminata’ (Nyssaceae) However, the 
disadvantages of utilizing the anti-cancer drug is the deprived stability and 
solubility at physiological states (Venditto and Simanek, 2010). A year later, they 
discovered paclitaxel, a broad-spectrum chemotherapeutic agent that showed 
promise. Novel camptothecin derivatives have been developed to reduce the 
limitations and increase bioavailability (Venditto and Simanek, 2010).  
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          Camptothecin has two forms: when active it is a lactone whereas when it is 
inactive it is a carboxylate. Lactone associates with the DNA-topoisomerase 1 
complex preventing re-ligation of the DNA strands; this causes apoptosis. 
Preclinical studies have demonstrated its anti-tumour effect in several 
experimental murine tumour models in in vivo studies and human tumour 
xenografts of the breast, lung, malignant melanoma and colon (Ewesuedo and 
Ratain, 1997). It is toxic to cells in the S-phase causing growth arrest in G-2 phase 
and stimulates chromosomal DNA fragmentation by preventing DNA of 
chromosomal DNA by inhibiting DNA synthesis through strand scission 
(Venditto and Simanek, 2010). 
          Another functional role of camptothecin is the stimulation of the ribonucleic 
acid (RNA) synthesis of the dihydrofolate reductase (DHFR) gene. It caused a 
high accumulation of RNA polymerases in the 5’ end of the DHFR gene 
preventing elongation (Ljungman et al., 1996). Its pentacyclic ring structure 
facilitates in its anti-tumour activity predominantly the D and E rings and is most 
effective in high-proliferating cells (Ljungman et al., 1996). The water-soluble 
derivatives of camptothecin, topotecan and irinotecan, were developed by the 
modification of the A and B rings (Venditto and Simanek, 2010; Dancey and 
Eisenhauer, 1996). 
           Topoisomerase II is the target for antineoplastic agents (Larsen et al, 
2003). There are two broad types of inhibitors of topoisomerase II: topoisomerase 
II poisons and catalytic inhibitors (Bower et al., 2010; Larsen et al., 2003; Andoh 
and Ishida 1998; Nitiss, 2009). Topoisomerase II poisons specifically stabilize the 
cleavage complex. Examples include clinically active chemotherapeutic agents 
such as doxorubicin and etoposide (Nitiss, 2009; Nitiss and Nitiss 2014). This 
increases the number of covalent complexes between topoisomerase II and DNA. 
Catalytic inhibitors act on other areas of the catalytic cycle to kill cancer cells 
such as preventing the binding of ATP (novobiocin) and interference between the 
linkage of cleaving complex (merbarone) that can affect other targets (Larsen et 
al., 2003; Nittis, 2009).     
           Other modes of action of topoisomerase II inhibitors blocks the catalytic 
cycle causing DNA damage which subsequently affects replication and 
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transcription (Serre and Duguet, 2003; Andersen et al., 1989; Nittis, 2009). 
Several compounds prevent the enzymatic activity of topoisomerase II and DNA 
cleavage. An example is bisdioxopiperazine which induces non-competitive 
inhibition of the ATPase activity (Jain, 2017; Nittis, 2009). Several novel 
secondary metabolites are produced by plants to prevent adverse side effects. For 
instance, polyphenols, alkaloids and quinones have been used to improve the 
treatment of cancer by preventing the enzymatic activity of DNA topoisomerases 
(Malpathak and Baikar, 2010). 
         Cancer researchers have a major interest in topoisomerase II inhibitors 
particularly etoposide and doxorubicin that mediate DNA damage and their 
clinical activities in various human tumours in the initiation and curative stages 
(McClendon and Osheroff, 2007; Nittis, 2009). The aim is to improve further 
understanding of their mechanism to maximise the efficacy of anti-cancer drugs 
whilst minimizing risks of secondary malignancies (McClendon and Osheroff, 
2007). 
          One of the topoisomerase II inhibitors utilised in this study is doxorubicin 
that has been utilized to treat solely and in combination with other drugs for 
various cancers. It is the first line of treatment for cancers of the breast, thyroid, 
bladder, and blood malignancies (Watt and Hickson, 1994). Besides their 
inhibitory effect on topoisomerase II activity, it intercalates DNA and produces 
ROS (Watt and Hickson, 1994). Another way in how doxorubicin exerts its anti-
tumour effects is through the cleavage of the transcription factor CREB 3L1 (Patel 
and Kaufmann, 2012). Cardiotoxicity is one of the adverse effects of doxorubicin 
causing nuclear and mitochondrial damage (Watt and Hickson, 1994).  
          However, there have been recent developments on doxorubicin where a 
liposomal encapsulated version is available for treatment of patients with Kaposi 
sarcoma, multiple myeloma, and advanced stages of ovarian and breast tumours. 
It increases anti-tumour activity and plasma circulation time decreasing the risk of 
cardiomyopathy (Kwok et al. 2017). Novel findings discovered several de novo
and acquired mechanisms of resistance that contribute to decreased sensitivity of 
doxorubicin (Lovitt et al., 2018).  
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          Etoposide is another topoisomerase inhibitor utilised in this study. It is a 
semi-synthetic demethylepipodophyllotoxin derivative utilized for a broad 
spectrum of solid tumours such as tumours of the endocrine, germline, small cell 
lung cancer, neuroblastomas, and sarcomas (Baldwin and Osheroff, 2005; Watt 
and Hickson, 1994). It has been used for patients with testicular cancer who had 
previous surgery, radiation therapy or the former chemotherapeutic agents did not 
improve his or her condition. Moreover, etoposide has also been utilized as a part 
of a combination therapeutic strategy for breast cancer (Höffken, 1982; Nichols, 
1992). In comparison to podophyllotoxins, it functions independently from 
tubulin. Another function of etoposide that differs from that of doxorubicin is the 
mechanism of trapping etoposides succeed in doing this to both topoisomerase 2 α 
and β to prevent the carcinogenesis of secondary leukaemia whereas doxorubicin 
targets solely topoisomerase II-β (Watt and Hickson, 1994).  
1.1.4.3 Dihydrofolate reductase inhibitors
          Methotrexate is another anti-tumour drug that is utilized in this project. It is 
a folate analogue that inhibits dihydrofolate reductase (DHFR), tetrahydrofolate 
(THF) and the production of pyrimidines and purines (Jolivet et al., 1983; Hagner 
and Joerger, 2010; Llado et al., 2009; Gracia-Cazana et al., 2016, Keystone et al., 
2017, Lima et al., 2014). Folates are essential in the de novo production of 
thymidylate, purines and pyrimidines that are critical for DNA in mammalian 
cells (Hagner and Joerger, 2010; Ndiaye et al., 2010). They belong to a family of 
B9 vitamins and folic acid undergoes two consecutive steps of reduction mediated 
by DHFR: to dihydrofolate (DHF) followed by a further reduction to THF 
(Hagner and Joerger, 2010). The dietary form of folate is 5′-methyl-THF (5′-
MTHF). MTHF is a cofactor for the conversion of homocysteine to methionine, 
catalysed by methionine synthase (Hagner and Joerger, 2010; Touroutoglou and 
Pazdur, 1995). The progressive addition of glutamates to the γ-carboxyl residues 
by the enzyme folylpolyglutamate synthetase (FPGS) to its main substrate THF 
produces folate polyglutamates (Hagner and Joerger, 2010).  
          Folate analogues were initially developed based upon the functional and 
molecular aspects of thymidylate synthase (TS) and folate (Touroutoglou and 
Pazdur, 1995; Schweitzer et al., 2010). It is also dependent on the activity of the 
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reduced folate carrier (RFC) proteins which normally function for cellular entry 
and polyglutamation by FPGS (Touroutoglou and Pazdur, 1995; Hagnet and 
Jorger, 2010). Methotrexate is utilized for the treatment of leukaemias, 
lymphomas and cancers of the lung, breast and head cancer (Hagner and Joerger, 
2010; Lehman, 2002; Schweitzer et al., 2010; Touroutoglou and Pazdur, 1995). 
1.1.4.4 Microtubule-targeting agent
         Microtubule-targeting agents (MTA) affect microtubule dynamics by 
influencing the normal mechanism of the mitotic spindle formation and 
disassembly, causing cell cycle arrest and apoptosis (van Vuuren et al., 2015; 
Rohena and Mooberry, 2014; Mukhtar et al., 2014). Microtubules are highly 
dynamic, intracellular cytoskeleton framework and have vital cellular functions 
that are induced by the polymerization by α and β dimers at either side of the 
microtubules (Jordan et al. 2005; van Vuuren et al., 2015; Risinger et al., 2009; 
Risinger et al., 2011). They are involved in processes of growth, intracellular 
trafficking, motility, division and adapting to various conditions of the 
environment (Jordan et al. 2005; van Vuuren et al., 2015; Risinger et al., 2009; 
Risinger et al., 2011)  
         MTAs are used in the treatment of solid and haematopoietic tumours. They 
are anti-mitotic agents that reduce the rate of cell proliferation and act on the 
polymerization of the spindle (van Vuuren et al., 2015). Tubulin is the monomer 
of microtubules and MTAs associate with tubulin to induce its anti-cancer 
response (Yang and Horwitz 2017). MTAs are divided into two groups: 
microtubule-stabilizing agents activate polymerization of microtubules, stabilize, 
and increase the mass of the polymer (van Vuuren et al., 2016). An example of 
this is Paclitaxel which is utilized in this study. Microtubule destabilisers which 
prevents polymerization, reduces the rate of the transition between metaphase and 
anaphase by blocking mitosis and inducing apoptosis (Jordan et al. 2005; 
Dumontet and Jordan, 2010; Nolte et al., 2016; van Vuuren et al., 2016; Risinger 
et al., 2009; Risinger et al., 2011). An example is Vincristine utilized in this 
study.  
          Recent evidence emphasizes that stimulation of the mammalian target of 
rapamycin (mTOR) is dependent on the dynein-mediated transport. Thus, MTA 
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causes dysfunction of microtubules by preventing the activation of the 
AKT/mTOR signalling mechanism preventing cell proliferation (van Vuuren et 
al., 2015). This signifies the various mechanisms to induce mitotic arrest. 
           Toxicology reports emphasise that the paclitaxel concentration (> 10nM) 
prevents the proliferation of the endothelial cells (van Vuuren et al., 2015; 
Risinger et al., 2009; Risinger et al., 2011; Chang et al., 1993; Murphy et al., 
1993; Weaver, 2014). Paclitaxel stimulates the phosphorylation of various 
proteins that can stimulate survival mechanisms. For instance, Bcl-2, Cox-2 and 
Akt (van Vuuren et al., 2015). This consequently induces cell death. Several 
protein kinase enzymes are involved such as MAPK and p53. The stimulation of 
the apoptosome (caspase-9/Apaf-1/cytochrome c) in the mitochondrial apoptotic 
pathway leads to the activation of caspase-3 enzymes (Mekhail and Markman, 
2002). However, Ofir et al. discovered that procaspase-9 is not activated 
following treatment with paclitaxel in in vitro studies: human leukaemia (e.g. HL-
60), ovarian (e.g. SKOV3) and the breast cancer cell line (e.g. MCF-7) (Ofir et 
al., 2002). This emphasises that it is cell type specific. Alternatively, Lin et al.
(2000) revealed that taxol-induced apoptosis is via ROS independent pathway. 
Combination therapy has proved effective especially in metastatic breast cancer. It 
is composed of cisplatin and platinum compound (Xu et al. 2010).  
           Vincristine is a plant alkaloid extracted from periwinkle that is utilized to 
treat acute lymphoblastic leukaemia and other lymphoid malignancies (Douer, 
2016; Stengel et al., 2008). However, despite its capacity to be utilized in 
combined therapy and mechanism of action, it is prescribed to patients minimally 
due to the potential risk of experiencing neurotoxicity (Douer, 2016). Vincristine 
disrupts microtubule synthesis in the mitotic spindle causing cell arrest at 
metaphase. It also prevents replication and induces cell death (Douer, 2016). 
Other functions include interference with the synthesis of nucleic acids and 
proteins by prohibiting contact with glutamic acid (Douer, 2016). Microtubule 
disruptors such as vincristine cause growth arrest in G2/M phase by stimulating 
the G2-M checkpoint (Bhat and Setaluri, 2007). This induces p53-independent 
apoptosis and cells can escape at this checkpoint. Vincristine can also stimulate 
the G1-S checkpoint leading to p53-dependent cell death (Bhat and Setaluri, 
2007). 
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1.1.4.5 Resistance to Chemotherapy
          Cancer chemotherapy is one of the treatment modalities for cancer which 
has effectively improved treatment for several solid tumours such as childhood 
malignancy, haematological malignancies, and germ cell tumours. Resistance to 
chemotherapy is, however, a major factor as to why patients who have refractory 
tumours become unresponsive to various cancer treatments and have high 
mortality rates (Holohan et al., 2013; Patel and Rothenberg, 1994; Baskar et al., 
2012). Failure to respond to cancer chemotherapy is linked to multidrug resistance 
(MDR) and adverse side effects (Tsuruo, 2003; Tsuruo et al., 2003). This was 
found in the treatment of local, disseminated, and recurrent human tumours 
(Luqmani, 2005; Patel and Rothenberg, 1994). For instance, the resistance 
mechanisms to platinum-based chemotherapeutic agents are through several 
varied pathways (Liu, 2009). Several pharmacodynamic and pharmacokinetic 
causes of MDR have been discovered and addressed by countermeasures. This 
emphasises that the management of cancer remains to be a challenge. 
          MDR is a multifactorial phenomenon that is influenced by various 
mechanisms that limit response to drug-induced inhibition of tumour growth - 
Figure 5 (Luqmani, 2005; Harris and Hochhauser, 1992). Alterations in the 
expression and activity of enzymes (e.g. topoisomerase II) and drug-metabolising 
enzymes, membrane transport (p-glycoprotein, ABC transporters), deactivation of 
drugs in response to the conjugation with glutathione and increased DNA repair of 
cancer cells that fail to undergo apoptosis due to mutated proteins that have a 
functional role in cell cycle such as p53 (Housman et al., 2014; Luqman, 2005). 
This increases degradation and promotes the inhibition of anti-cancer drugs. 
Epigenetic effects and the heterogeneity of the cells at the tumour site also plays a 
pivotal role in resistance to chemotherapy (Byler and Sarkar, 2014; Housman et 
al., 2014; Sarkar et al., 2013). Extracellular matrix proteins and cell adhesion 
molecules on stromal cells associated with the cell adhesion molecule on cancer 
cells (Housman et al., 2014). Cancer and stromal cells also secrete factors that 
regulate epithelial-mesenchymal transition (EMT) (Housman et al. 2014). 
            Therapeutic attempts have been made to strategically overcome MDR. For 
instance, the inhibition of drug efflux by adenosine triphosphate-binding cassette 
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(ABC) transporter proteins led to the discovery of promising compounds (Fletcher 
et al., 2010; Luqmani, 2005; Szakacs et al., 2004). Other therapeutic targets 
include nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), 
proteasome, Ras monoclonal antibodies, immunotoxins, gene therapy Ras have 
been discovered (Wilkens, 2015; Wang et al., 2004; Adams et al., 1999; Luqmani, 
2005). Angiogenesis and the altered expression of the Bcl-2 protein involved in 
apoptosis and other physiological factors have also been investigated (Fujita et al., 
2005; Kirkin et al., 2004).  
             The current standard is the use of combination therapy of different 
cytotoxic drugs has been investigated to increase therapeutic efficacy and narrow 
the cycle interval to allow the recovery of the bone marrow (Luqman, 2005). P-
glycoprotein inhibitors with adjuvant therapy and protein kinase inhibitors have 
also been experimented to delay the onset of resistance to chemotherapy 
(Luqman, 2005). Nevertheless, with the increasing prevalence and cancer 
mortality rates, it is likely there remain causes of MDR unaddressed and 
impairing current traditional therapies. This necessitates further research and this 
project aims to discover the intervention of the overlooked glyoxalase system in 
the development of MDR.  
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Figure 5: Mechanisms of resistance to chemotherapy (Adapted from: Housman et al. 2014). 
There are many types of resistance mechanisms that can occur against each and every effect anti-tumour drug which includes: increased drug efflux, 
decreased drug uptake, increased DNA repair mechanisms, altering drug target, evading drug-induced cell death, inhibiting epigenetic effects and the 
activation of detoxification systems. 
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            The primary mechanism of MDR is the enhancement of drug efflux 
(Ughachukwu and Unekwe 2012). There are two types of transporter protein 
superfamilies: ABC transporter and the solute carrier transporter (Liu, 2009). 
ABC transporters are energy-requiring efflux pump whose role is to emit 
chemotherapeutic agents from the cancer cells (Liu, 2009). The solute carrier 
transporter facilitates the uptake of chemotherapeutic agents to cells (Liu, 2009). 
           ABC transporters are transmembrane proteins and are important regulators 
at the plasma membrane that transport several substances (Housman et al., 2014; 
Xue and Liang, 2012). For instance, they are highly expressed in the liver and 
intestinal epithelium where they pump drugs into the intestinal lumen and bile 
duct to protect the body (Borst and Elferink, 2002; Housman et al., 2014). Other 
functions include preserving the blood-brain barrier (Housman et al., 2014; 
Schinkel et al., 1994). Their structures differ from protein to protein and are 
distinguished by the presence of two domains: the variable transmembrane 
domain and a conserved nucleotide binding domain (Chang and Roth, 2001). The 
efflux mechanism initiates when the substrate attaches to the transmembrane 
domain. This triggers ATP hydrolysis at the nucleotide binding site which causes 
an alteration in their conformation. This causes the substrate to undergo 
exocytosis (Sauna and Ambudkar, 2001; Shukla et al. 2007). Despite the efflux 
conducted by ABC transporters, it is a physiological mechanism that occurs 
normally, it can also occur in cancer cells where there are three types of 
transporters whose presence are found in drug resistant cancers (Housman et al., 
2014).  
          The second type of transporter is the Permeability-glycoprotein 1 (P-gp) 
otherwise known as the multi-drug resistance protein 1 (MDR1). It is a 170 kDa 
glycoprotein comprises of 1280 amino acids and resides at the plasma membrane 
along the gastrointestinal tract where its primary location is the small intestine 
where anti-cancer drugs administered orally can be absorbed through the 
epithelium (Thorn et al., 2005; Xue and Liang, 2012; Wacher et al., 2001). It is 
also situated in several sites such as around the blood-brain barrier, placenta, 
colon, renal, testes and pancreas (Schinkel, 1999; Zhou et al. 2008). However, its 
location differs in cancer-resistant cell lines where it resides in the mitochondrial 
cristae, rough endoplasmic reticulum, and the Golgi apparatus (Solazzo et al., 
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2009; Wong et al., 2006). It is widespread through several drug-resistant tumours 
such as cancers of the kidneys, pancreatic, breast, lung liver and leukaemias 
(Gottesman and Pastan, 2015). On the other hand, other cancers such as lung, 
ovarian and oesophageal cancer have low expression of P-gp (Gottesman and 
Pastan, 2015). 
          P-gp can also indirectly deactivate by stimulating the expression of 
cytochrome P450 3A4 (CYP3A4) (Bendayan et al., 2006). Dietrich et al.
discovered that a high expression of P-gp influences the bioavailability of several 
anti-cancer drugs such as Imatinib, doxorubicin and paclitaxel (AlFarouk et al., 
2015; Dietrich et al. 2001a; Dietrich et al., 2001b; Schellens et al., 2000; 
Sparreboom and Baker, 2016). The high expression of P-gp correlates with the 
overexpression of proteins that function as receptor tyrosine kinase in the MAPK 
pathway such as HRas and ERK-1 / 2. This is why inhibitors of tyrosine kinase 
and HSP90 chaperone protein can down-regulate the expression of P-gp (Zanini et 
al. 2017). The expression can be relieved by the presence of growth factors such 
as Fibroblast Growth Factor (FGF) and Epidermal Growth Factor (EGF) (Segerer 
et al. 2018). 
The third type is called the breast cancer resistance protein (BCRP) 
otherwise known as the multixenobiotic resistance protein, ABCG2, mitoxantrone 
resistance protein (MXR) or ABCP (Litman et al., 2002). It emits large, positively 
charged, hydrophobic molecules that can protect normal cells from xenobiotic 
effects and maintains the homeostasis of folate and haem (Alfarouk et al., 2015; 
Gottesman and Pastan, 2015). If cancer cells do not have MRP nor P-gp, MXR 
comes in position for causing resistance (Noguchi et al., 2009).  
          However, by using the tyrosine kinase inhibitor, Gefitinib, it inhibits BRCP 
causing transporter dysfunction, decreasing drug efflux and preventing drug 
resistance (Gottesman and Pastan, 2015; Yanase et al. 2004; Yanase et al. 2006). 
Doyle et al. discovered that oestrogen plays a pivotal role in regulating the 
expression of BCRP whereby 17b estradiol was able to downregulate its 
expression in breast cancer cells. This enhanced the sensitivity of anti-cancer 
drugs such as anthracyclines (Doyle et al.,1998). The three types of ABC 
transporters have a broad substrate specificity and can efflux several different 
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anti-cancer drugs such as taxanes, vinca alkaloids and anthracyclines from the 
cells (Gottesman et al., 2002). 
          Hydrophilic nanoparticles can improve the stability and solubility of 
chemotherapeutic agents by inhibiting the drug efflux, increasing the half-life, 
exposure time and to treat resistant cancer cells (Xue and Liang, 2012). 
Nanoparticles can be modified with image moieties, antibodies, anti-cancer drugs 
and specific to increase the accumulation of the anti-cancer drugs (Xue and Liang, 
2012). Patil and Panyam (2009) discovered that siRNA-based nanoparticles can 
modulate drug resistance by decreasing the expression of MDR1 in combination 
with an anti-cancer drug (Patil and Panyam, 2009). This was successfully 
established with doxorubicin (Wang et al., 2018; von Roemeling et al., 2017). 
          Alterations to the drug targets such as modifications and mutations to their 
expression and signal transduction mechanism can cause chemotherapy resistance 
(Housman et al., 2014). For instance, some anti-cancer drugs target the 
topoisomerase II enzyme which causes damage to the coiling of DNA and 
prevents synthesis. However, when topoisomerase II is genetically mutated it 
leads to drug resistance (Stavrovskaya, 2000).  
          Another example of how genetic mutations cause drug resistance are beta-
tubulins that affect the mechanism of action of paclitaxel in ovarian cancers 
(Mehta et al., 2009). Chromosomal rearrangements in the structure of anaplastic 
lymphoma kinase have been found in lymphoma (Housman et al., 2014; Holohan 
et al., 2013). This emphasizes how drug target alterations cause drug resistance. 
          Anti-cancer drugs that target signalling kinases such as epidermal growth 
factor receptor (EGFR) family are associated with cellular proliferation. 
(Housman et al., 2014). For example, there is a high level of expression of human 
epidermal growth factor receptor 2 (HER2) tyrosine kinase in ca. 30 % of breast 
cancers and resistance to anti-cancer drugs can result in targeting the kinase for a 
significantly long period of time (Housman et al., 2014; Holohan et al., 2013; Lal 
et al., 2003). Another example of an alteration that causes resistance in breast 
cancer treatment is the malfunction of the oestrogen receptor signalling that 
influences the antagonistic activity of tamoxifen causing cancer progression (Shou 
et al., 2004) 
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         Inactivation of drugs is another prominent mechanism in how cancer 
resistance arises. For instance, the nucleoside drug, cytarabine (AraC) is utilized 
in the treatment of acute leukaemia and is stimulated to form AraC-triphosphate 
following phosphorylation (Zahreddine and Borden, 2013). Resistance to AraC 
can occur when there is a mutation or down-regulation in this mechanism. 
Another example of drug inactivation is resistance to platinum-based drugs caused 
by glutathione which activates the detoxification mechanism (Mehta and Fok, 
2009). 
          Another example of drug inactivation is through the detoxifying enzymes 
Glutathione S-transferase (GSTs). GSTs can inhibit the MAPK pathway and when 
highly expressed it increases detoxification of the anti-cancer drugs reducing 
cellular damage and cytotoxicity (Manolitsas et al., 1997). 
           There have been several recent developments with the aim to decrease 
patient-specific resistance. For instance, a bio-printed chip of the pathological 
characteristics of patients with native tumours can be created to determine drug 
combinations that increase tumour killing. For instance, a chip has been 
reconstituted for glioblastoma containing decellularised extracellular matrix, 
tumour cells and vascular endothelial cells from the brain tissue. They underwent 
concurrent treatment with chemoradiation and the oral DNA-alkylating agent 
temozolomide and revealed they were ineffective (Yi et al. 2019). This suggests 
how this methodology can be used to determine the first line of treatment of 
patients with cancer. 
          Another technique that can assist patients with metastatic solid tumours is 
molecular profiling. Treatments can be approved based on the molecular testing of 
genomic drivers of tumourigenesis rather than the location of tumour (El-Deiry et 
al. 2019). This is known as precision oncology. However, initially, there have 
been low matching rates with monotherapies due to several limitations such as the 
drug availability, deterioration of patients with advanced tumours and limited 
gene panels (Sicklick et al. 2019). The current clinical trial paradigm for 
personalised medicine is to optimize heterogeneous tumours with multidrug 
regimens to yield a higher matching score and increase the progression-free and 
overall survival rates (Sicklick et al. 2019). 
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          Moreover, the pentose phosphate pathway (PPP) induces chemotherapeutic 
resistance by various mechanisms: it facilitates DNA damage repair by assisting 
in nucleotide synthesis, PPP provides cancer cells with NADPH that protects 
cancer cells from oxidative stress-induced by chemotherapy. It increases tumour 
survival during treatment by reducing the intracellular levels of reactive oxygen 
species limiting access of cancer cells to mitochondrial respiration (Phan et al., 
2014; Wallace, 2012). Increasing the flux of PPP causes the levels of glutathione 
and glucose-6-phosphate dehydrogenase to increase, this decreases the 
accumulation of drugs in cancer cells (Phan et al., 2014; Riganti et al., 2012). 
        Ultimately, there are a number of mechanisms that induce chemotherapy 
resistance; however, the focus of this project is the role of Glo1-linked multidrug 
resistance in cancer chemotherapy. To understand the pathophysiological 
mechanisms, the structure and function of the glyoxalase system and its role in 
MG metabolism is addressed. 
1.2 The glyoxalase system
1.2.1 Introduction
          The glyoxalase system is a cytosolic enzymatic system that consists of two 
enzymes: glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2) and a catalytic amount of 
the cofactor reduced glutathione (GSH) (Thornalley, 2003a, Thornalley, 2008). 
The enzymatic system is present in eukaryotes and most prokaryotic organisms 
(Rabbani and Thornalley, 2018a, Rabbani et al., 2016, Thornalley, 1990). It is 
found in animals, plants, fungi, bacteria, and protists (Xue et al., 2011).   
              The primary role of the glyoxalase system is to catalyse the 
detoxification and metabolism of reactive α-aldehydes or dicarbonyl metabolites 
such as methylglyoxal (MG) to the relatively non-toxic metabolic product, D-
lactate via the intermediate S-D-lactoylglutathione in vivo (Rabbani and 
Thornalley, 2014a, Thornalley, 2003a). MG is the major substrate of the 
glyoxalase pathway in physiological systems (Rabbani et al., 2016). This, in turn, 
protects host systems from cell dysfunction and disease (Rabbani et al., 2014b, 
Xue et al., 2012). Other functions of the glyoxalase system are to regulate the 
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microtubule assembly, control growth and glycolytic bypass in microbial systems 
(Thornalley, 2003a). 
            The process of detoxification consists of two sequential reactions to 
prevent an increase of reactive α-oxoaldehydes and its associated reactions – 
Figure 6. Glo1 catalyses the isomerisation of the hemithioacetal formed non-
enzymatically from MG and GSH to form the intermediate S-D-lactoylglutathione 
(Shinohara et al., 1998). Glo2 catalyses the hydrolysis of S-D-lactoylglutathione 
to form D-lactate and GSH is regenerated. However, other substrates have a 
different intermediate, for instance, glyoxal is converted to glycolate via the 
intermediate glycolylglutathione whereas hydroxypyruvaldehyde is converted to 
L-glycerate via S-L-glyceroylglutathione (Clelland and Thornalley, 1991, 
Jerzykowski et al., 1973). 
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Figure 6: The glyoxalase system. 
(A) The glyoxalase system. (B) “Leakage” of metabolic flux from the Embden-Meyerhof pathway by non-enzymatic degradation of 
triosephosphates to form MG (Rabbani and Thornalley, 2014c).
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1.2.1.1 Historical development
            The glyoxalase system was discovered in 1913 independently by: (i) Carl 
Neuberg, and concurrently (ii) Henry Drysdale Dakin and Harold Ward Dudley 
(Dakin and Dudley, 1913; Neuberg, 1913). In the late 1920s, Neuberg did further 
experiments where he revealed there was an association between MG and the 
glyoxalase system in glycolysis where the enzymatic system catalyses the 
conversion of MG to lactate (Neuberg and Kobel 1929). However, Neuberg’s 
findings were opposed by Embden who found that glycolysis produced only the 
L-enantiomer of lactate whereas with the addition of methylglyoxal to tissues he 
found both L- and D-lactate (Neuberg and Kobel, 1929).  
              Furthermore, Embden revealed that fructose 1,6-bisphosphate (F-1,6-BP) 
was converted into 3-phosphoglycerate; an oxidation product of glyceraldehyde-
3-phosphate (GA3P) (Warburg and Christian, 1939, Meyerhof., 1933). F-1,6-BP 
was fragmented into two triosephosphates, GA3P and dihydroxyacetone 
phosphate (DHAP). He also hypothesised that 3-phosphoglycerate was a 
precursor of pyruvate and L-lactate (Embden, 1932). His findings on the 
alternative glycolytic intermediates were consolidated by Otto Meyerhof. This led 
to the introduction of the Embden–Meyerhof pathway that involves the 
conversion of glucose into L-lactate (Embden 1932; Meyerhof, 1933). 
    Moreover, further developments were made between the years 1930s and 
1950s which advanced and shaped our current understanding of the characteristics 
and physiological aspects of the glyoxalase system. The leading investigators of 
this period were: Karl Lohmann who discovered GSH, Juda Quastel and Maurice 
Jowett who revealed that GSH and MG interacted to form a hemithioacetal 
substrate, and Samuro Yamazoye who showed that the hemithioacetal is 
converted to S-D-lactoylglutathione (Jowett and Quastel, 1933; Lohmann, 1932; 
Yamazoye, 1936). The distribution of the glyoxalase system in living organisms 
was studied by Edward Morgan and Frederick Gowland-Hopkins who discovered 
it occurred widespread in living organisms (Hopkins and Morgan, 1945).  
    Efraim Racker found that there were two sequential metabolic steps of 
glyoxalase system catalysed by Glo1 and Glo2, respectively, and that the terminal 
product of metabolism of MG was D-lactate (Racker, 1951; Thornalley, 1990). 
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The terminal protein stereoselectivity for D-lactate was subsequently analysed by 
Ekwall and Mannervik who confirmed the unexpected finding of Racker (Ekwall 
and Mannervik, 1973). In 1960, a study was conducted on the human arterial 
tissue where the results put an emphasis on the functional role of Glo1 and how 
low activity of Glo1 influences the ageing process and increased the risk of 
cardiovascular disease (Kirk, 1960). 
              With the role of MG and the glyoxalase system being dissociated from 
glycolysis, further investigations were conducted on the function of the glyoxalase 
system. The glyoxalase system was hypothesised to be a regulator of growth 
control and high doses of exogenous MG provide novel cancer treatment: MG 
was hypothesised to be a ‘retine’ that restricts growth whereas Glo1 was seen as a 
‘promine’ that counteracts this effect (Szent-Györgyi et al., 1967; Szent-Gyorgyi 
et al., 1963). However, the subsequent finding of other, more potent and effective 
growth factors and their receptors led to this hypothesis being rejected.        
          Bonsignore et al. revealed that GA3P underwent non-enzymatic hydrolysis 
to form MG (Bonsignore et al., 1973). The arginine-directed protein glycation 
induced by MG was discovered by Takahashi and was later revealed to be the 
major protein adduct: hydroimidazolone (MG-H1) (Ahmed et al. 2002, Henle et 
al., 1994; Takahashi, 1977; Thornalley et al., 2003). MG-derived advanced 
glycation endproducts (AGEs) were quantified using a stable isotopic dilution 
analysis liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
(Thornalley et al., 2003). 
           In 1988, it was discovered that the formation of MG was elevated in 
erythrocytes that were incubated in high glucose concentrations in vitro
(Thornalley, 1988). This led to the detection of other metabolites of D-lactate and 
S-D-lactoylglutathione that were increased in patients with diabetes in comparison 
to healthy participants which emphasises that there is an increase in Glo1 activity 
(Atkins and Thornalley, 1989; Thornalley et al., 1989). 
          Vince and Wadd pursued the hypothesis that elevated concentrations of MG 
were toxic to tumour cells and proposed a novel strategy to achieve this: by 
targeting Glo1 with small molecule inhibitors. The Glo1 inhibitors derived from 
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glutathione thioethers may be effective anti-cancer agents via the accumulation of 
MG (Vince and Wadd, 1969).  
The molecular and structural characteristics of the glyoxalase enzymes and 
their catalytic mechanisms were detected in the 1970s-1990s. Wilson and his 
colleagues discovered that Glo1 gene was an inherited factor associated with the 
body mass index (BMI) and part of the obesity genome (Wilson et al., 1991). 
Glyoxalase enzymes were purified and characterized by several groups – as 
reviewed (Rabbani and Thornalley, 2014b). The non-enzymatic degradation of 
triosephosphates – GA3P and DHAP, to form MG was characterized using a 
specific and validated MG assay under physiological state conditions (Phillips and 
Thornalley, 1993). This represents a minor “leak” of ca. 0.05% - 0.1 % 
glucotriose flux from the Embden-Meyerhof pathway. Despite this low level, the 
high reactivity of MG with protein and DNA required effective and efficient 
metabolism of MG to suppress these reactions to low, tolerable levels (Phillips 
and Thornalley, 1993).        
        The physiological function of the glyoxalase pathway has been accepted to 
be a natural damage protective system by detoxifying potent reactive MG that 
otherwise induces dicarbonyl glycation and forms advanced glycation end-
products (AGEs) (Lo et al., 1994a; Lo et al., 1994b). It was also discovered 
during the same year that aminoguanidine prevented the formation of AGEs by 
preventing the development of diabetic complications (Lo et al., 1994a). This 
suggests a fundamental and conserved role required by all glycolytic life forms 
unless there is an alternative, compensatory route to MG detoxification 
(Thornalley, 2003a). 
  Up to the 1990s, glyoxalase research was still lacking an effective 
inhibitor of Glo1 in situ. Despite the development of potent Glo1 inhibitors by 
Vince and Wadd in 1969, it lacked cell permeability and hence could not reach 
the Glo1 receptor in the cytoplasm of cells. This was resolved in 1992 by Lo and 
Thornalley who produced a cell permeable Glo1 inhibitor, S-p-
bromobenzylgluthathione (SpBrBzGSH) diester that exerted its anti-tumour 
effects in vitro and in vivo by the accumulation of MG leading to apoptosis, 
anoikis and necrosis. The diesterification provided a pro-drug modification that 
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facilitated cell permeability inside the cells forming the active Glo1 inhibitor. It 
also stabilised Glo1 inhibitors from extracellular degradation by ɣ-glutamyl 
transferase (Lo and Thornalley, 1992; Thornalley, 1996; Thornalley et al., 1996). 
This was further developed by Creighton and co-workers (Creighton et al., 2003).  
    Several in vitro and in vivo studies revealed there was an increase in the 
concentration of MG and MG-derived AGEs but there was a reduction in Glo1 
and Glo2 activities; this is associated with oxidative stress and ageing (McLellan 
and Thornalley, 1989; Abordo et al., 1999, Dunn et al., 1991, Ahmed et al., 1997; 
Sharma-Luthra and Kale, 1994; Baynes, 1991). This was also observed in patients 
with type 2 diabetes mellitus who underwent metformin therapy where there was 
a reduction in the concentration of MG in plasma (Beisswenger et al., 1999). 
Shinohara and colleagues discovered that overexpression of Glo1 in endothelial 
cells reduced the accumulation of MG and the production of associated AGEs in 
vitro (Shinohara et al., 1998). This suggests how Glo1 is the major enzyme 
involved in MG metabolism. 
  Sakamoto et al. revealed there was an association between GLO1 
overexpression and MDR in cancer chemotherapy (Sakamoto et al., 2000). MDR 
is defined as the innate and/or acquired aptitude of tumour cells to avoid the drug-
induced tumour growth inhibition (Alfarouk et al., 2015). It is the central 
mechanism in how tumours develop chemotherapeutic resistance and remains a 
continuous, central challenge for medicine today in the treatment of disseminated 
and local disease (Luqmani, 2005; Persidis, 1999). It was also discovered that 
MDR is connected to the overexpression of Glo1 in tumour cells lines in vitro and 
tumour-bearing mice in vivo; this was lifted by the S-p-bromobenzylgluthathione 
diester (Sakamoto et al., 2001).  
               Further developments were also made in understanding the genetic basis 
of Glo1 in the late 2000s. Redon and his colleagues identified Glo1 after 
constructing a copy number variation (CNV) map. This led to the introduction of 
the non-transcribed region of the Glo1 gene that played a major role in increasing 
the amplification of the Glo1 gene (Redon et al., 2006; Cahan et al., 2009). In 
2007, Zender and his colleagues conducted a genome-wide study consisting of 
tumour suppressor genes and discovered that Glo1 was linked to the functional 
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role of tumour suppression which in turn influences the production of MG-derived 
nucleotide AGEs: MG-derived imidazopurinine (MGdG) and N2-(1-
carboxytheyl)deoxyguanosine  (CEdG); these are associated with mutagenesis and 
DNA instability in vivo (Zender et al; 2008, Santarius et al., 2010). The level of 
Glo1 gene expression was discovered to be influenced by the lifespan of
Caenorhabditis elegans. When Glo1 was overexpressed in Caenorhabditis
elegans, the median lifespan was increased ca. 30%; and when Glo1 was silenced 
by transfecting with Glo1 small interfering ribonucleic acid (siRNA), the median 
lifespan was decreased by ca. 50% (Morcos et al., 2008). 
              In 2010, Santarius et al. revealed that a driver of increased Glo1 
expression was, in some cases, increased GLO1 copy number in tumours that 
have innate MDR. Highest prevalence of increased GLO1 copy number was 
found in breast cancer (22%), non-small cell lung cancer (NSCLC) (11%) and 
small cell lung cancer (SCLC) (16%) of 520 human tumours were assessed 
(Santarius et al., 2010). 
           Another cause of Glo1 overexpression was discovered in 2012. The 
transcription factor nuclear factor-erythroid 2 p45 subunit related factor 2 (Nrf2) 
binds to a regulatory antioxidant response element (ARE) in the 5’-untranslated 
regions of exon-1 of the mammalian GLO1 gene to increase the basal and 
inducible expression of Glo1 (Xue et al., 2012). This increases the detoxification 
and metabolism of MG to protect cells from oxidative stress-induced damage 
(Xue et al., 2012).  
            Besides, Nrf2 can also increase intracellular levels of GSH (Frandsen et 
al., 2017). The activation of Nrf2 increases the transcription of proteins under the 
states of stress and cytotoxicity by ROS and anti-tumour drugs respectively to 
initiate antioxidant defence mechanisms (Surh et al., 2008). Amongst the products 
of Glo1 is GST, glutamylcysteine synthetase (GCS) and haem oxygenase-1 (HO-
1) (Serafini et al., 2010). Under the resting phase, Nrf2 associates with its 
negative regulator, Kelch-like ECH-associated protein 1 (Keap1) to form a 
complex and is sequestered into the cytoplasm where it undergoes subsequent 
ubiquitination by Cullin-3 and is transferred to the proteasome for degradation 
(Frandsen et al. 2017; Kobayashi et al. 2004; Kobayashi et al., 2006). 
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           Since Glo1 is a tumour suppressor protein, small molecule Nrf2 activators 
and Glo1 inducers developed from dietary bioactive compounds may be utilized 
to increase the mRNA expression, protein, and enzymatic activity of Glo1 to 
prevent tumour progression. Other therapeutic uses of Glo1 inducers is to treat 
vascular diabetic complications and act as dietary supplements to promote healthy 
ageing (Rabbani et al, 2018; Rabbani et al., 2014, Xue et al., 2011).  
          Currently, we are in the position of joining the bridge between the 
regulatory process of the glyoxalase system and its effects on physiological stress, 
chemotherapeutic resistance, ageing, and disease to develop novel pharmaceutical 
strategies. 
   1.3 Glyoxalase 1
           1.3.1 Molecular characteristics and structure
            Human Glo1 has a molecular mass of 42 kDa by sequence whereas its 
mass is determined experimentally by gel filtration is 46 kDa. The isoelectric 
point (pI) value is in the range of 4.8 - 5.1 (Thornalley, 2003a; Thornalley, 
1990). Human Glo1 is a dimeric protein and each subunit consists of 184 amino 
acids with a molecular mass of 21 kDa by sequence (Thornalley, 2003a). The 
two monomers are associated by non-covalent bonds (Birkenmeier et al., 2010). 
Each monomer contains two, structurally equivalent domains that have risen by 
a gene duplication and 3D domain swapping of the N-and C-terminal domains 
(Thornalley, 2003a; Thornalley, 2003c). One domain comprises residues 31-104 
amino acids and the other domain residues 124-183. These domains are linked 
by two regions: 20 amino acid connecting region and a long N-terminal region. 
Each domain also contains a βαβββ-motif and a mixed β-sheet. When the 
subunits undergo dimerization, a β-barrel structure is formed that contains the 
active site. The dimers have enzymatic activity whereas the individual 
monomers do not (Thornalley, 2003a). 
             The expression and activity of Glo1 is found in different organisms, 
from prokaryotes to eukaryotes but the prosthetic metal ion varies. For example, 
the Glo1 found in the bacteria Escherichia coli is a dimeric Ni2+-metalloenzyme 
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whereas the Glo1 found in humans is a dimeric Zn2+- metalloenzyme with a 
stoichiometry of one zinc ion per monomer (Marmstål et al., 1979; Thornalley, 
2003a). The crystal structures of human and bacterial Glo1 has been solved to 
1.7 and 1.5 Å resolution (Cameron et al., 1997).  
             The prosthetic Zn2+ binding site in the human Glo1 consists of two 
structurally equivalent residues from each domain: Gln-33A, Glu-99A, His-126B, 
Glu-172B and two water molecules. It is organised in an octahedral coordination 
whereas the Ni2+ binding site of bacterial Glo1 comprises His-5A, Glu-56A, His-
74B, Glu-122B and two water molecules (Thornalley, 2003a). In human Glo1, the 
active site is located in the dimer interface particularly in the β-barrel motifs. This 
can be compared to other enzymatic structures, several studies have highlighted that 
Glo1 belongs to the bleomycin resistance protein and Fe2+ dependent 
dihydroxybiphenyl dioxygenase (Cameron et al., 1997). The substrate and 
prosthetic Zn2+ ions interact with the side chains from both subunits (Thornalley, 
2003a). 
    1.3.2 Genetics and polymorphism
             The GLO1 gene encodes two subunits and is expressed at a diallelic 
genetic locus on chromosome six found between the centromere and Human 
Leukocyte Antigen - antigen D-Related (HLA-DR). The genetic locus is 6p21.2 
(38,751,680 - 38,778,930) whereas the GLO1 gene consists of 27,250 bp, six 
exons and five introns (Thornalley, 2003a; Tripodis et al., 1998). The length of 
the GLO1 gene is ~12.0kb (Gale and Grant, 2004).     
             GLO1 has two alleles, GLO1 and GLO2 in heterozygotes, which are 
inherited autosomally in a co-dominant technique (Thornalley, 1991). GLO1 
arises via mutation whereas the GLO2 allele is the ancestral allele. The 
difference between them is caused by the point mutation at position 332 in 
cDNA sequence (Thornalley, 2003a). Thus, the possible genotypes of the human 
GLO1 are GLO1(1-1), GLO1(1-2) and GLO1(2-2). These allozymes represent 
the homozygous and heterozygous expressions of the diallelic gene in all tissues. 
This common polymorphism is produced by the mutation C419A in the coding 
region giving rise to amino acid residue polymorphism Ala111Glu (A111E). The 
expression of GLO1 produces a Glo1 subunit with Ala111, whereas the 
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expression of GLO2 produces a subunit with Glu111 (Degaffe et al., 2008, Kim 
et al., 1995).  
          Allozymes may be distinguished by their molecular shapes and charge 
densities which are resolved by ion-exchange chromatography and gel 
electrophoresis (Kim et al., 1995). Human population genetic studies revealed 
that the GLO1 allele-frequency is at its highest in native tribes in Alaska, 0.67 – 
0.85 and decreases geographically from the South and East to Europe and South 
America, through Africa, the Middle East and India, to the very low GLO1 allele 
frequencies of the Far East and Oceania, 0–0.16 (Thornalley, 1991). Deletion of 
GLO1 is embryonically lethal in mice and humans unless the compensatory 
increased expression of MG reductase occurs (Arai et al., 2010). 
          The GLO1 promoter region presented in Figure 7 consists of several 
binding sites for regulatory elements that vary in position and are hot spots for 
an increase in the functional copy number. The human GLO1 promoter region is 
982 bp and the main elements present are: metal responsive element (MRE) 
positioned from -647 to -654bp, glucocorticoid responsive element (GRE) (-363 
to -368bp), activating enhanced binding protein 2 alpha (TFAP2A) (-24 to -
32bp), insulin response element (IRE) (-842 to -848 bp), antioxidant response 
element ARE-1 (-10 to -19), ARE-2 (-252 to -261), ARE-3 (1051 to -1060), The 
activating enhancer binding protein 2 alpha (AP-2α) and E2F-binding to the 
transcription factor EDF4 (Ranganathan et al., 1999; Lewis et al., 2010; Donato 
et al. 2018; Xue et al., 2012; Conboy et al., 2007).  
           Some of the functionalities, IRE and MRE were validated by reporter 
assays where there was an increase in the transcriptional response (2-fold) due to 
the exposure of zinc chloride and insulin (Ranganathan et al., 1999). No 
functional activity was established for the GRE but there was activity in 
hormone response element (HRE) which decreased the expression of GLO1 
(Ranganathan and Tew, 1993; Ranganathan et al., 1999; Zhang et al., 2012). 
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Figure 7: The structure of the human GLO1 gene (Adapted from Shafie et al., 2014) 
(A) A schematic presentation of the different domains in the human GLO1 gene (Blue: promoter region, red: exon, green: untranslated region.  
(B) Promoter sequence of human GLO1 with positions of regulatory elements (Yellow)
79 
1.3.2.1 Copy number variation (CNV) of GLO1 gene
          Advances in technology provided an insight into the genetic rearrangement 
of various sites in the genome of a species. These could be deletions, duplications, 
inversions, and insertions that cause alterations in the structural arrangement of 
chromosomes and genes. Copy number variation (CNV) is defined as a genomic 
segment of at least 50 bp that differs in copy number based on the comparison of 
two or more genomes (Zarrei et al., 2015). This can cause genetic diversity that 
has been revealed in mammalian species and plays an influential role in evolution 
and susceptibility to disease (Choy et al.,2010, Freeman, 2006; Schrider and Han, 
2010; Kehrer-Sawatzki, 2006; Shlien and Malkin, 2009).  
          There was an increase in GLO1 CNV and this can be found in adipose, 
hypothalamus and hematopoietic cells (Cahan et al., 2009). Williams and his 
colleagues identified GLO1 locus as a hotspot for CNV in mice strains that are 
undergoing duplications. The duplication is associated with increasing the levels 
of GLO1 expression (Shafie et al., 2014 Williams et al., 2009; Cahan et al. 2009; 
Perry et al., 2008). 
1.3.3 Enzyme kinetics and catalytic mechanism
         Glo1 is the first line of defence in how MG and associated reactive 
metabolites such as glyoxal and 3-deoxyglucosone (3-DG) are removed in most 
human tissues (Rabbani et al. 2014, Thornalley, 1993; Shinohara et al., 1998; 
Thornalley, 2003a, Thornalley, 2003b). Glo1 catalyses the isomerisation of the 
hemithioacetal formed non-enzymatically from the reaction of MG and GSH to 
form the corresponding α-hydroxyacid, S-D-lactoylglutathione (Phillips and 
Thornalley, 1993; Thornalley, 2003a). In cells and tissues in vivo, this decreases 
the steady-state concentration of α-oxoaldehydes and associated glycation 
reactions (Thornalley, 1999). Glo1 has a broad specificity for α-oxoaldehydes 
such as glyoxal (CHO)2), MG (CH3COCHO), hydroxypyruvaldehyde 
(HOCH2COCHO), 4,5-dioxovaleric acid HO2C(CH2)2COCHO and other acyclic 
glyoxal derivatives (Rabbani and Thornalley, 2012a). The KM and kcat values 
decrease as the hydrophobicity of the side chain of the glyoxal derivative substrate 
increases (Van der Jagt et al., 1975). For human Glo1 interacting with the GSH-
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MG hemiothioacetal, CH3COCHOH-SG, the Michaelis-Menten constant (KM) is 
71-130 µM and the turnover number kcat is 7-11 x 104 min-1 (Thornalley, 2003a).  
The catalytic reaction consists of a proton transfer in the hemithioacetal 
from   C-1 to C-2 to produce an ene-diol intermediate (Thornalley, 2003a). This is 
followed by rapid ketonization to form the thioester product (Thornalley, 2003a). 
Two types of stereoisomers are formed in the pre-equilibrium forming the 
hemithioacetal: R - and S-substrate diastereoisomers. Glo1 accepts them both and 
once bound to the active site, it displaces the water molecules in the metal ion 
primary co-ordination shell. There is a difference in the catalytic base found in 
both types of diastereoisomers: Glu-172 is the base for the S-substrate 
diastereoisomer whereas Glu-99 is the base for the R-substrate diastereoisomer. 
Glu-172 can re-protonate the ene-diol to produce the R-2- hydroxyacylglutathione 
product (Rabbani and Thornalley, 2014b; Rabbani and Thornalley, 2008a; 
Thornalley, 2003a). 
1.3.4 Glo1 expression, transcriptional regulation, and post-
translational modification
          In the adult human tissues and blood cells the basal expression 0.2 μg Glo1 
protein per mg total protein. This was increased up to 2-fold in foetal tissues 
(Larsen et al., 1985). The expression of Glo1 can decrease causing accumulation 
of MG in three major respects: when levels of Glo1 are suppressed in situ by GSH 
depletion, the expression of Glo1 is decreased by siRNA silencing and in the 
presence of cell permeable Glo1 inhibitors (Abordo et al. 1999; Thornalley, 1993; 
Thornalley et al. 1996; Thornalley, 2003b, Xue et al. 2017).  
          The expression of Glo1 may also be decreased by the activation of the cell-
surface receptor for advanced glycation end-products (RAGE), although the 
mechanism remains unclear (Bopp et al. 2008; Reiniger et al., 2010; Zeng et al., 
2012). The function of RAGEs is to act as decoy receptors for the ligands and 
influence RAGE-ligand interactions and signal transduction pathways (Park et al., 
1998; Vazzana et al. 2009). For instance, Mitogen activated protein kinases 
(MAPK), phosphoinositol-3-kinase (PI3K), Rho GTPase, Jak/STAT, extracellular 
regulated (ERK) and c-Jun N-terminal kinase (JNK) (Hejab et al., 2012; Vazzana 
et al., 2009).  
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         Endothelial RAGE binds with circulating AGEs causing endothelial 
dysfunction which activates nicotinamide adenine dinucleotide phosphate oxidase 
(Hejab et al., 2012; Vazzana et al., 2009). This increases the synthesis of ROS 
and nuclear transcription factors such as NF-kB. NF-kB is translocated to the 
nucleus and initiates target gene transcription such as E-selectin, ICAM-1 and 
endothelin-1 (Vazzana et al. 2009; Sparvero et al., 2009). This highlights the 
importance of RAGE as a central player for several pathological states: chronic 
inflammaion, diabetes and atherosclerosis (Bopp et al., 2008; Hejab et al., 2012). 
Moreover, the expression of Glo1 can be decreased by the activation of hypoxia-
inducible factor 1α; see Section 1.10 (Zhang et al., 2012; Zhang et al., 2015). 
During post-translational processing of human Glo1, the N-terminal Met is 
removed, and the remaining N-terminal Ala is blocked by acetylation (Xue et al.
2011). There is a vicinal disulphide bridge between the cysteine residues 19 and 
20 and a mixed disulphide with glutathione on cysteine-139. Cysteine-139 may 
also form an intra-molecular disulphide with cysteine-61. N-Acetylation and the 
oxidation state of C19/C20 did not affect Glo1 activity whereas glutathionylation 
strongly inhibited Glo1 activity in vitro (Birkenmeier et al., 2010).  
Glo1 is modified by S-nitrosylation by the reaction with nitric oxide (NO) 
on cysteine-139. The presence of both C19 and C20 were influential on S-
nitrosylation which occurred preferentially on the acidic, α-form of Glo1. The 
NO-responsive form of Glo1 is the basic, reduced form of Glo1 without 
intramolecular disulphide bonding (De Hemptinne et al., 2007). Glo1 is a 
substrate for calcium, calmodulin-dependent protein kinase II and is 
phosphorylated at Thr-107 preferentially but not exclusively on the basic, reduced 
and NO-responsive form (Santarius et al., 2010; de Hemptinne et al., 2009; De 
Hemptinne et al., 2007, Birkenmeirer et al., 2010). 
The expression of Glo1 was quantified in NIH3T3 mouse fibroblasts in a 
genome-wide study by Selbach and colleagues (Schwanhäusser et al., 2011). For 
Glo1, the number of copies per cell of mRNA and protein was: mRNA – 22 
(median of transcriptome 17); and protein – ca. 584,000 (median of proteome ca.
50,000). The half-lives of mRNA and protein were mRNA – 7.8 h (median of 
transcriptome 9 h); and for protein, 179 h (median of proteome ca. 46 h). The 
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transcription rate (molecules per cell per h) was: 2.4 (median for transcription, 
1.8). The translation rate (molecules protein per molecule mRNA per h) was: 
750 (median for genome-wide translation, 117). The view emerging from this is 
that Glo1 has protein abundance ca. 10-fold higher and half-life 4-fold higher 
than the median value. The quantitative level of Glo1 protein is in reasonable 
agreement with that estimated for the human tissues by immunoassay of ca. 0.2 
µg per mg protein or Glo1 is ca. 1/5000th of total protein (Larsen et al., 1985). 
Glo1 is a highly efficient enzyme and so these relatively high levels of protein 
probably reflect a requirement for high in situ activity. There were 677 Glo1 
proteins detected from the overall 5028 proteins and was present in the top 13% 
of proteins detected by abundance. This is similar abundance to that of other 
glycolytic enzymes – such as transketolase. 
              There have been a few comprehensive studies of the relationships 
between the levels of transcripts and proteins they encode in mammals. In a 
genetic approach in which natural variations were used to perturb both transcript 
levels and protein levels amongst the inbred strains of mice, in quantifying levels 
of the 7,185 most heritable transcripts and 486 related proteins, the mRNA levels 
of Glo1 had one of the strongest correlations with Glo1 protein; r = 0.87). Only 
50% of the genes tested had a significant correlation of mRNA and protein and 
the average correlation was r = 0.27 (Ghazalpour et al., 2011). The post-
transcriptional mechanisms that converted Glo1 mRNA into Glo1 protein are 
relatively constant – at least in the liver, and the half-life of Glo1 may be little 
changed in good health. This suggests that Glo1 shows a moderate increase in 
proteolysis on the activation of autophagy (Kristensen et al., 2008). 
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1.3.5 The association between glyoxalase 1 and cancer 
1.3.5.1 Glyoxalase 1 as a tumour suppressor protein
           Increased MG concentration may cause increased DNA strand breaks, 
cytotoxicity and mutation frequencies mediated by the increased production of 
MG-derived imidazopurinone adducts and glyoxal-derived nucleotides of DNA 
(Rabbani et al., 2018; Thornalley et al., 2010; Xue et al., 2016). This is 
countered by the nucleotide excision repair (Thornalley, 2003a; Thornalley, 
2003b). In studies of liver carcinogenesis, a p53 knockout Ras overexpression 
rodent model was utilized to scan for tumour suppressor genes (Zender et al., 
2008). Hits were identified by the augmented tumour growth with selective gene 
silencing achieved by introducing pools of short hairpin RNAs into pre-
malignant progenitor cells and selection for those that promote tumour formation 
after transplantation. Thirteen tumour suppressor genes (in addition to p53) were 
identified, including Glo1 (Zender et al., 2008). If this rodent model translates to 
clinical carcinogenesis, an elevated expression of Glo1 is linked with reduced 
risk of cancer and this can be observed through the example of hepatocellular 
carcinoma (Rabbani et al., 2018; Xue et al., 2016). Therefore, Glo1 inducers can 
be utilized as a cancer therapeutic strategy for patients who are at high risk 
(Rabbani et al., 2017).  
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1.3.5.2 Glyoxalase 1 gene amplification in tumours
         High Glo1 expression has been discovered in various clinical tumours as 
illustrated in Figure 8. For instance, lung, stomach, liver, skin, prostate, breast and 
colon cancer (Bair et al., 2010; Ranganathan et al, 1995; Rulli et al., 2001; Geng 
et al., 2014; Cheng et al., 2012; Amatschek et al., 2004; Davidson et al., 1999; 
Sakellariou et al. 2016; Fonseca-Sanchez et al., 2012; Zhang et al., 2014; Zhou et 
al. 2015). Glo1 expression presented robust nuclear and cytoplasmic positivity 
where it is ca. 2-fold relative to normal tissues. Tumours that have an elevated 
expression and activity of Glo1 may have increased tumour growth with a high 
glycolytic rate. 
              There is a positive correlation between the GLO1 high copy number with 
the expression of Glo1 mRNA and protein and is a common feature in how 
multiple human malignancies progress. It is also positively correlated with 
tumour grade where the grade is based on how the morphological appearance of 
the tumour cells and growth patterns differ with normal cells, which is essential 
for the prognosis of patients (Fonseca-Sánchez et al., 2010). Patients with grade 3 
tumours have an undifferentiated, aggressive phenotype due to a loss of tubules 
and the elevated activity of mitosis where the 5-year overall survival rate is 50|% 
(Fonseca-Sánchez et al., 2010).  
             On the other hand, patients with tumours with grade 1 and 2 have an 
overall survival rate of 90% and 75% respectively. This highlights the potential 
use of GLO1 as a novel biomarker for tumours and to diagnose patients with and 
without aggressive tumours (Fonseca-Sánchez et al., 2010). However, the 
presence of GLO1 in the nuclear fraction can be found in approximately 10% of 
tumours which illustrates the role of GLO1 in MG metabolism to prevent the 
formation of nuclear-advanced glycation end-products (Fonseca-Sánchez et al., 
2010).  
            Santarius et al. revealed that the cancer that had the highest expression of 
Glo1 gene amplification was breast cancer by (22%), followed by sarcomas at 
(17%) and NSCLC by (11%) (Santarius et al., 2010). In addition, triple negative 
breast cancers that do not comprise of HER-2, oestrogen and progesterone 
receptors have high GLO1 gene amplification (Shafie et al., 2014). This suggests 
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that the increase in the expression and activity of GLO1 implemented by tumour 
cells with an aggressive phenotype has been induced by the high intracellular 
levels of MG with high glycolytic rates. Therefore, GLO1 plays a significant role 
in when the tumour initiates, during malignant progression and treatment failure. 
             siRNA knockdown of Glo1 in tumours with high glycolytic rates 
increases the formation and cytotoxicity of methylglyoxal (Santarius et al., 2010). 
Xue et al. discovered that siRNA knockdown of Glo1 increases sensitivity to 
doxorubicin and in absence of the drug treatment in the metastatic human 
carcinoid pancreatic tumour cell line (BON-1) in vitro (Xue et al., 2016). This 
emphasises that Glo1 expression is associated with the resistance of doxorubicin 
in BON-1 cell lines and can be inhibited through the cell permeable Glo1 
substrate inhibitor (Sakamoto et al., 2001; Santarius et al., 2010). 
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Figure 8: The Protein expression files of GLO1 in varied tumours. A. Quantitative analysis of the expression of Glo1 in different 
tumours B. The immunohistochemistry profile of protein expression of Glo1 (The Protein Atlas, 2018)
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1.3.5.3 Overexpression of Glo1 causing multi-drug resistance 
             An elevated expression of Glo1 was found in clinical refractory tumours 
where Glo1 was discovered to be a negative survival factor for cancer treatment 
by preventing the accumulation of the cytotoxic MG which suppresses the ME-
defrived glycation leading to the formation of AGEs (Rabbani et al., 2018, 
Beroukhim et al., 2010; Cheng et al., 2012; Xue et al., 2016; Thornalley et al., 
1996; Hudis and Gianni, 2011; Santarius et al., 2010). There are two main causes 
of Glo1-linked MDR: high glyoxalase 1 gene amplification and elevated 
transcriptional activity of Nrf2 via ARE-linked up-regulation of GLO1 
transcription (Rabbani and Thornalley and Rabbani, 2011; Rabbani and 
Thornalley, 2015; Rabbani et al., 2017; Rabbani et al., 2018). Xue et al. 
discovered that Nrf2 undergoes translocational oscillations between the cytoplasm 
and the nucleus and this is associated with a stress-stimulated cytoprotective 
response which suggests that the stimulation of Nrf2 improves treatment of 
disease with current therapy (Xue et al., 2015). Glo1 may contribute to both 
acquired and innate MDR but the degree of resistance is dependent on the types of 
chemotherapeutic agents (Rabbani and Thornalley, 2011a).  
             High Glo1 expression was discovered in hepatocellular carcinoma (HCC) 
where there was a low prevalence of GLO1 gene amplification (6%) which 
emphasises that increased expression of Nrf2 may cause high Glo1 expression 
reducing survival (Zhang et al., 2015; Thornalley et al., 2009). Nevertheless, 
despite there were recent advances in the modalities of treatment, HCC still has 
chemotherapeutic resistance (Hollebecque et al., 2015).  
             Glo1-linked MDR was at first studied by Ranganathan et al. using 
fibroblasts as a model and they discovered that resistance increased to the anti-
cancer drugs doxorubicin and mitomycin C (Ranganathan et al., 1995). Tsuruo et 
al. also observed that Glo1 overexpression caused MDR in leukaemia cells. The 
DNA segment amplified in tumour GLO1 amplification was larger than in low 
level duplication in the healthy population (Shafie et al., 2014). However, Glo1 
inhibitor improved the effectiveness of treatment for Glo1-mediated MDR tumour 
cell lines and tumour-bearing mice (Sakamoto et al., 2000; Hosoda et al., 2015; 
Santarius et al., 2010; Sakamoto et al., 2001). This indicates that current anti-
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cancer drugs increase the cellular concentration of MG and cytotoxicity as part of 
their mechanism. This can be through directly inhibiting the expression and the 
modification by MG of the Mitochondrial Permeable Transition Pore (mtPTP) - 
Figure 9. mtPTP is a non-specific channel that resides in the inner mitochondrial 
membrane and translocates <1.5 kDa such as cyclophilin D and VDAC 
contributing to the formation of mtPTP (Rabbani et al., 2018; Vianello et 
al.,2012). MG modification of mtPTP stimulates the release of cytochrome c from 
mitochondria (Speer et al., 2003; Thornalley and Rabbani, 2011c). The third cell 
death mechanism induced by MG is the modification of DNA which causes DNA 
strand breaks resulting in replicative stress and caspase 2 induced apoptosis – 
“replication catastrophe” (Rabbani et al., 2018).  
           Another study revealed that MG-induced apoptosis prevented proliferation, 
migration and invasion of colon cancer cells by down-regulating c-Myc protein. 
Consequently, this lowered glucose consumption, lactate, and ATP production 
and lowered c-Myc protein levels. This emphasises the anti-tumour role of MG in 
colon cancers (Du et al., 2000; Taniguchi et al. 2012). 
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Figure 9: Cell death mechanisms stimulated by methylglyoxal (Rabbani et al., 2017)
 High levels of methyglyoxal can induce apoptosis, necrosis, and anoikis. There are three main mechanisms: the modification of the extracellular 
matrix (ECM), the modification of the mitochondrial permeable transition pore (MPTP) and the modification of DNA.
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1.3.6 Therapeutic approaches to Glo1-linked MDR 
1.3.6.1 Anti-tumour activity of glyoxalase 1 inhibitors 
          Vince and Wadd first proposed that inhibition of Glo1 might also lead to 
increased endogenous MG to cytotoxic levels and Glo1 inhibitors as a potential 
new class of anticancer therapeutic agents (Vince and Wadd, 1969). Their initial 
design of Glo1 inhibitors was based on GSH conjugates which were Glo1 
substrate analogues. A prototype Glo1 inhibitor was S-p-bromobenzylglutathione; 
Ki for human Glo1 = 160 nM (Allen et al., 1993b; Vince et al., 1971). GSH 
conjugates have poor cell permeability and are unstable to cleavage by γ-glutamyl 
transferase on the cell surface and extracellular fluid.  
          These barriers to Glo1 inhibitor development were solved by Lo and 
Thornalley (1992) where cell permeability was facilitated and stability to γ-
glutamyl transferase acquired by diesterification of GSH conjugate inhibitors. 
GSH conjugate diesters are prodrugs of Glo1 inhibitor and when delivered to the 
tumour, the ester groups were removed by non-specific esterases and the Glo1 
inhibitor revealed. This led to the first evidence of potent antitumour activity of a 
Glo1 inhibitor prodrug in vitro and in vivo illustrated in Figure 10 (Lo and 
Thornalley, 1992; Thornalley et al., 1996). The optimum ester derivative was S-p-
bromobenzylglutathione cyclopentyl diester SpBrBzGSHCp2 (Thornalley et al.,
1996). SpBrBzGSHCp2 had antitumour activity in vitro and in vivo and lifted 
multidrug resistance against tumours with high Glo1 expression. SpBrBzGSHCp2 
remains today the most effective treatment for some experimental MDR tumors in 
mice (Sakamoto et al., 2001; Thornalley et al., 1996). 
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Figure 10: Experimental studies determining the effect of Glo1 inhibitor in in 
vitro and in vivo studies. (A) Inhibition of human leukaemia 60 cell growth by the 
cell-permeable Glo1 inhibitor prodrug, SpBrBzGSHCp2. The viable cell number 
(percentage of control %) decreases as the concentration of the Glo1 inhibitor 
increases. The most significant effect was with 200 mg/kg of the Glo1 inhibitor in 
comparison to the control. (B) Murine mouse models: MAC15A (colon), 
DMS114 (lung) and DU145 (prostate).  MAC15A illustrates that as the dose of 
the Glo1 inhibitor (mg/kg) increases, the tumour mass decreases whereas for 
DMS114 and DU145 illustrate that the relative tumour volume increases as the 
duration of the incubation with the Glo1 inhibitor increases. The relative tumour 
volume can be determined by multiplying the absolute tumour volume of the 
respective tumour on the day by the absolute tumour volume of the same tumour 
on the baseline when the treatment was initiated. (Thornalley et al. 1996; 
Sakamoto et al. 2001). 
                 Further developments of substrate analogue Glo1 inhibitors produced 




including bivalent inhibitors – two substrate analogue inhibitors with a linker 
structure where the inhibitor binds to both of the two active sites of Glo1. The 
most potent inhibitor of Glo1 has an inhibitor constant Ki values of 0.96 nM for 
human Glo1 (More and Vince, 2009; Murthy et al., 1994; Zheng and Creighton, 
2003). These inhibitors are based on the glutathione peptide backbone and hence 
require pro-drug ester modification for delivery into tumour cells and tissue. 
Delivery of the prodrug inhibitors is potentially impaired by plasma non-specific 
esterase where the essential prodrug modification maybe removed prior to tissue 
delivery.  
            Creighton and co-workers made the critical observation that plasma 
esterase activity of in-bred strains of laboratory mice have markedly higher 
plasma esterase activity than in human serum such that the half-life of S-(N-p-
chlorobenzyl-N-hydroxycarbamoyl) glutathione ethyl diesters was ca. 9 h in 
human plasma but < 30 s in serum samples obtained from inbred strains of 
laboratory mice used to evaluate chemotherapeutic agents against murine 
tumours. Fortunately, esterase deficient DBA/2 C57BL/6 mice were identified 
that could be used for appropriate evaluation of these prodrugs. Potent anti-
tumour activity in vivo of Glo1 inhibitor prodrugs was thereby achieved (Cameron 
et al., 1999; Sharkey et al., 2000). 
          Some other compounds have been claimed to be Glo1 inhibitors – such as 
methotrexate (Ki = 20 μM) and curcumin (Ki = 5.1 μM) (Bartyik et al., 2004; 
Santel et al., 2008). However, this is ca. 120 and 30-fold less potent than 
BrBzGSH. Peak plasma concentrations of methotrexate are ca. 16 μM in cancer 
chemotherapeutic use, so some anti-tumour activity of methotrexate may be 
linked to inhibition of Glo1. Extremely high doses of curcumin, 8 g per day, 
achieved peak plasma concentrations of ca. 1.8 μM and it is unlikely to provide 
potent inhibition of Glo1 in vivo (Cheng et al., 2001; Widemann and Adamson, 
2006). Delphinidin is a dietary anthocyanidin that is found in berry fruits and was 
found to inhibit human Glo1 (Ki = ca. 280 nM) but was ca. 10-fold less potent 
than SpBrBzGSHCp2 against HL60 cells in vitro (Takasawa et al., 2010). 
Troglitazone inhibited Glo1 (Ki = ca. 8 μM) but peak plasma concentrations in 
vivo were only ca. 4 μM; suggesting this too is unlikely to be an effective Glo1 
inhibitor (Loi et al., 1999; Wu et al., 2001). Anti-cancer drugs showing little 
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Glo1-mediated MDR are likely an optimum choice for tumours with high Glo1 
expression (Thornalley and Rabbani, 2011b; Thornalley and Rabbani, 2011c). 
        Despite cell permeability of SpBrBzGSHCp2, relatively high doses (50-
200 mg/kg) were required for antitumour activity in mice. This may have been 
due to the high esterase activity of mice – not present in human subjects.  MG is 
metabolised by AKR enzymes that have been upregulated by Nrf2 and this causes 
overactivation in tumours (Rabbani et al., 2017). They are highly expressed in 
adenocarcinomas and there is evidence that AKR activity influences its potency 
(Rabbani et al., 2018). Moreover, there are some tumour cell lines that are 
resistant to Glo1 inhibitor and some are sensitive. A recent study discovered that 
there are Nrf2 activators that induce the expression of Glo1, AKR and 
dehydrogenase enhances to increase MG metabolism (Chen et al., 2012).  
1.3.6.2 Anti-tumour activity by silencing Glo1 by siRNA. 
Small interfering ribonucleic acid (siRNA) is non-coding double-stranded 
RNA molecule that consists of 21-23 nucleotides with the 3′ two-nucleotide 
extended (Lam et al., 2015). It is formed by the processing and cleavage of the 
long double-stranded RNA mediated by the enzyme RNase III-like enzyme Dicer 
(McNamara et al., 2006; Dana et al. 2017). It is a potential therapeutic target due 
to its ability to evade specific genes in the treatment of cancer and other diseases 
(Dana et al. 2017). It has also been utilized as a tool to investigate the function of 
single genes in vivo and in vitro.  
              The siRNA can enter the cytoplasm where it directly associates with the 
multiprotein component complex called RNA induced silencing complex (RISC) 
(Hammond et al., 2000). The RISC protein is part of the argonaute family (Ago2) 
(Meister et al., 2004). The siRNA strands are separated where the strand with a 
stable 5’-end is incorporated into the RISC complex whereas the passenger strand 
leaves. The RNA interference is initiated by the anti-sense single-stranded siRNA 
that aligns and cleaves the target mRNA via the catalytic mechanism of the RISC 
protein causing degradation (Zamore et al., 2000). The siRNA-RISC complex has 
also been linked with the nucleolus region where it can enter or leave the nucleus 
(Dana et al. 2017). 
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            Previous studies have shown that GLO1 silencing can increase the 
concentration of MG and increase cell sensitivity to chemotherapeutic agents 
(Chen et al. 2017; Sakamoto et al. 2000; Hutschenreuther et al., 2016). This, in 
turn, increases anti-proliferative, apoptotic, and oxidative stress-induced effects 
(Bair et al. 2010, Xue et al., 2017). Chen et al. revealed that a combination of MG 
with GLO1 silencing further increases the synergistic inhibitory effect on cell 
viability and proliferation (Chen et al. 2017). This can be achieved through 
increased expression of the tumour suppressor signal transducer and activator of 
transcription 1 (STAT1) and the proapoptotic protein Bcl-2-associated X (Bax) 
and the reduction in the level of the enzyme metalloproteinase 9 (MMP9) and the 
B-cell lymphoma protein-2 (Bcl-2) where the latter consists of anti-apoptotic and 
pro-apoptotic proteins that modulate the cell cycle (Chen et al. 2017; Guo et al., 
2016). Bcl-2 plays a major role in regulating the intrinsic apoptotic pathway 
particularly in the mitochondrial release of cytochrome C and its ability to 
associate with Apaf-1 via the interaction with Bax (Guo et al. 2016). Moreover, 
Braun et al. revealed that the increased level of methylglyoxal that downregulate 
migration and invasion depend on the 53 kDa phosphoprotein, p53 (Braun et al.
2019; Berkers et al. 2013). 
            Moreover, recent studies have suggested that miRNAs also have a role in 
how Glo1 silencing can inhibit tumour progression. For instance, high levels of 
miR-137 can decrease the endogenous expression of GLO1 causing anti-
proliferative effects in melanoma (Lv et al., 2018).
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1.3.6.3 Glo1 inducers
              Dietary bioactive compounds were screened for their ability to induce 
expression of Glo1 or “Glo1 inducer” activity. The optimum Glo1 inducer was 
composed of two compounds: trans-resveratrol and hesperetin. Trans-Resveratol 
is a natural polyphenol found naturally in red grapes (Shakibaei et al., 2009). Its 
structure has 2 aromatic rings associated with methylene bridge and has trans 
isomers (Baur and Sinclair, 2006). Hesperetin is a flavanone that is naturally 
found in lemons, oranges and citrus fruits and could be used for natural traditional 
remedies (Khan et al., 2014; Bai et al. 2016). The suggested mechanism of action 
involves anti-inflammatory activity – Figure 11.  Clinical treatment with the Glo1 
inducer decreased expression of RAGE in healthy human subjects (Xue et al., 
2016). Decreased expression of RAGE may decrease tumour development, 
growth and metastasis which may also contribute to a cancer chemopreventive 
response (Taguchi et al., 2000). 
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Figure 11: The role of Glo1 inducer in cancer and diabetes (Xue et al. 2016). 
Glo1 inducer has a chemopreventative effect in non-malignant states where it can decrease the expression of RAGE which influences AGEs. Yellow and 
red arrows reflect improvements of health and suppression of damaging mechanisms respectively.
97 
            Moreover, resveratrol increases the cytotoxicity of anti-cancer drugs and 
this has been demonstrated through doxorubicin (Mitani et al., 2014). Under 
hypoxic conditions, MCF-7 breast cancer cells acquire doxorubicin-resistance and 
at a concentration of 10 µM, Mitani et al. discovered that resveratrol and one of 
its derivative 3,5-dihydroxy-4'-methoxy-trans-stilbene can alleviate this resistance 
(Mitani et al., 2014). 
1.4 Glyoxalase 2
1.4.1 Structure
          Human Glo2 is a monomeric zinc thiolesterase that consists of two major 
isoforms: mitochondrial Glo2 with a molecular mass of 33,806 Da and the 
cytosolic Glo2 with a molecular mass of 29, 200 Da (Xue et al., 2011). The pI in 
both isoforms was 8.3 (Xue et al., 2011). Cytosolic Glo2 is composed of two 
domains: N-terminal that contains 1-173 amino acids and the C-terminal consist 
of 174-260 residues that are folded into five alpha helices (Cameron et al., 1999). 
It is a four-layered beta sandwich with two mixed β-sheets that is flanked with an 
α-helical domain and resembles that of metallo-β-lactamases (Cameron et al., 
1999; Xue et al., 2011). The topology of the first half of the sandwich has a 
βββαβαββ whereas the second half is aligned at 20° to the first and consists of a 
ββββαβ unit. The ββββαβ motif from the two halves: β1β2β3α1β4 and 
β8β9β10α3β11 can be overlaid by a two-fold rotation. The residues 136-141 
reside directly after β10 to create a β hairpin at 80° to the direction of β10. This is 
a fragment of an extended loop structure that is not present in the N-terminal half 
of the sandwich (Xue et al., 2011). 
   The active site of Glo2 contains the substrate binding site that spreads 
over the domain interface and binuclear metal ion-binding location (Cameron et 
al., 1999; Limphong et al., 2009; Xue et al., 2011). There are two metal ion 
binding sites that contain iron and zinc (Xue et al., 2011). The zinc site is a vital 
factor for the structure of the protein and the catalytic activity-substrate 
hydrolysis. The first metal-binding site consists of three conserved histidine 
residues linking water/hydroxide with aspartic acid. The second metal binding site 
contains two histidines that associate water/hydroxide ions that are fused with the 
water; these bounds terminally to aspartic acid and an associated aspartic acid 
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(Limphong et al., 2009). Besides, there is a hydroxide ion arranged to both metal 
ions and reside 2.9˚A from the carbonyl carbon of the substrate and acts as a 
nucleophile during catalysis (Xue et al., 2011). Moreover, there are several amino 
acids in the active site: lysine, arginine and histidine based on the chemical 
modification of Glo2 (Dragani et al., 1999).  
             The activity of Glo2 mainly takes place in the cytosol where it accounts 
85-90%. The mitochondrial Glo2 does not play a major role in MG detoxification 
even when overexpressed (Cordell et al., 2004). Therefore, MG and S-D-
lactoylglutathione are produced in the cytosol where glycolysis takes place. 
However, there is a possibility that the mitochondrial Glo2 is involved in the 
regulation of the redox state because mitochondria are where ROS are mainly 
produced (Cordell et al., 2004). Moreover, Rabbani et al. suggested it may play a 
role in hydrolysing S-acyl glutathione esters in mitochondria formed during the 
acyl exchange from acyl-CoA to GSH (Rabbani et al., 2014; Rabbani and 
Thornalley, 2015). 
1.4.2 Genetics and Polymorphisms
          HAGH (hydroxyacylglutathione hydrolase) is the gene for human Glo2 
(Thornalley, 1990). It is localized on chromosome 16p13.3 (Xue et al., 2011). 
Genetic polymorphisms are rare and two genotypes are known: HAGH1 and 
HAGH2 (Allen et al., 1993a; Thornalley, 1990). HAGH consists of 10 exons 
which are transcribed to dual distinct mRNA species from 9 and 10 exons that 
vary in function (Thornalley, 1993; Xue et al., 2011; Shafie et al., 2014). The 10-
exon-derived transcript compromises of a termination codon between two 
initiating AUG codons and encodes the cytosolic form of Glo2 whereas the 9-
exon-derived transcript encodes both the cytosolic and mitochondrial types 
whereby the AUG codon in the mRNA sequence initiates Glo2 to target 
mitochondria. On the other hand, the cytosolic Glo2 starts by the entry of the 
internal ribosome entry at a downstream AUG codon (Xue et al., 2011, Cordell et 
al., 2004, Choudhary et al. 2009). 
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1.4.3 Substrate specificity
             Glo2 has broad substrate specificity for glutathione thiol esters, 
particularly S-2-hydroxyacylglutathione derivatives (Xue et al., 2011). The 
glutathione moiety is tightly linked to the protein via glycine and cysteine 
residues. The γ-glutamyl does not interact with the protein. This varies with what 
has been observed in Glo1, whereby in the same ligand, the γ-glutamyl and 
glycine residues are involved in hydrogen-bonding interactions with the protein. 
The three basic residues that are in proximity to the carboxylate group of glycine: 
Lys-143, Lys-252 and Arg-249 (Rabbani and Thornalley, 2012b; Xue et al., 
2011). Lys-252 and Arg-249 form part of the α-helix of the second domain and 
within the range of the hydrogen-bonding distance of the carboxylate (Xue et al., 
2011). In addition, other hydrogen-bonding interactions solidify Arg-249 into a 
position whereby the carboxylate of Asp-253 and the carbonyl oxygen of Cys-141 
is situated on the hairpin (Cameron et al., 1999). 
1.4.4 Enzyme Kinetics
          Glo2 catalyses the hydrolysis of S-D-lactoylglutathione to GSH and D-
lactate. The Km is 146 M and the kcat value is 727s-1 (Xue et al., 2011). Glo2 is an 
efficient enzyme; the kcat/Km value is close to the diffusion limit using S-D-
lactoylglutathione as the substrate (Cameron et al., 1999). It has a broad optimum 
pH as Glo2 is isolated from human liver and have shown no difference in activity 
between the ranges 6.8 and 7.5 (Xue et al., 2011). The catalytic mechanism 
involves a nucleophilic attack on C1 atom of the substrate by the active site bound 
water molecule (which has a low pKa value) (Xue et al., 2011). The product is 
then formed by hydrolysing the C-S bond (Wendler et al., 2009; Xue et al., 2011; 
Cameron et al. 1999). 
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1.4.5 Glyoxalase 2 and its association with cancer 
             Despite the focus of the project is related to the role of Glo1 
overexpression in multidrug resistance in cancer chemotherapy, it is important to 
highlight the role of Glo2 in tumours because it hydrolyses S-D-lactoylglutathione 
to the less toxic D-lactate (Martins et al., 2001). Moreover, the regeneration of 
GSH from the oxidized glutathione produced from Glo1-catalysed reaction 
maintains the redox state within the cell. This represents a critical step in cellular 
defence against MG toxicity (Thornalley, 2008).  
                  Xu and Chen (2006) revealed that Glo2 is a novel target of the 
transcription factors p63 and p73. Both p63 and p73 share a similar structural 
homology with the tumour suppressor p53 and can bind to p53 responsive element 
to activate some of its target genes such as mouse double minute 2 (MDM2), p21, 
DNA polymerase Eta (POLH) and ferredoxin reductase (FDXR) that aid in the 
development of cells (Harms et al., 2004; El-Deiry et al., 1993; Wu et al., 1993; 
Liu and Chen, 2002). Mutations of p63 and p73 rarely occur in tumours. It can 
also upregulate the GLO2 gene by bounding to intron 1 on its gene.
              Overexpression of cytosolic Glo2 protects cells from MG-induced cell 
death by inducing DNA damaged-induced apoptosis in a p53-dependent manner. 
Godbout et al. have shown that knockdown of GLO2 synergistically acts with 
cisplatin to induce apoptosis (Godbout et al., 2002). This emphasises the 
association between p53 and the glyoxalase system in the normal development 
and pathogenesis of various human diseases especially in tumours (Moll and 
Slade, 2004). 
             There is evidence that there are high genetic expression and activity of 
Glo1 and Glo2 in breast and bladder cancer and this is due to the limited supply of 
oxygen during tumour progression where they increase aerobic glycolysis to 
produce sufficient energy and maintain balance (Rulli et al., 2001; Moll and 
Slade, 2004). 
However, in other tumours, there are high levels of Glo1 but low Glo2 
emphasising the role of these enzymes in chemotherapy resistance by decreasing 
MG. For instance, Antognelli et al. discovered that there are low levels in kidney 
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adenocarcinoma which emphasises the role of S-D-glutathione in supplying 
energy in high proliferating cells. It also highlights the importance of Glo1 
inhibitors as anti-tumour drugs (Antognelli et al. 2006).  
             Ngyuen et al. revealed that Glo2 correlates with redox signalling and 
increases expression of oxidative genes, for instance, catalase, nicotinamide 
nucleotide transhydrogenase, hydroxyacid oxidase 1, hydroxyacid oxidase 2, 
paraoxonase 1, paraoxonase, epoxide hydrolase 2, arylamine N-acetyltransferase 
1 and glutaredoxin. This suggests the significant role of Glo2 in hepatocellular 
carcinoma progression where elevated levels increase better clinical survival 
outcomes and is a potential prognostic marker of precision medicine and potential 
therapeutic target in its treatments (Ngyuyen et al. 2018).  
             Antognelli and Talesa (2018) revealed that Glo1 and Glo2 maintain the 
metastatic phenotype non-enzymatically in some malignant tumours via 
PTEN/PI3K/Akt/mTOR pathway involving pyruvate kinase isozymes M1/M2 
(PKM2) and oestrogen receptor-alpha (ERα). Therefore, Glo1 silencing and the 
Glo2 ectopic expression (pCMV-GLO2) are needed to maintain migration, 
invasion and EMT (Antognelli and Talesa, 2018).  Recent studies have suggested 
that Oleuropein, a bioactive plant-derived compound exhibits anti-tumour activity 
via the mitochondrial apoptotic pathway by upregulating mitochondrial Glo2 that 
is stimulated by the superoxide anion and the Akt signalling pathway by 
interacting with the proapoptotic protein Bax (Antognelli et al. 2019). 
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1.5 Other putative enzymatic pathways of MG detoxification
          Aldehyde dehydrogenases (ADHs) and aldo-keto reductases (AKRs) also 
metabolise MG to contribute to the enzymatic defence against MG glycation. This 
prevents the formation of glycation adducts and repair damaged sites caused by 
early glycation (Allaman et al., 2015; Rabbani and Thornalley, 2014b; 
Thornalley, 2003). Nevertheless, both enzymes have a minor role in their 
metabolism compared to the glyoxalase system (Rabbani et al., 2016a; Rabbani 
and Thornalley, 2016). 
MG is metabolised to hydroxyacetone (95%) and D-lactaldehyde by 
NADH-dependent aldo-ketoreductase isozyme 1B1 (aldose reductase) 
(Thornalley, 1994). Both products can then be reduced further by AKR to 
propanediol. This mechanism was observed using the yeast Hunsenulu mrakii as a 
model. Besides, studies have revealed that Glo1 activity exceeds AKR activity by 
>30-fold in all human tissues with exception of the renal medulla whereby the 
AKR expression is advanced (Rabbani et al., 2016). 
           There are two types of dehydrogenases: NAD+-dependent betaine aldehyde 
dehydrogenase and NADP+-dependent dehydrogenase which catalyses the 
oxidation of MG to form pyruvate (Rabbani et al. 2014; Rabbani et al., 2016). 
This mechanism can be observed in the gram-negative bacterium; Pseudomonas 
putida as a model (Allaman et al., 2015). The expressions of AKRs, ADH and 
Glo1 under basal and inducible conditions are regulated by Nrf2 via regulatory 
AREs (Rabbani et al., 2016; Xue et al., 2012; Rabbani and Thornalley 2011a). 
Metabolism of MG and glyoxal by reductase occurs in the renal medulla where 
the expression of AKR outweighs that of Glo1 (Nishimura et al., 1993). 
          There is a third type of glyoxalase called glyoxalase III. It is an MG 
oxidoreductase purified from Escherichia coli (Misra et al., 1995). Its distinctive 
functional role is to convert MG to D-lactate without utilizing the GSH cofactor 
and does not form the intermediate S-D-lactoylglutathione. The specificity 
constant of glyoxalase III in E. coli was discovered to be 7.4 x 108 M-1min-1 and 
this was ca.7,000 fold higher than the specificity constant found by Lee et al. 1.1 
x 105 M-1min-1 (Lee et al., 2012, Clugston et al., 2004). Moreover, another 
oxidoreductase is DJ-I isoenzymes but has a significantly low specificity ca.
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10,000-fold less in comparison to human Glo1. The low specific activity 




         The cofactor GSH is a linear tripeptide with a mass of 307 Da and is 
composed of three amino acids: L-cysteine, glycine and L-glutamate. It is highly 
abundant in cells and consists of more than 90% total cellular non-protein sulphur 
(Meister, 1988). The intracellular concentration of GSH is between 0.5 to 10 mM 
whereas the extracellular level is much lower (Lushchak, 2012). 
         The concentration of glutathione is high in the liver which is crucial for 
detoxification and is a natural part of the immune system. The levels of GSH is 
decreased by oxidative stress and low in situ glutathione reductase activity in 
diabetic patients (Thornalley et al., 1996). In the latter, this increases the risk of 
oxidative damage and glycation mediated by α-oxoaldehydes by lowering the 
activity of Glo1 (Thornalley et al., 1996). 
          GSH is a pivotal redox agent that is under homeostatic control between its 
synthesis, recycling and utilization. The formation of GSH consists of two 
enzymatically-controlled reactions that employ ATP: cysteine and glutamate 
condense by γ-glutamyl cysteinyl synthetase to form γ-glutamylcysteine. This is 
followed by conversion of γ-glutamylcysteine to GSH, catalysed by GSH 
synthetase (Franco et al., 2007). The recycling of GSH is catalysed by glutathione 
reductase where nicotinamide adenine dinucleotide phosphate, reduced form 
(NADPH) is used to re-convert oxidised disulphide (GSSG) to GSH.  
          GSH is consumed in many processes, for instance, conjugation, oxidation 
and hydrolysis (Halliwell and Gutteridge, 1988). It is directly oxidized by ROS 
and reactive nitrogen species (RNS). It is also indirectly oxidized during the GSH-
dependent peroxidase-catalysed reactions (Zhang and Forman, 2009). 
Conjugation with exogenous and endogenous electrophiles consumes a significant 
amount of cellular levels of GSH (Zhang and Forman, 2009). Extracellularly, 
GSH is hydrolysed by γ-glutamyl transpeptidase and the transfer process can 
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result in the glutamyl moiety of GSH to the peptides and amino acids or the 
glutamyl functional group to water to produce free glutamate (Zhang and Forman, 
2009). As GSH is being consumed, the glutathione redox cycle keeps GSH 
repleted. γ-glutamyl transpeptidase and cysteinyl-glycine dipeptidase catalyse the 
degradation of GSH into its amino acid subunits (Griffith, 1999; Meister, 1988; 
Meister and Anderson, 1983). 
           The principle biological mechanism of GSH is to protect against ROS, 
RNS and electrophiles (Lushchak, 2012). GSH is the primary protectant of the 
skin, retina, lens and cornea against radiation. It has additional functions in the 
cells such as storing and transporting nitric oxide, facilitates the metabolism for 
oestrogens, prostaglandins and leukotrienes (Birben et al., 2012). It can also be 
used as a cofactor to detoxify several endogenous compounds and to reduce 
ribonucleotides to form deoxyribonucleotides (Deponte, 2013; Lushchak, 2012).  
1.6.1.1 Reduced glutathione and its association with cancer 
The homeostasis of the antioxidant GSH plays a significant role in various 
cell parameters, for instance, differentiation, proliferation and apoptosis 
(Balendiran et al. 2004). Increased production of GSH and NADPH combats the 
effects of the relatively elevated levels of oxidative and nitrosative stress which is 
often linked with chemotherapy-induced apoptosis (Hussain et al., 2003; Cairns et 
al., 2011; Couto et al. 2016). This has been found in various tumours, for 
instance, liver cancer, melanoma, NSCLC and medulloblastoma, making 
neoplastic tissues more resistant to chemotherapy (Carretero et al. 1999; Marengo 
et al. 2010; Joseph et al. 2002; Costantini et al. 2000; Yoo et al., 2019; Colvin et 
al., 1993).  It is caused by high activities of the GSH-associated enzymes, for 
instance, γ-glutamylcysteine ligase (GCL) and γ-glutamyl-transpeptidase (GGT) 
and high expression of GSH-transporting export pumps (Estrela et al. 2006; 
O’Brien and Tew, 1996). GSH is effluxed by cells via GGT metabolism and is 
implied in tumour development (Pompella et al. 2007). 
              One of the chemotherapeutic agents in which GSH mediated resistance 
against are DNA alkylating agents and nitrogen mustards induce resistance by 
conjugating with glutathione and this reaction is catalysed by GST (Fujitani et al.,
2019). This suggests that the intracellular levels of GSH correlate with tumour 
105 
progression and drug resistance (Ballatori et al., 2009; Lv et al., 2019; Ortega et al. 
2011). Low intracellular levels of GSH or the fluctuations of the GSH: GSSG ratio 
can increase susceptibility to oxidative stress and cytotoxicity of several 
chemotherapeutic agents without increasing toxicity to normal tissues (Lau et al., 
2008; Russo et al., 1986; Hussain et al., 2003; Meister 1991). 
             Several mechanisms have been studied to deplete GSH and increase 
sensitivity to chemotherapy, for instance inhibiting GCL, buthionine sulfoximine 
(BSO) and glutathione analogues (Griffith, 1982; Wu and Batist, 2012). Recent 
studies have discovered that GCL induces depletion of GSH at a transcriptional level 
where Nrf2 binds to the ARE in the promoter region of genes encoded by GCL and 
GST (Yoo et al., 2019; Nguyen et al. 2009; Maher et al. 2007). 
1.6.2 S-D-Lactoylglutathione
         In the biological systems, S-D-lactoylglutathione is the physiological 
intermediate of the glyoxalase system (McLellan et al., 1993). It is synthesised 
endogenously from MG and GSH by Glo1 and is then metabolised to D-Lactate 
and GSH by Glo2 (Xue et al., 2011). The location of S-D-lactoylglutathione is 
restricted to the cytosol. This is due to S-D-lactoylglutathione incapable of 
crossing the biological membranes (McLellan et al., 1993).  
          S-D-lactoylglutathione is metabolised by three enzymes: thiolesterases, γ-
glutamyl transferases and dipeptidases. Glo1 hydrolyses S-D-lactoylglutathione to 
GSH and D-lactate. However, when S-D-lactoylglutathione is in the extracellular 
compartment, γ-glutamyltransferase cleaves S-D-lactoylglutathione to S-D-
lacoylcysteineylglycine. S-D-lactoylcysteinylglycine is then spontaneously 
rearranged to N-D-lactoylcysteinylglycine (Tate, 1975; Thornalley and Tisdale, 
1988).  
          N-D-lactoylcysteine inhibits the synthesis of pyrimidines by preventing 
dihydro-oratase (Edwards et al., 1993, Edwards et al., 1996). The addition of 
exogeneous S-D-lactoylglutathione to human leukaemia cells, HL-60 cells results 
in cytotoxicity, growth arrest and preventing the synthesis of DNA where the 
growth inhibitory concentration (GC50) was 82 and 72 µM respectively 
(Thornalley and Tisdale, 1988). It was discovered that the quantity of cells in G0-
G1 phase was relatively higher than that of G2-M phase (Hooper et al., 1987; 
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Hooper et al., 1988). This cytotoxic effect was not observed with GSH, D-lactate 
and a combination of both. The inhibitory effect of S-D-lactoylglutathione on 
proliferation is stimulated by the prevention of uridylate synthesis (Edwards and 
Thornalley, 1994).  
1.6.3 D-Lactate
          There are two major stereoisomers of lactate formed in the human 
intermediary metabolism: D-Lactate and L-Lactate – Figure 12. The concentration 
of L-lactate is efficiently metabolised in humans and has higher fractional renal 
clearance than L-lactate (Connor et al.,1983). It is permeable to cell membranes 
through the inorganic anion transporter, specific lactate transporter and passive 
diffusion of unionised conjugate acid (Oh et al., 1985). D-Lactate is produced 
from the detoxification of methylglyoxal via the glyoxalase system in erythrocytes 
and is a measure of the flux of formation of MG in red blood cells and lens fibre 
cells (Phillips and Thornalley, 1993; Ranganathan et al. 1995). The concentration 
of D-lactate in the blood of normal healthy patients is 11.0 +/- 1.2 (mean +/- SE 
nmol/ml) whereas in diabetic patients there is a significant increase 20.0 +/- 1.3 
(mean +/- SE nmol/ml) (McLellan et al., 1992a). The D-lactate concentration in 
plasma of healthy controls is 2 – 20 µM (De Vrese and Barth, 1991; McLellan et 
al., 1992a).  
              D-lactate can also be ingested in yoghurt and absorbed from the gut flora 
(Ohmori and Iwamoto, 1988; Mortensen et al., 1991). The metabolism of D-
lactate to pyruvate is via the 2-hydroxyacid dehydrogenase; a mitochondrial FAD-
linked enzyme (Ohmori and Iwamoto, 1988; Phillips and Thornalley, 1993).  
          D-Lactate can be quantitatively measured by fluorescent end-point 
enzymatic assay and reverse phase high phase liquid chromatography (HPLC). 
The assay method comprises measuring the concentration by the production of 
NADH linked to the oxidation of D-lactate to pyruvate using the enzyme D-lactic 
dehydrogenase (McLellan et al., 1992a). In the HPLC method, D-Lactate is 
measured by the derivatization of pyruvate with 1,2-diaminobenzene (Ohmori et 
al., 1991). 
107 
Figure 12 - Optical forms of lactate: L (+) and D (−) lactate. (Adapted from Lipsa 
et al. 2010). Lactic acid is chiral and has two optically active isomers. The two 
enantiomers are D-lactate and L-lactate and can be produced by fermentation 
from pyruvate via the enzyme lactate dehydrogenase. The other product from the 
reaction is NAD which is utilized in glycolysis to produce ATP. 
1.6.3.1 The association of D-Lactate with cancer
Tumours have been associated with the dysregulation of glucose 
metabolism which increases the uptake of glucose and cause alterations in the 
metabolic fluxes where there is an increase in the conversion rate from pyruvate into 
lactate; this is known as the Warburg effect (Romero-Garcia et al., 2016; Wu et al., 
2016). Both lactate and pyruvate are utilised by tumour cells to undergo Kreb's cycle 
and oxidative phosphorylation to increase the production of ATP, proliferation and 
the survival rate of the malignantly transformed cells (Pavlides et al., 2012). This 
aids in the prognosis of patients with various tumours (Yao et al., 2014). For 
instance, overexpression of LDH5 increases the risk of mortality by 60% 
emphasising poor clinical survival outcomes, more proliferation and advanced 
Tumour Node Metastasis (TNM) staging in patients with breast cancer (Huang et al. 
2016a). Similar reports have been discovered in patients with cancers of the stomach, 
bladder, pancreas, colon and kidney (Sun et al., 2015; Koukourakis et al., 2016; 
Mohammad et al., 2016; Koukourakis et al., 2011; Girgis et al., 2014).  
              Lactate is a monocarboxylate and it undergoes proton-associated transport 
alongside lactate and ketone bodies across the plasma membrane and into cells 
(Simchowitz and Textor, 1992). This is catalysed by monocarboxylate transporters 
(MCTs) that reside on the plasma membrane, for instance, neutrophils, tumour cells 
and erythrocytes (Halestrap, 2012; Simchowitz and Textor, 1992). MCTs have 
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distinctive affinities for substrates which influences the efflux and influx rate of 
lactate (Halestrap, 2012). MCT1 has low expression and is primarily involved in the 
importation of lactate. MCT2 is expressed in the neurons, kidney, and liver whereas 
MCT3 is found at the choroid plexus and the basolateral retinal pigment epithelium 
(Halestrap, 2012). MCT4 is primarily involved in the exportation of lactate and is 
expressed in the white skeletal muscle. Low levels of MCT4 can be found in the 
lungs, testis, placenta, leukocytes and glial cells such as astrocytes (Halestrap, 2012). 
Several tumours have been associated with the increased expression of MCT1 
whereas MCT4 is linked with tumours associated with poor prognosis (Pinheiro et 
al. 2008). 
           Another factor that influences lactate secretion besides the substrate is the pH 
(Dimmer et al., 2000). The Warburg effect decreases the extracellular pH to 6.0 - 6.5 
(Xie et al., 2014). Lactate can increase vascular endothelial growth factor (VEGF) 
signalling pathway via MCT1 and autocrine angiogenesis under normoxic conditions 
which can trigger the phosphorylation and degradation of  I-kappa-B-alpha (IKB-
alpha) stimulating the nuclear factor kappaB (NF-KBa)/interleukin 8 (IL-8) causing 
T-cell dysfunction and immunosuppression (van der Mijn et al., 2017; Goodwin et 
al., 2019; Fischer et al., 2007; Hunt et al., 2007; Vegran et al., 2011; Fukumura et 
al., 2001; Shi et al., 2000). Lactic acidosis can also increase metastasis by increasing 
the production of MM9 (Kato et al., 2007; Wu et al., 2012). 
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1.6.4 Dicarbonyls
          Dicarbonyl compounds such as α-oxoaldehydes are reactive intermediates 
and saccharide derivatives of the Maillard reaction to form AGES on functional 
arginine residues (Ahmed et al. 2008; Thornalley, 2005). The interrelationship 
between the degradation of glucose to form α-oxoaldehydes was discovered by 
Pinkus in 1898. This led to further developments in understanding their 
quantitative and functional role in the physiological systems. It is important to 
note that the α-oxoaldehydes are 20,000-fold more reactive than glucose to 
produce AGEs (Rabbani and Thornalley, 2008b; Thornalley, 2005). However, the 
concentration of dicarbonyl compounds in the physiological systems is 10,000 - 
50,000 times lower than glucose (Thornalley, 2005).  
          The three main dicarbonyls are glyoxal, MG and 3-DG presented in Figure 
13. The most reactive dicarbonyl that has a relatively high flux of formation in 
vivo and     in vitro is MG which causes arginine-directed glycation to form AGEs 
(Ahmed, 2005; Thornalley 2005). For instance, the glycation of mitochondrial 
proteins induces damage by nitration and oxidation (Pun and Murphy, 2012; 
Thornalley, 2008; Thornalley and Rabbani, 2011a; Thornalley and Rabbani, 
2011b). 
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Figure 13: The Maillard Reaction and Physiological dicarbonyl metabolites (Rabbani and Thornalley, 2008a).
A. the Maillaird chemical reaction. B. Dicarbonyls. The Maillard reaction is a non-enzymatic reaction that increases the production of AGEs that 
contribute to ageing and the pathogenesis of diseases.  
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1.6.4.1 Advanced Glycation End-products (AGEs)
          AGEs are a heterogenous group of compounds. AGEs are formed by the 
degradation of fructosamine-modified proteins and also by the glycation of 
proteins by dicarbonyls. Proteins susceptible to glycation by dicarbonyls are 
called the ‘dicarbonyl proteome’ (DCP) (Thornalley et al., 2003; Rabbani and 
Thornalley, 2008b). Protein damage in vivo are caused by early glycation – 
forming fructosamines, advanced glycation - forming AGEs, oxidation and 
nitration in the physiological systems – Figure 14. They are increased in many 
pathological conditions: diabetes, renal failure, arthritis, and other diseases and 
ageing (Beechtold et al., 2009; Geoffrion et al., 2014; Rabbani and Thornalley, 
2008c; Rabbani and Thornalley, 2009; Thornalley and Rabbani, 2014b; Rabbani 
et al., 2016; Sparvero et al. 2009; Waris et al., 2015).
           An example of an early-stage glycation adduct is Nε-(1-deoxy-D-fructos-
1yl) lysine (FL). It is formed from glucose and increases the concentration of 
glucose. Fructosamine 3-phosphokinase repairs this intracellularly (Rabbani and 
Thornalley, 2008b; Thornalley and Rabbani, 2014b). Methionine sulphoxide is an 
example of an oxidation adduct. It is formed by exposing to hydrogen peroxide, 
peroxynitrite and hypochlorite (Thornalley and Rabbani, 2014b).  
           Other AGEs are also formed in physiologically systems from lysine but 
limitedly: Nε(1-carboxyethyl)lysine (CEL) and Nε-carboxymethyl-lysine (CML) 
from MG and glyoxal, respectively. CML is mainly formed by the oxidative 
degradation of FL (Masania et al., 2016; Rabbani et al., 2016b). There are also 
bis(lysyl) crosslinks: MOLD and GOLD, and trace level formation of fluorescent 
AGEs – pentosidine and argpyrimidine (Rabbani and Thornalley, 2014b; 
Thornalley, 2008). 
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Figure 14 The advanced glycation end-products formed from protein and DNA 
glycation by glyoxal and methylglyoxal (Thornalley, 2008). A. protein-derived 
AGEs with a peptide backbone. B. DNA-derived AGEs with modifications in a nucleic 
acid base with the 3-(2′-deoxyribosyl) moiety.
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1.6.4.2 Quantification of dicarbonyls
            An ongoing problem is the reliable estimation of the α-oxoaldehyde 
metabolites, MG and glyoxal in the physiological systems due to three major 
respects: they may be synthesized by the degradation of glycolytic intermediates, 
monosaccharides and glycated proteins (Thornalley and Rabbani, 2014a; 
Thornalley and Rabbani; 2011a). They do not have strong chromophores 
necessary for spectrophotometric analysis. Interferences during sample processing 
can cause the estimates to be 10-1000-fold higher. One of the potential 
interferences is peroxidase as it catalyses the conversion of 1,2-diaminobenzene 
into trace amounts of these dicarbonyl compounds causing poor specificity 
(Thornalley and Rabbani, 2014a). This causes artefactual overestimation of 
glyoxal and MG measurement. In order to prevent this interference, sodium azide 
is added in the derivatizing buffer (Rabbani and Thornalley, 2014d; Thornalley 
and Rabbani, 2014a). Chemical derivatisation is vital to obtain sensitivity in the 
assay (Rabbani and Thornalley, 2014d; Thornalley, 2008; (McLellan et al., 1992a). 
             The current method employed is the derivatisation with 1,2-
diaminobenzene and two detection methods: LC-MS/MS with stable isotopic 
dilution analysis or via gas chromatography with mass spectrometry (GC-MS) 
(Ohmori et al., 1987; Rabbani and Thornalley, 2012a; Rabbani and Thornalley, 
2014d; Selicharová et al., 2007; Thornalley and Rabbani, 2014a; Lopez-Clavijo et 
al., 2014).  There are several advantages of utilizing 1,2-diaminobenzene, for 
instance, there is high reactivity at low, neutral and high pH, good adduct 
stability, high sensitivity and is commercially available in high purity (Cordeiro 
and Freire, 1996; Beisswenger et al., 2005). However, it has poor sensitivity and 
the 1,2-Diaminobenzene degrades oxidatively to form glyoxal and methylglyoxal. The 
estimated concentrations of MG and glyoxal in human blood plasma are between 
100 – 120 nM (Beisswenger et al., 1999; Strzinek et al., 1972). The cellular 
concentrations of methylglyoxal and glyoxal are in the range 1-5 µM and 0.1 – 1 
µM respectively (Dobler et al., 2006). 
            There are several reasons why the levels of methylglyoxal are measured: 
the characterization of medicinal products, for instance, dialysis fluids. Another 
reason is to develop therapeutics such as Glo1 inducer and Glo1 inhibitor 
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(Rabbani and Thornalley, 2014d). Thirdly, thermally processed beverages and 
foods can be characterized because dicarbonyls are produced from carbohydrates 
during Maillard reactions and Degen et al. discovered that the main dicarbonyl 
found in cookies, fruit juices and balsamic vinegars was  3-DG with a 
concentration of ca. 385 mg/kg, 410 mg/L and 2622 mg/L respectively (Degen et 
al., 2012). There were minimal concentrations of MG in these foods, but a higher 
concentration was established for manuka honey (Degen et al., 2012).  
             Similar reports have been discovered where the concentration of MG 
ranged between 48 and 742 mg/kg-1 and other studies discovered it to be within 
189 to 835 mg/kg-1 (Mavric et al., 2008; Atrott and Henle 2009; Majtan, 2011). 
The level of MG in manuka honey may correlate with the anti-bacterial properties 
that manuka honey holds (Majtan, 2011). These concentrations are higher than 5-
Hydroxymethylfurfural (5-HMF) which is a flavouring compound produced from 
the thermal dehydration of fructose in heat-processed food products (Morales, 
2009).  
              Degen et al. discovered that the concentration in cookies, fruit juices and 
balsamic vinegar was ca. 448 mg/kg, 714 mg/L and 3760 mg/L, respectively. 
However, Ruiz-Matute et al. discovered that levels of 5-HMF in dried fruits are 
above 1 g/kg (Ruiz-Matute et al., 2010). Therefore, due to the presence of MG 
and glyoxal in food, the estimated dietary intake is between the ranges 5 to 20 
mg/day and 20 to 160 mg/day for 3-DG and MG respectively (Degen et al., 
2012). 
          Thus, to investigate the effects of MG, there are two methods: Glo1 
knockdown by siRNA and inhibiting Glo1 via the cell permeable inhibitors such 
as S-p-bromobenzylglutathione cyclopentyl diester (SpBrGSHCp2) (Riboulet-
Chavey et al., 2006; Thornalley et al., 1996). Validation of the estimates gained 
from the physiological samples such as plasma, animal tissue, plant tissue, and 
cultured cells can be performed by kinetic modeling of in situ rates of protein. 
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1.7 Dicarbonyl stress
          Dicarbonyl stress is the abnormal accumulation of α-oxoaldehyde 
metabolites that are developed as a result of an imbalance between the formation 
of dicarbonyl metabolites and their metabolism as well as an enhanced exposure 
to exogenous dicarbonyls (Rabbani and Thornalley, 2015). This increases the 
glycation and modification of proteins and DNA leading to cell and tissue 
dysfunction which contributes to ageing and disease (Rabbani and Thornalley, 
2014a; Rabbani and Thornalley, 2015). There is evidence that there is an increase 
of dicarbonyls particularly MG in diabetes, ageing human lens, renal failure and 
ageing (Rabbani and Thornalley, 2015). The reference ranges of the dicarbonyls 
in human plasma are 50 – 150 nM, 1- 4 µM in mammalian and plant cells 
(Rabbani and Thornalley, 2015). 
          There are a number of clinical implications of reactive dicarbonyls and their 
glycation adducts in pathological processes, ageing and diseases such as 
tumorigenesis, multi-drug resistance, neurodegenerative diseases and diabetes 
(Kuhla et al., 2005; Morcos et al., 2008; Rabbani and Thornalley, 2011; 
Thornalley, 2008; Thornalley and Rabbani, 2011a; Thornalley and Rabbani, 
2011b). An increase in the expression of Glo1 in transgenic rats and mice 
prevented the development of diabetic complications: neuropathy, nephropathy 
and retinopathy (Brouwers et al., 2011; Giacco et al., 2014; Berner et al., 2012; 
Maessen et al., 2014). There was also evidence of an increase in GLO1 mRNA, 
protein and enzymatic activities in the early stage of Alzheimer’s disease with 
levels decreasing during the advanced disease stage (Chen et al., 2004; Kuhla et 
al., 2007).  
               Similarly, there was ca. 50% reduction of the activity of Glo1 and a 
frameshift mutation of GLO1 forming a non-functional peptide in heterozygotes 
that have severe schizophrenia (Arai et al., 2010). However, there was an increase 
of Glo1 mRNA, protein and activity and MG concentration in the mid-brain and 
cortex of alpha-synuclein knockout mice, in comparison to wild type controls 
(Kurz et al., 2011). This emphasises that α-synuclein plays a role in regulating the 
mechanisms that suppress the formation and deletion of MG, thus the expression 
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of Glo1 is increased in response to stress (Kurz et al., 2011). These studies are of 
interest in relation to Parkinson’s disease and other α-synuclein-related diseases. 
              Furthermore, there is evidence that low expression of Glo1 enhances the 
progression in cardiovascular disease (CVD) by increasing atherosclerosis in ApoE 
deficient mice (Makinen et al., 2014; Schalkwijk, 2015; Tikellis et al., 2014). 
Overexpression of Glo1 inhibited the apoptosis of cardiomyocytes, vascularity and 
angiogenesis (Blackburn et al., 2013, Ahmed et al., 2008, Vulesevic et al., 2014). 
It was suggested that downregulation in hypoxia is associated with tissue 
ischaemia (Zhang et al., 2012). 
                There is also an emerging role of Glo1 in chronic kidney disease where 
there was a profound increase in the concentration of MG, 8-fold in comparison to 
control (Rabbani and Thornalley, 2012c; Rabbani and Thornalley, 2018a). An 
experimental study in rats revealed decreased development of renal senescence 
(Ikeda et al. 2011). A reduction in Glo1 expression by frameshift mutation was 
linked to a reduced glomerular filtration rate which may increase the risk of CVD 
(Ikeda et al., 2011; Miyata et al., 2001). 
                Several tumour cell lines have a high activity of Glo1 and are sensitive to 
Glo1 inhibitor, S-p-bromobenzylglutathione cyclopentyl diester (Sakamoto et al., 
2001). There was high Glo1 expression found in refractory clinical tumours. The 
level of Glo1 expression is a negative survival factor in cancer treatment e.g. breasts 
cancer, lung cancer, neuroendocrine tumours and others (Rabbani et al, 2018; Xue et 
al., 2017). It was suggested that GLO1 gene amplification is one of the main causes 
of increased GLO1 expression in some human tumours (Santarius et al., 2010). 
Overexpression of GLO1 is acquired by oncogene-linked malignant transformation 
(Rabbani et al, 2018). It also blocks the activity of several clinical anti-cancer drugs 
in vitro. Glo1 inhibitor, BBGD, improved effectiveness of treatment of MDR 
tumour-bearing mice in vivo (Sakamoto et al. 2000). 
          There have been reports of an anti-stress gene response induced by the 
increased expression of GLO1 via Toll-4 receptor to endotoxaemia (Rabbani et al., 
2016). 
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1.7.1 Biochemical and physiological effects of glycation by 
methylglyoxal 
1.7.1.1 Formation and metabolism of Methylglyoxal
                 MG formation is a fundamental aspect of the Embden-Meyerhof 
pathway. It is produced predominantly inside cells at a relatively high flux (0.05-
0.1%). This is achieved by the non-enzymatic and enzymatic degradation and 
fragmentation of triosephosphate glycolytic intermediates in all organisms with 
anaerobic glycolysis as shown in Figure 15 (Rabbani and Thornalley, 2014a; 
Rabbani et al., 2016; Szent-Györgyi et al., 1967; Thornalley, 1994; Thornalley, 
1996). It has a molecular mass of 72 Da and is highly toxic when in contact with 
proteins and DNA. The most abundant adduct is Nδ-(5-hydro-5-methyl-4-
imidazolon-2-yl)-ornithine (MG-H1) (Rabbani and Thornalley, 2012c). A 
spontaneous small fraction, as a result, is leaked from the metabolic flux and is 
elevated with increased glucose metabolism. It can also occur from other metabolic 
ways: for instance, glyceroneogenesis, photosynthesis and gluconeogenesis where 
triosephosphate is also an intermediate (Thornalley 2005, Rabbani and Thornalley, 
2015). 
         GA3P is 8-fold more reactive than DHAP in degrading to MG whereas 
the concentration ratio of DHAP: GA3P in cells in situ is ca. 9. Consequently, both 
GA3P and DHAP are approximately equally important sources in forming MG 
(Phillips and Thornalley, 1993). Nevertheless, MG formation represents a minor 
fate of triosephosphates based on studies conducted on erythrocytes, endothelial 
cells and fibroblasts whereby only 0.089% glucotriose were converted to MG 
(Rabbani et al., 2016). The overall rate of the cellular formation of MG was 
predicted to be ca. 125 μmol/kg cell mass per day whereby the adult human body 
mass and body cell mass is 70 kg and 25 kg respectively. This equates to an 
estimated whole-body rate of formation of ca. 3 mmol MG per day (Aronsson et 
al., 1978; Rabbani et al., 2016). 
             Other ways in how MG is formed are via the metabolism of acetone (the 
oxidation of acetone from ketone bodies is catalysed by cytochrome E4502 E1), 
monosaccharides via glucose glycation, threonine (degradation of this amino acid 
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via the aminoacetone) and proteins via glucose glycations (Rabbani et al., 2016; 
Thornalley, 1996, Thornalley, 2005). However, these are minor contributions 
especially the oxidation of acetone whose levels are elevated in diabetic 
ketoacidosis (Rabbani and Thornalley, 2014b). It has been reported that MG 
synthases can form MG enzymatically in bacteria but there is no evidence for the 
enzymatic formation of MG from triosephosphates found in the mammalian cells 
(Phillips and Thornalley, 1993). The formation of MG from enzymatic and non-
enzymatic pathways is dependent on the type of organism (Thornalley, 2008).
119 
Figure 15: The sources of formation of methylglyoxal, metabolism and glycation of proteins and DNA in vivo (Rabbani et al., 2016). 
The levels of MG and MG-H1 adducts in tissues are for mice. The levels of the PBMC DNA AGEs, the MG metabolism by the glyoxalase system 
and the urinary excretion of MG-H1 are for human subjects. The concentration of methyglyoxal and MG-H1 is higher in the liver cells (4.3 µM) 
and 0.5 mmol/mol arg respectively in comparison to other cells however the levels of MG-H1 adduct varied in cells of the brain where in the range 
of 0.4 - 0.8 mmol/mol arg. 
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The level of efficiency of MG detoxification is dependent on the 
hemithioacetal formation. At pH 7 in aqueous solution, MG is present in solution 
in three forms under physiological conditions: unhydrated α-oxoaldehyde (1%), 
monohydrated (71%) and dehydrated forms (28%) (Thornalley, 1996; Rabbani and 
Thornalley, 2012a). The unhydrated form can produce the hemithioacetal that 
enters the active site of Glo1. The equilibrium is shifted towards the formation of 
the hemithioacetal when GSH is present resulting in the removal of MG from the 
glyoxalase system (Rabbani et al., 2016; Thornalley et al., 1999; Thornalley, 
2003a). 
              The activity of glyceraldehyde-3-phosphate dehydrogenase (GADPH) 
may also influence the cellular concentration of triosephosphates and thereby the 
formation of MG (Karachalias et al., 2005; Rabbani et al., 2016). The low activity 
of GADPH results in the accumulation of triosephosphate which in turn increases 
the production of MG (Rabbani et al., 2016; Phillips and Thornalley, 1993). 
1.7.1.2 Protein glycation by methylglyoxal
          Glycation of proteins by MG is usually low, occurring on 1 - 5% protein but 
can increase in response to disease and ageing (Rabbani et al., 2016). The major 
MG-derived protein glycation adduct, hydroimidazolone MG-H1, has a urinary 
excretion rate of healthy humans of ca. 10 μmol per day. This indicates that less 
than 1% of MG formed endogenously modifies proteins; the remainder, >99% is 
metabolised by the glyoxalase system as little MG is excreted (Rabbani et al., 
2016). 
             MG reacts with arginine residues forming two adducts: 
dihydroxyimidazolidine and then hydroimidazolone MG-H1. The former is a 
minor unstable adduct whereas MG-H1 has a chemical half-life of ca. 12 days 
through slow reversibility of the formation reaction. This suggests that the protein 
content of hydroimidazolones can be decreased if the concentrations of MG and 
other precursor α-oxoaldehydes are lowered (Ahmed et al., 2003; Thornalley, 
2008).  
          Protein glycation by MG is damaging because the arginine residues modified 
have a high probability of being located in the functional domains of proteins and 
121 
this modification results in loss of charge of the side chain guanidino group 
(Rabbani et al., 2016; Perkins et al., 2008; Duran-Jimenez et al., 2009). For 
instance, arginine residues in the GFOGER and RGD motifs of the integrin-
binding domains of collagen IV that lines the blood vessel walls can undergo MG 
glycation. Modification of MG induces endothelial cell detachment, increasing the 
risk of thrombus formation, anoikis, contact with subendothelium and prevents 
angiogenesis (Rabbani and Thornalley, 2014a; Thornalley, 2008; Dobler et al., 
2006; Yamagishi et al., 2005). The sites where arginine and lysine glycation are 
prone to take place have been hypothesised to be near positively and negatively 
charged amino acid residues that differ by 3-4 residues in the primary sequence. 
Nevertheless, this needs to be experimentally confirmed (Rabbani and Thornalley, 
2012c). 
          After proteins are modified, they are mis-folded and undergo proteolysis in 
the proteasome. Cellular proteins have a median half-life of 32 hours (Gerner et 
al., 2002). Other MG-modified proteins undergo lysosomal degradation in 
macrophages and monocytes (Rabbani et al., 2016; Thornalley, 1996; Thornalley, 
2008). Amongst the consequences of dicarbonyl glycation are: increased formation 
of ROS in response to the dysfunction of mitochondrial protein which in turn 
causes oxidative stress, mitochondrial-activated apoptosis and cell detachment 
from the extracellular matrix and anoikis (Morcos et al., 2008; Rabbani and 
Thornalley, 2015; Rabbani et al., 2016b).  
          Protein glycation also causes covalent cross-linking of proteins producing 
resistance to proteolysis (Rabbani and Thornalley, 2012c; Thornalley, 2008). Non-
sulfhydryl cross-links are also formed between proteins reducing the solubility of 
proteins triggering enzymatic digestion (Schnider and Kohn, 1981). This is crucial 
as they affect the extracellular matrix and connective tissues that consequently 
influence their structural properties and physiological function that increase with 
age (Cárdenas-Leon et al., 2009). For instance, the capillary basement membrane’s 
thickness and rigidity is increased (Lee, 1993; Lee et al., 2016). Thus, AGEs 
influence the function of proteins and the interactions between proteins (Rabbani 
and Thornalley, 2012c). 
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Glycation of proteins affects the proteome in the living systems causing 
many pathological conditions. Protein modification is increased in diabetes and its 
vascular complications causing further damage (Thornalley et al., 2003). 
Methylglyoxal modifies high density lipoproteins (HDL) and low-density 
lipoproteins (LDL). This reduces the concentration of HDL. MG modification of 
LDL leads to the formation of small atherogenic LDL (Godfrey et al., 2014; 
Rabbani et al., 2011a; Rabbani et al., 2011b). Modification of neural voltage gate 
sodium channels by MG increases hyperalgesia in patients with diabetic 
neuropathy (Bierhaus et al., 2012). Glycation of plasminogen decreases the 
generation and function of plasmin in diabetes (Ajjan et al., 2013). 
1.7.1.3 DNA glycation by methylglyoxal
               DNA is susceptible to glycation by glyoxal and MG. Deoxyguanosine 
(dG) is the most reactive nucleotide towards dicarbonyl glycation under 
physiological conditions (Thornalley et al., 2010). The main nucleotide AGEs 
derived from dicarbonyls are imidazopurinones. The glycation of DNA by glyoxal 
forms GdG, CMdG and gdC. Glycation of DNA by MG forms MGdG and CEdG. 
MGdG is the predominant nucleotide AGE. The MGdG content of DNA of the 
peripheral blood mononuclear cells of healthy human subjects was higher than the 
DNA oxidative damage adduct, 8-hydroxydeoxyguanosine. The formation of 
CEdG is linked with DNA depurination (Thornalley, 2003b; Thornalley, 2008). An 
increase in GdG and MGdG is associated with elevated mutation frequency, 
cytotoxicity and the production of DNA strand breaks (DSB) (Thornalley et al., 
2010). 
          Nucleotide excision repair (NER) suppresses glycation of nucleotide and its 
detrimental effects (Murata-Kamiya et al., 1986, Murata-Kamiya et al., 1999, 
Pischetsrieder et al., 1999). A mutation by MG-derived nucleotide AGEs leads to 
carcinogenesis that may underly why Glo1 is considered a tumour suppressor 
protein (Zender et al., 2008). 
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1.7.2 Biochemical and physiological effects of glycation by glyoxal 
 1.7.2.1 Formation and metabolism of Glyoxal
          Glyoxal is an endogenous α-oxoaldehyde substrate and metabolite of the 
glyoxalase system (Thornalley and Rabbani, 2014a). It is produced in early and 
advanced glycation mechanisms from the slow, non-enzymatic oxidative 
degradation of glucose (Abordo et al., 1999). This is predominantly 
monosaccharides and saccharide derivatives. Glyoxal is also formed by the 
degradation of glycated proteins, Schiff’s base adducts, lipid peroxidation and 
auto-oxidation of linoleic and linolenic acids (Loidl-Stahlhofen and Spitelier, 
1994; Thornalley et al., 1999; Thornalley, 2005). The concentration of glyoxal in 
human blood is ca. 150 nM (Thornalley, 1999). It is present in aqueous solution in 
three hydration forms: unhydrated, monohydrate and dihydrate and can produce 
dimers.  
1.7.2.2 Protein glycation by Glyoxal 
          Similarly, to methylglyoxal, the modification of proteins and nucleotides by 
glyoxal induces cell dysfunction and death. Glyoxal interacts with lysine, arginine 
and cysteine residues of protein to form the AGE adducts: Nε-carboxymethyl-
lysine (CML), Nω-carboxymethylarginine (CMA) and S-carboxymethylcysteine 
(CMC) respectively (Thornalley, 2008). Another arginine-derived adduct formed is 
Nδ-(5-hydro-4-imidazolon-2-yl)ornithine (G-H1) and its related isomers G-H2 and 
G-H3 (Ahmed et al., 2002; Thornalley, 2008).  
1.7.2.3 DNA glycation by Glyoxal 
In DNA glycation, the most reactive nucleotide under physiological conditions 
is deoxyguanosine (dG). The major nucleotide AGE is the imidazopurinone derivative 
3-(2’-deoxyribosyl)-6,7-dihydro-6,7-dihydroxyimidazo [2,3-b]purin-9(8)one (GdG).   
However, other nucleotide AGEs have been reported which are CMdG and GdC 
(Anwar et al., 2018; Murata-Kamiya et al., 1998).  
          The host research group have created an LC-MS/MS based assay technique 
to quantify nucleotide adducts using acid nuclease digestion and isotopic dilution 
analysis (Fleming et al., 2008). Using this method, a major finding has been 
established: the level of GdG estimated in the human mononuclear leukocytes were 
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1.59 ± 0.08 adducts per 106 nucleotides (n=3). This emphasises how DNA 
glycation via glyoxal is a vital type of DNA damage quantitatively in vivo. Under 
physiological conditions, GdG is moderately stable and can be stabilised by 
forming single- and double-stranded DNA. Its presence has been associated with 
increased DNA mutations, strand breaks and cytotoxicity. Thus, glyoxal and 
methylglyoxal are efficiently metabolised by the glyoxalase system to glycolate 
and D-lactate respectively (Rabbani and Thornalley 2014b; Rabbani and 
Thornalley, 2016; Thornalley, 2008). The intermediate formed by the reaction with 
glyoxal by Glo1 is S-glycolylglutathione.  
1.7.3 Biochemical and physiological effects of glycation by 3-
deoxyglucosone 
          3-Deoxyglucosone (3-DG) is produced as a major carbonyl intermediate via 
the polyol pathway and the Maillard reaction (Kato et al., 1988). In the early stage 
of the Maillard reaction, glucose reacts with protein amino groups non-
enzymatically. This involves the conversion of reversible Schiff base adducts to 
stable, covalently bound N-terminal amines or lysine side chains called Amadori 
products (Ashraf et al.,2015; Kato et al., 1987; Kato et al., 1988; Tsukushi et al., 
1999). The quantity of Amadori products is in proportion to the hyperglycaemic 
levels in diabetes mellitus (DM) (Tsukushi et al., 1999).  During the intermediate 
phase of the Maillard reaction, the Amadori products under various dehydration 
and rearrangements form reactive dicarbonyl compounds such as 3-DG (Niwa et 
al., 1996; Niwa, 1999).  
          3-DG is a potent and reactive glycating agent that undergoes further 
reactions with proteins predominantly cysteine, arginine, and lysine to form AGEs 
(Niwa et al., 1996, Niwa, 1999). It also has several biological functions such as 
cellular toxicity (Lo et al., 1994a). However, the reaction of 3-DG with amino 
groups varies. For instance, irreversible reactions are formed when interacting with 
arginine and lysine residues resulting in protein polymerisation whereas with 
cysteine residues reversible hemithioacetal adducts are produced but has not been 
well characterised (Biemel et al., 2002; Edwards and Wedzicha, 1992). The 
predominant AGE is a mixture of isomeric hydroimidazolones (3DG-H). A further 
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AGE formed is pyrraline (Beisswenger et al., 2003a; Niwa, 1999; Tsukushi et al., 
1999, Thornalley et al., 1999; Thornalley et al., 2003b).  
          The polyol pathway is also involved in 3-DG synthesis. The oxidized 
product of sorbitol is fructose and is converted into 3-DG in vitro involving 
sorbitol dehydrogenase (Igaki et al., 1990; Hayase et al., 1991; Hayase et al., 1995; 
Kato et al., 1987). Szwergold et al. discovered using the lens of diabetic rats that 3-
DG is the hydrolytic product of fructose-3-phosphate which is enzymatically 
synthesised from fructose (Szwergold et al., 1990).  
          A further source of the formation of 3-DG is the phosphorylation of 
fructoselysine by the enzyme fructosamine-3-kinase (F3K); this leads to the 
hydrolysis of fructoselysein-3-phosphate (Beisswenger et al. 2003a). 
          Ashraf et al. discovered that upon histone H3 glycation by 3-DG, it affects 
the structure and function of chromatin. This may be involved in uraemic and 
diabetic complications (Ashraf et al., 2015; Niwa, 1999). 3-DG is detoxified to 2-
keto-3-deoxygluconic acid and 3-deoxyfructose via the enzymes 3-DG 
dehydrogenase and 3-DG reductase respectively (Brings et al., 2017; Niwa, 1999).  
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2.0 Project-specific background  
            Many refractory clinical tumours with high glycolytic rate have 
overexpression of Glo1 and it is hypothesised that an accumulation of methylglyoxal 
potentiates the cytotoxic effects of current chemotherapy treatment (Rabbani et al., 
2017; Rabbani et al., 2018). The main physiological substrate of Glo1 is 
methylglyoxal. MG is efficiently metabolised by Glo1 to suppress the formation of 
damaging protein and DNA AGEs to low, tolerable levels (Thornalley, 2003b; 
Thornalley, 2008). 
           The activity of Glo1 can be suppressed in situ which can significantly 
accumulate methylglyoxal to toxic levels by three mechanisms investigated in this 
study: cell-permeable Glo1 inhibitors, Glo1 silencing and GSH depletion (Abordo et 
al. 1999; Thornalley, 1993; Thornalley et al. 1996; Thornalley, 1998a, Thornalley, 
2003). High levels of methylglyoxal enhance protein and DNA glycation that may be 
involved in stimulating G1-induced growth arrest and apoptosis (Kang et al. 1996). 
Biswas et al. have shown that methylglyoxal can inhibit glycolysis and the flow of 
electrons via the mitochondrial complex I of the respiratory chain which are common 
characteristics of malignant cells (Biswas et al. 1997). This suggests how GLO1 is 
involved in the proliferation and survival of tumours and is a potential biomarker for 
diagnosis (Geng et al., 2014; Rabbani et al., 2018). 
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2.1 Cell culture models in cancer studies   
2.1.1 HEK-293 cell line
             The cell line utilized in this project is the human embryonic kidney 293 
(HEK-293) cells. Graham et al. developed the semi-adherent embryonic renal tubular 
epithelial cell line with cell transformation produced by human adenovirus type 5 
DNA (Graham et al., 1977). HEK-293 cells have been used for many applications, for 
instance, cell biology, electrophysiology and biotechnology (Lin et al., 2014; Lemtiri-
Chlieh and Ali, 2013; Stepanenko and Dmitrenko, 2015). Recent studies revealed that 
HEK-293 cells were used to produce glycoproteins to form adenoviral vaccines and 
protein therapies that have been approved by the Medicines and Healthcare products 
Regulatory Agency (MHRA), Europeans Medicines Agency (EMA) and the United 
States Food and Drug Administration (FDA) (Rijal et al., 2019; Chin et al., 2019; 
Dumont et al., 2016). This implies the therapeutic use of HEK-293 cells where it has 
good biosafety risks from viral contamination (Dumont et al., 2016). 
             Until today, it is still debated on the origin of HEK-293 cells and whether 
they have a tumour-like phenotype. HEK-293 cells share morphological 
characteristics that are analogous to tumour cells. The mammalian cell line does not 
have an actin cap and has premature peripheral F-actin structures (Haghparast et al., 
2015). It has a round shape with a mean cell diameter of 15.5 ± 0.3 µm (Dietmair et 
al., 2012). HEK-293 cells can detach from the substrate and its round shape did not 
cause significant changes to the structure of F-actin at the apical cell surface 
(Haghparast et al., 2015).  
               HEK-293 cells are a low tumorigenic immortalized cell line that can 
undergo malignant transformation following the transfer of oncogenes via a non-
classical mechanism that phenotypically present a neoplastic state (Ha et al., 2010; 
Lin et al., 2011; Canis et al., 2013). This increases the instability of the chromosomes 
that promote tumour progression and metastasis (Abdouh et al., 2014; Stepanenko 
and Dmitrenko, 2015; Gisselsson and Hoglund, 2005). This suggests that HEK-293 
cells are not a model for mammalian cell line. 
                  HEK-293 cells have a high proliferation rate where it has a population 
doubling (PD) time of 24 hours (Stepanenko and Dmitrenko 2015). Their 
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tumorigenicity increases with passage where it reaches 100% when the passage 
exceeds 65 whereas below passage 53, no tumours can be induced (Shen et al., 
2008). This suggests that HEK-293 cells can become highly malignant. 
2.1.1.1 Biochemical characteristics of HEK-293 cells.
                HEK-293 cells can concomitantly co-metabolize glucose and lactate even 
through their exponential growth. The metabolic shift from the production of lactate 
to glucose and lactate metabolism is dependent on the pH where it is efficiently 
triggered at pH 6.8 (Liste-Calleja et al., 2015). The two glucose transporters that are 
mainly expressed by HEK-293 cells are GLUT1 and GLUT3 where they increase the 
uptake of glucose and the flux of methylglyoxal formation – Figure 16 (Castro et al., 
2008). They also express Sodium Vitamin C Transporter 2 (SVCT2) that facilitates 
in the uptake of ascorbic acid (Castro et al., 2008). Ascorbic acid is a hydrophillic 
anti-oxidant and cofactor in many enzymatic systems. It prevents the consumption of 
glucose during glutamatergic synaptic activity intracellularly. This increases the 
uptake of glutamate and sodium ions to induce glucose transport and metabolism and 
lactate efflux (Castro et al., 2008). It also prevents the transport of 2-deoxyglucose in 
HEK-293 cells. However, when the uptake of ascorbic acid is halted, glucose 
becomes the substrate that facilitates the glutamatergic transmission (Castro et al., 
2008). 
129 
Figure 16: The expression of GLUT1, GLUT3 and SVCT2 in HEK-293 cells. 
A reverse transcription – polymerase chain reaction qualitative analysis of the transporters: 
GLUT1, GLUT3 and SVCT2. (H) HEK-293 cells mRNA, 100 base pair (bp) DNA standard 
(st.). The rat brain mRNA as positive control (C+) and a negative control (C-). The 
expression of GLUT1 and GLUT2 was between 400 to 500 bp. The expression of SVCT2 
was between 200 to 300 bp. B. Immunofluorescence analyses of the three transporters 
(green) where the nuclei were stained with propidium iodide (red). Scale bar, 20 µm. (Castro 
et al. 2008) 
               Another way in how a metabolic switch can occur from respiration to an 
increase in aerobic glycolysis and glutaminolysis is through the stabilization of 
hypoxia-inducible factor 1 (HIF-1) by the cytoplasmic enzyme called fumarase 
otherwise known as Fumarate Hydratase (FH) (Frezza et al. 2011; Lin et al., 2014). 
Focal deletions of fumarase can be found in kidney tumours (Linehan and Rouault, 
2013).  
             HEK-293 cells are also efficient in the γ-carboxylation of glutamic acid and 
the sulfation of tyrosine which is required to produce therapies such as recombinant 
factors IX-Fc2 and Drotrecogin alfa (Kannicht et al., 2013; Peters et al., 2013). Other 
fermentative features of HEK-293 cells are the increase of ammonia and alanine (Lee 
et al. 2008, Nadeau et al. 2000; Lin et al., 2014).  
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2.1.1.2 Molecular characteristics of HEK-293 cells.
                One of the advantages of utilizing HEK-293 cells is its ability to produce 
recombinant proteins and has high transfection efficiency to overexpress target genes 
of interest whereas vectors can be engineered synthetically to add introns and codons 
that are optimized (Kavsan et al., 2011; Thomas and Smart, 2005; Gustafsson et al., 
2004; Chin et al., 2019).  
               HEK293 cells are also involved in the post-translational modification and 
processing to increase the yield of target proteins in comparison to other mammalian 
cells such as chinese hamster ovary (CHO) cells (Bollin et al., 2011; Ooi et al. 2016; 
Wurm, 2004; Mariati et al., 2010). This suggests that the expression of the 
recombinant proteins in HEK-293 cells is dependent on two factors: delivery of the 
recombinant vector via transfection and the detection of expressed proteins.  
              HEK-293 cells can transform on chromosome 19 where there is a 332.5 kbp 
genomic region containing the adenoviral sequence insertion site, human adenovirus 
type 5 DNA E1A and E1B that express SV40 large T antigen (Graham et al. 1977; 
Lin et al., 2014; Stepanenko and Dmitrenko, 2015).  It can be amplified to maintain 
the high copy number of the adenoviral sequence (Lin et al. 2014). The telomere of 
chromosome 1q can be rearranged via deletions and mutations causing ectopic 
expressions of genes, dysregulation of cell cycle control, primarily retinoblastoma 
gene (pRB) retinoblastoma and tumour suppressor p53 (Graham et al., 1977; Lin et 
al. 2014; Eisenberg, 2011; Londono-Vallejo, 2004). Most polymorphisms are 
heterozygous which decreased the rate of senescence in HEK-293 cells and increased 
the rate of proliferation (Louis et al., 1997; Ha et al., 2010; Graham et al., 1977; 
Wang et al., 2008; Lin et al., 2011 Hamilton, M., et al. 2006). This highlights the 
potential of HEK-293 cells to form cancer influencing apoptotic mechanisms and can 
be applied in transfection experiments (Stepanenko and Dmitrenko, 2015).  
               Transfection is an analytical procedure to study the function and regulation 
of genes in cells. There are three types of transfection: biological, chemical and 
physical and have been further advanced to deliver nucleic acids (DNA and RNA) to 
specific subcellular structures by laser-microscope systems and have also combined 
with mRNA transfection (Kim and Eberwine, 2010). This can subsequently produce 
131 
recombinant proteins that can inhibit and increase expressions of specific genes in 
mammalian cells (Kim and Eberwine, 2010; Wurm, 2004).  
              However, it is dependent on the objective and experimental design wherein 
this project, stable and transient transfection are utilized to overexpress and 
knockdown GLO1 respectively (Lemtiri-Chlieh and Ali, 2013; Ooi et al., 2016; 
Spidel et al. 2016). Transient transfection was not performed to overexpress GLO1 
as a member of the host team has conducted this previously. Wildtype and empty 
vector-transfected cells where the latter are used as control can form colonies and 
tumours of different size (Stepanenko and Dimitriko, 2015). The mechanism in how 
genetic material can be stably or transiently transfected is illustrated in Figure 17. In 
stable transfection, a selective marker such as green fluorescent protein (GFP) acts as 
a marker for transgenes integrated into the genome of HEK-293 cells and the 
expression of the transgene is sustained even after replication – Figure 17A (Kim and 
Eberwine, 2010; Bestvater et al., 2002; Lin et al., 2015). On the other hand, HEK-
293 cells that are transiently transfected are expressed for a limited period and are 
not integrated into the genome and are more prone to losing the genetic expression 
via cell division and environmental factors – Figure 17B (Wurm, 2004; Pfeifer and 
Verma, 2001; Hamilton and Baulcombe, 1999; Kim and Eberwine, 2010). 
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Figure 17 The mechanisms of stable and transient transfections (Adapted from Kim and Eberwine, 2010). (A) Stable transfection: 
foreign DNA is translocated to the nucleus and is integrated into the host genome to increase expression. (B) Transient transfection: 
foreign DNA is translocated into the nucleus but is not integrated into the genome. Foreign mRNA can undergo translation in the 
cytosol. The proteins expressed are presented as hexagons whereas the green arrows present the process of delivering nucleic acids. 
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              For stable transfection, previous studies have discovered that HEK-293 cells 
can produce stable recombinant proteins using xenogenic genes as selection markers 
and antibiotic selection (Spidel et al. 2016). Lipofectamine 2000 is the transfection 
reagent used in this investigation. Lipofectamine 2000 is a liposome complex that 
transmits nucleic acids that resides in a phospholipid bilayer into cells by fusing with 
the cellular outer-membrane. This mode of action is known as lipofection. 
Advantages of using this transfection reagent are due to its high efficiency and 
minimal cell toxicity (Shi et al., 2018). 
              In this project, the pIRES2-EGFP-GLO1 vector illustrated in Figure 18 is 
stably transfected into HEK-293 cells to overexpress GLO1 protein and enzymatic 
activity to analyse its effect on chemotherapeutic agents, cell metabolism, tumour 
proliferation and survival (Hutschenscheur et al. 2016). The pIRES2-EGFP consists 
of an internal ribosome entry site (IRES) of the encephalomyocarditis 
cytomegalovirus virus (ECMV). The IRES is situated between the multiple cloning 
site (MCS) and the enhanced green fluorescent protein (EGFP) region (Jackson et 
al., 1990). This allows the gene of interest, GLO1, that contains the starting codon, 
ATG and the selection marker GFP to be translated from the 3’ end of the singular 
bicistronic mRNA to enter the MCS (Jackson et al., 1990; Jang et al.; 1990; 
Cormack et al., 1996). EGFP is a red-shifted variant of wild-type form that has been 
optimised to increase fluorescence and gene expression in mammalian cells. The 
excitation and emission maximum wavelengths are 448 and 507 nm respectively 
(Cormack et al. 1996; Haas et al. 1996). 
               HEK-293 cells transfected with pIRES-EGFP-GLO1 plasmid are resistant 
to the aminoglycoside antibiotic G-418 and contains the neomycin and kanamycin-
resistant genes (Gorman, 1985; Küng et al., 1997). G-418 eradicates mammalian 
cells by binding to 80S subunit of the ribosome, this prevents the elongation step in 
ribosomes preventing protein synthesis (Küng et al., 1997). They also express 
aminoglycoside 3’-phosphotransferase (APT) that covalently modifies G418 to 3’-
phospho-G418. 3’-Phospho-G418 contains negligible potency and low affinity for 
prokaryotic and eukaryotic ribosomes (Davis et al., 1986).  
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Figure 18: The restriction map and multiple cloning site for the pIRES2-EGFP vector 
(Clontech, 2019).
The EGFP encodes a mutant variant that consists of two amino acid substitution: 
Phenylalanine-64 (Phe-64) to Leucine. Serine-65 (Ser-65) to Threonine. There are more than 
190 changes to the silent bases. The MCS is between the early promoter of CMV and the 
IRES sequence. The SV40 polyadenylation aids the GFP expression. The SV40 origin (ori) is 
for the replication of mammalian cells expressing the SV40 T antigen. The vector contains 
Tn5 gene that is resistant to the antibiotic’s neomycin and kanomycin. The neomycin resistant 
(Neor) cassette comprises the SV40 early promoter. There are also polyadenylation sites in 
the herpes simplex virus thymidin kinase (HSV TK) gene that allows the selection of stable 
transfectant cells using G-418. The pUC origin (ori) of replication allows the bacterial 
transformation and propagation in E-coli to take place. The f1 origin allows the production of 
single-stranded DNA. The restriction sites are in bold and the two restriction enzymes are: 
Bgl II (Bacillus globigii) and Pst I (Providencia stuartii).  
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              Previous studies have successfully overexpressed GLO1 in HEK-293 cells 
where there was a 20-fold increase in GLO1 mRNA, protein and activity in 
comparison to mock-transfected cells – Figure 19 (Hutschenreuther et al. 2016). 
Figure 19: The effect of GLO1 overexpression in HEK-293 cells in vitro 
(Hutschenreuther et al. 2016). 
Cytosolic cell extracts were used to measure the GLO1 mRNA, protein and enzymatic 
activity whereby the GLO1 protein and mRNA were normalized B-actin. The grey dashed 
line presents the wild-type cells (n=3). The GLO1 protein, mRNA and enzymatic activity 
increased significantly in comparison to the HEK-293 mock cells. Statistical Significance: * 
p < 0.05; ** p < 0.01; *** p < 0.001 (t-test) with respect to control. 
                 Transient transfection of HEK-293 cells does not require inducible vectors 
nor does the mRNA need to be in the nucleus to be expressed and can be used for 
therapeutic purposes (Job and Eberwine, 2001; Sul et al. 2009; Sullenger and Gilboa 
2002; Subedi et al. 2015). There are four sites that can undergo nucleoside 
modifications and are vital in the translation of mRNA: cap, open reading frame 
(ORF), poly-A tail, 5′ untranslated region (5′UTR) and 3′ untranslated region (3′UTR) 
(Subedi et al., 2015). Transient transfection can be used to overexpress GLO1 and 
produce soluble recombinant proteins via transient gene expression and target the 
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secretory pathway (Kaufman, 2003; Berlec and Strukelj, 2013; Thomas and Smart, 
2008).    
              RNA interference (RNAi) is used to knockdown down specific genes and 
observes the phenotypic changes and potential to treat disease (Kim and Eberwine, 
2010). In this project, small inhibitory RNA (siRNA) form the RNA-induced 
silencing complex (RISC) in the cell preventing the expression of target genes 
(Brazas and Hagstrom, 2005; Castanotto and Rossi, 2009). Lipid-mediated and virus-
mediated delivery of siRNA is the two most common methods (Davis et al. 2000). 
Previous studies have successfully knocked down GLO1 by siRNA > 95% where 
they potentiated the toxicity of chemotherapeutic regimens in tumour cell lines – 
Figure 20 (Xue et al., 2017). The GC50 and logistic regression coefficient were 
calculated to determine the maximal concentration at which 50% of cell growth has 
been inhibited. The GC50 value and logistic regression coefficient with wild-type 
BON-1 was 3.06 ± 0.13 μM and n = 2.23 ± 0.20. However, upon treatment of BON-
1 with GLO1 siRNA with doxorubicin, the proliferation rate decreased by 27 ± 2% 
(Xue et al., 2017). 
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Figure 20: The dose-response curve presenting the effect of doxorubicin with and 
without silencing of GLO1 on the growth of BON-1 pancreatic neuroendocrine 
tumour cell line in vitro (Xue et al. 2017).  
BON-1 was treated with doxorubicin at 6 different concentrations (μM): 0.25, 0.50, 2.5, 5, 
10 and 20 μM. A concentration of 25 nM of Accell Human GLO1 SMART siRNA was used 
to silence GLO1. The higher the concentration of Doxorubicin, the more anti-proliferative 
effects it exerts. The GC50 value and logistic regression coefficient with wild-type BON-1 
was 3.06 ± 0.13 μM and n = 2.23 ± 0.20. However, in combination with BON-1, cell growth 
decreased by 27 ± 2% (n = 3, P<0.001).  Key:      and ---- represent the wild-type of BON1 
cell line.  and   BON-1 with GLO1 silencing; Data mean ± SEM (n=3).  
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2.1.2 Human cancer cell lines 
Human cancer cell lines are in vitro model systems that are widely used 
for experimentation under the right condition and control to develop anti-tumour 
drugs, study their mechanism of action and how MDR can develop (Gillet et al., 
2013; Mirabelli et al. 2019; Masters, 2000). However, they do not have equal value 
where some have succeeded whereas others have failed and there is a continuous 
increase in the development of novel pre-clinical models in vitro (Gillet et al., 2013; 
Borrell, 2010; Weinstein, 2012).  
                  The first tumour cell line was HeLa and was derived from cervical cancer 
cell lines by Henrietta Lacks in 1951 (Scherer et al., 1953). This subsequently led to 
the establishment of various cancer cell lines that were propagated as monolayer 
primary cultures in vitro or xenografts in tumour-bearing rodents in vivo (Mattern et 
al. 1988; Rockwell, 1980). Tumour cell lines can be obtained from the American 
Type Culture Collection (ATCC) and the European Collection of Cell Cultures 
(ECCC). Some of the most common cancer cell lines are summarised in Table 2. 
They differ in their anti-tumour drug response due to the complexity and biological 
mechanisms of the disease, percentage of oxygen, growth factors and their 
interaction with stromal and immune cells (Ferreira et al. 2013; Klijn et al., 2015; 
Ferriera, 2005). It is important to publish the tissue or cell type and immortality for 
each established cell line to be used in Biomedical research according to the United 
Kingdom Coordinating Committee on Cancer Research (UKCCCR) (Geraghty et al.
2014; Monks et al. 1991). 
                 We are in a position where the molecular and cellular status of each cell 
line has been defined with accuracy in databases such as The Cancer Genome Atlas 
(TCGS) which mutations, copy number variations and the expression of genes and 
proteins and when contaminated with mycoplasma via omics technology (genomics, 
transcriptomics and proteomics) (Goodspeed et al. 2016; Barretina et al. 2012). 
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 Table 2: Examples of tumour cell lines used in cancer research. Their morphological and mortality status have been described. 
Name of cell line Abbreviation Morphology Cell Origin Immortalized status and age of sampling 
Cervix adenocarcinoma HeLa Epithelial Homo sapiens, Human It was developed by Henrietta Lacks in 1951. 
The cells were obtained from a Black female 
patient aged 31. 
Acute promyelocytic 
Leukaemia 
HL-60 Promyelocyte Homo sapiens, Human It was developed by Collins 1987. The cells 
were obtained from Caucasian female patient 
aged 36. 
Breast adenocarcinoma MCF-7 Epithelial Homo sapiens, Human Caucasian female patient aged 69. 
Pancreatic neuroendocrine 
tumor
BON -1 Lymph node from the 
carcinoid
Homo sapiens, Human 28 years old male patient. 
pancreatic carcinoma QGP-1 Epithelial-like from the 
islet cell origin of the 
cellosaurus tumour.
Homo sapiens, Human 61 year old male patient 
Glioblastoma  U87MG Epithelial Homo sapiens, Human Unknown male patient 
Colon adenocarcinoma HT-29 Epithelial Homo sapiens Caucasian female patient aged 44. 
Lung carcinoma A549 Human alveolar basal 
Epithelial 
Homo sapiens, Human They were developed by Giard et 
al.,1973. Caucasian male patient aged 58. 
Hepatocellular carcinoma HEP-G2 Epithelial Homo sapiens Caucasian male patient aged 15.
Chronic myeloid leukaemia K-562 Lymphoblast Homo sapiens 53 years old female patient.
SV40 transformed kidney Cos7 Fibroblast Cercopithecus aethiops The grivet/African green monkey. 
Grade IV Prostate 
adenocarcinoma 
PC3 Epithelial Homo sapiens,  62 years old male Caucasian patient. 
Malignant melanoma A375 Epithelial. Homo sapiens, Female patient aged 54
Burkitt’s lymphoma Raji Lymphoblast Homo sapiens humans Black male patient aged 11
humn acute promyelocytic 
leukemia 
NB4 premyomyoblast Homo sapiens humans Female patient aged 23 in second relapse 
in 1989.
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2.1.3 Tumour Biopsies 
               Amongst the characteristics of tumour cells are uncontrollable growth, loss 
of attachment, invasion and metastasis. The ability for tumour cells in a neoplastic 
state to lose their cohesiveness can allow tumour biopsies or lesions to take place that 
requires a needle aspiration for microscopic examination and diagnosis (Shyamala et 
al. 2014). However, there is a risk of seeding these tumour cells into the interstitial 
tissue fluid to transfer through lymphatic veins or via vasculature to other organs or 
tissues (Shyamala et al. 2014).  
              Several tumour biopsies have been utilised in cancer research where there is 
a positive correlation between the quantity of GLO1 protein and tumour grade 
(Fonseca-Sánchez et al. 2012). This emphasises that GLO1 gene amplification 
correlates with upregulation of the Glo1 overexpression and are essential in the 
proliferation and progression of tumours. There is also evidence that upregulation of 
the serum level of AFP is linked with Glo1 overexpression in hepatocellular 
carcinoma that affects TNM staging (Zhang et al. 2014).     
              Abdul-Maksoud et al. discovered that GLO1 overexpression was higher in 
breast cancer tissue and even more so at advanced stages; highlighting its potential as 
a diagnostic and prognostic biomarker (Abdul-Maksoud et al. 2017; Nokin et al. 
2019; Fonseca-Sanchez et al.  2012). Recent studies have discovered that in tumours 
that are highly malignant but has poor clinical outcome such as patients with 
paediatric diffuse midline glioma, liquid biopsy can be used to characterise and 
identify circulating tumour DNA (ctDNA) (Panditharatna et al., 2018). 
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2.2 Anti-cancer drugs used in this investigation.
          A broad spectrum of anti-cancer drugs will be utilized in this study: mechlorethamine, camptothecin, methotrexate, doxorubicin, 
cisplatin, etoposide, mitomycin c and vincristine. The molecular structure, molecular mass, mechanism of action and therapeutic use are 
summarised in Table 3. 
Table 3: The molecular mass, mode of action and examples of its the therapeutic use for the anti-cancer drugs utilized in this investigation. 
Class Anticancer drug Molecular mass 
(Da)
Mechanism of action Therapeutic applications Reference 
Nitrogen mustard Mechlorethamine 156.05 DNA alkylation   Lung cancer; chronic 
leukaemia,  Hodgkin’s disease. 
(Siddik, 2002; Siddik 2003) 
Bioreductive 
alkylator 
Mitomycin C 334.32 DNA alkylation Bladder, gastric and skin 
cancers 
(Iyer and Szybalski, 1963; 
Verweij and Pinedo, 1990) 
Metal complex Cisplatin 300.05 DNA-metal complexation DNA-metal complexation. 
Anti-metabolite Methotrexate 454.45 Dihydrofolate reductase 
inhibitor 
Bone, lung, bladder, 
gynaecological cancers. 
(Tian and Cronstein, 2007) 
Topoisomerase 
inhibitors
Camptothecin 348.36 Topoisomerase I inhibitor Ovarian and colorectal cancers (Brangi et al., 1999) 
Doxorubicin 543.53 Topoisomerase II inhibitor Breast, stomach, bladder and 
thyroid cancers. 
(Tacar et al., 2013) 
Etoposide 588.56 Topoisomerase II inhibitor Stomach cancer non-Hodgkin 
lymphoma.
(Van Maanen et al., 1988) 
Anti-tubulin Taxol 853.91 Microtubule stabilisation Brain, gynaecological, lung and 
pancreatic cancer.
(Koziara et al, 2005; Weaver, 
2014)
Vincristine 824.9 Microtubule 
disruption 





3.0 Aims and Objectives  
               The aim of this study is to characterise the level of MDR to clinical anti-
cancer drugs by Glo1 overexpression in a model human tumour cell line in vitro and 
to investigate the MDR mechanism for drugs where it is most marked.  
Objective 1: To characterise the glyoxalase system and dicarbonyl 
metabolism in HEK-293 cells under high glucose conditions in vitro.  
                The growth characteristics of HEK-293 cells was initially assessed by 
performing a growth curve in vitro to determine the time-point of evaluating the anti-
tumour drug effect on cell growth. The viable cell number was deduced using trypan 
blue exclusion assay method. This was performed at low (5 mM) and high glucose 
(25 mM) concentration in vitro. There is evidence that glucose deprivation reduces 
the cell proliferation rate significantly causing a low yield of lactate production and 
low glycolytic rate (Siegwart et al. 1999).  
                   The activities of the enzymes involved in the metabolism of the main 
dicarbonyl, methylglyoxal in HEK-293 cells was determined by validated methods 
using cytosolic cell extracts spectrophotometrically (Arai et al., 2014). Glo1 gene and 
protein in HEK-293 cells were measured by real-time reverse transcription-
polymerase chain reaction (RT-PCR) and Western blotting, respectively (Xue et al. 
2014). 
                  The concentration of the endogenous metabolites, dicarbonyls and 
glutathione were measured in HEK-293 cell extracts by stable isotopic dilution 
analysis LC-MS/MS (Rabbani and Thornalley, 2014d).  The normal concentration of 
dicarbonyls in mammalian cells is 1 – 4 µM and a level beyond this range causes 
dicarbonyl stress (Rabbani and Thornalley, 2015).     
                   The fluxes of glucose consumption, and net L-lactate, D-Lactate 
formation were determined to give an insight into the effect of drug treatment on 
aerobic glycolysis and the formation of methylglyoxal respectively in HEK-293 cells 
in vitro. D-glucose was measured in the cultured medium by enzymatic end-point 
absorbance assay whereas D-Lactate and L-lactate was measured in the cultured 
medium by enzymatic end-point fluorescence assay. 
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                  The effect of exogenous methylglyoxal on HEK-293 cells in vitro will be 
determined by conducting a concentration-response study. HEK-293 cells will be 
incubated for 48 h with varying concentrations of exogenous MG. There is evidence 
that exogenous MG affects the growth and sensitivity of HEK-293 cells in vitro 
(Kang et al., 1996; Santel et al, 2008). 
Objective 2: To evaluate the growth inhibition and toxicity of anti-tumour 
drugs in stable transfectant HEK-293 cell lines with overexpression of 
Glo1 and empty vector control to assess the level of resistance associated 
with increased Glo1 expression in vitro.
               Glo1 overexpression causes innate and acquired MDR in cancer treatment 
by Glo1 gene amplification and Nrf2 overactivation (MacLeod et al., 2016; Santarius 
et al. 2010; Thornalley and Rabbani, 2011c; Xue et al.; 2012b; Xue et al., 2015; 
Zhang et al. 2015). The level of MDR caused by Glo1 overexpression is unknown 
for current anti-anticancer drugs (Rabbani et al. 2018). According to the hypothesis, 
methylglyoxal accumulation may form part of the anti-tumour drug response to 
induce growth arrest and cytotoxicity in tumours with a high glycolytic rate. 
However, knowing that there is high GLO1 gene amplification and activity in 
tumours, screening for GLO1 gene in tumour biopsies can aid with optimising 
chemotherapeutic agents (Thornalley and Rabbani, 2011). The anti-tumour drug that 
has the least resistance can be the optimum choice for therapy (Rabbani et al. 2018). 
                To achieve the objective, HEK-293 cells are overexpressed with pIRES2-
GLO1-EGFP plasmid by stable transfection and the empty vector is transfected with 
pIRES2-EGFP plasmid as a control to study the effect of a wide range of different 
anti-tumour drugs. HEK-293 wildtype and stable-transfectant cell lines were 
incubated with 6 different concentrations of the anti-tumour drug for 48 h. Viable 
cell number was assessed by the trypan exclusion assay. The median inhibitory 
concentration and logistic regression coefficient were deduced from the dose-
response equation. This can then inform which anti-cancer drugs have the most 
resistance. Thereafter, the effect of the anti-cancer drugs that caused most resistance 
on the metabolic fluxes and glucose consumption will be explored. 
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Objective 3 To study the effect of Glo1 inhibitor and Glo1 silencing on 
MG metabolism and the potency of the chemotherapeutic drugs in HEK-
293 cells under high glucose conditions in vitro  
          The level of Glo1 overexpression in tumour influences the level of sensitivity 
to the Glo1 inhibitor or Glo1 silencing that accumulates methylglyoxal to induce 
apoptosis, anoikus and necrosis (Rabbani et al. 2018; Thornalley, 1998b). To achieve 
this objective, the effect of anti-tumour drugs on HEK293 cell growth in 
combination with Glo1 inhibitor at GC50 concentration will be studied. The effect of 
Glo1 inhibitor and Glo1 silencing on the glyoxalase system and dicarbonyl 
metabolism in HEK-293 cells will also characterised.    
          To confirm Glo1 knockdown, HEK-293 cells were treated with siRNA for    
72 h and the mRNA, enzymatic and protein levels of Glo1 were measured and were 
compared to scrambled siRNA that acted as a control. The anti-tumour drug that had 
the most resistance will be treated with Glo1 inhibitor and Glo1 silencing to 
determine their effect. 
Objective 4: To determine the effect of hypoxia (3% oxygen) on the 
potency of anti-cancer drugs and Glo1 inhibitor BBGD in high glucose 
conditions in vitro 
          There is evidence that there is an increase in chemotherapy resistance under 
hypoxic conditions and it also decreases the expression of Glo1 and increase the flux 
of MG formation (Forristal et al., 2013; Shafie et al, 2016). The glyoxalase system 
and dicarbonyl metabolism will be explored under normoxic conditions (20% 
oxygen) and hypoxic condition (3% oxygen with 92% nitrogen) at 37°C. The effect 
on the anti-tumour drug that had the most resistance will also be explored to 
determine its effect under hypoxic conditions in vitro. 
Objective 5: To explore why anti-tumour drugs suffer Glo1-linked MDR.  
              To achieve this objective, the direct and indirect effect of Glo1 on the anti-
cancer drugs was established by determining the effect of Glo1 activity 
spectrophotometrically and the level of GSH depletion by stable isotopic LC-MS/MS 
respectively (Thornalley, 1998a). The level of methylglyoxal will also be measured 
in drug-treated HEK-293 cells by LC-MS/MS to explore the effect of the broad 
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spectrum of anti-cancer drugs that vary structurally and mechanistically on MG 
production.  
4. Materials and Methods
4.1 Materials
4.1.1 Cell lines 
The HEK-293 cell line was acquired from the American Type Culture Collection 
(ATCC) (Virginia, USA).  
4.1.2 Cell culture 
4.1.2.1 Reagents
          HEK-293 cells were maintained in Dulbecco’s Modified Eagles Medium 
(DMEM) containing phenol red, L-glutamine and glucose concentration 4500 
mg/L (cat. no. 11965092, ThermoFisher, UK). The DMEM media was 
supplemented with a final concentration of 10% Foetal Bovine Serum (FBS) and 
100 U penicillin/0.1 mg/mL Streptomycin. The FBS (cat.no. F7524), 
penicillin/streptomycin solution (10,000 U/mL penicillin with 10 mg/mL 
streptomycin in 0.9% sodium chloride, cat.no. P4333), Trypan blue powder (cat. 
no.76146), tissue culture-grade dimethylsulphoxide (DMSO, cat. no. D4540) were 
all purchased from Sigma-Aldrich (Poole, Dorset, UK).   
4.1.2.2 Equipment
          Corning cell-culture grade plastic polystyrene T25 cm2 flasks (cat. No. 
CLS430639), T75cm2 flasks (cat. no. CLS430641), 6-well plates (cat. no. 
CLS3516), 12-well plates (cat. no. 156367), 100 mm x 20 mm tissue-culture 
treated culture dishes (cat. no. P7612) and Stripette serological pipettes (cat. no. 
CLS4488) were all purchased from Sigma-Aldrich. The Neubauer 
Haemacytometer for cell counting (Model no. 0630410, Marienfeld-Superior) was 
from Paul Marienfeld GmbH & Co. KG (Lauda-Königshofen, Germany). The 150 
µL cloning glass cylinders (cat.no. C1059) and the cloning discs (cat. 
no.  Z374431) were from Sigma-Aldrich and the inverted microscope Nikon 
Eclipse TE2000-S (Nikon UK Limited, Kingston Upon Thames, Surrey, UK) was 
used to select uniform fluorescence transfected colonies.   
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4.1.3 Molecular, biological and transfection reagents
4.1.3.1 Stable Transfection of GLO1 overexpression
                pIRES2-GLO1-EGFP plasmid and pIRES-EGFP plasmid were prepared 
by the host research team. The transfection reagent: Lipofectamine 2000 (cat. no. 
11668027) and OptiMEM serum-supplemented media (cat.no 31985062) were 
purchased from ThermoFisher (Paisley, UK). DH5α™ Competent Cells 
Escherichia coli (11 x 106/mL) were purchased from Thermo Fisher (Paisley, UK) 
and stored at -80oC. Luria Bertani (LB) broth, LB media and G-418 disulphate 
were obtained from Sigma-Aldrich. Geneticin G-418 (potency rating – a supplier 
estimates of bacterial growth inhibition, 700 µg/mg) was purchased from Fisher 
Scientific (Loughborough, UK). Reagents for fast, large-scale, anion-exchange-
based plasmid DNA preparation (Hi-Speed Plasmid Mini and Midi prep kits) were 
purchased from QIAGEN (Manchester, UK).  
4.1.3.2 Transient Transfection of GLO1 knockdown
         Accell Human GLO1 SMART siRNA pool (cat.no E-012277-00-0020) and 
Accell non-targeting Control siRNA pool (cat.no D-001910-0X) were obtained 
from GE Healthcare Dharmacon (Buckinghamshire, U.K.). Lipofectamine 
RNAiMAX (cat. no. 13778030) and the OptiMEM reduced serum-supplemented 
media (cat. no. 31985062) were obtained from ThermoFisher (Paisley, UK). The 
OptiMEM media consisted of sodium pyruvate, L-glutamine, thymidine, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sodium bicarbonate, growth 
factors, hypoxanthine and trace elements. 
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4.1.4 Enzymes, substrates and cofactors
4.1.4.1 Molecular biology enzymes
             Restriction enzymes Bgl II (Bacillus globigii) and Pst I(Providencia 
stuartii 164) were obtained from New England Biolabs (Hitchen, UK). A unit is 
defined as the quantity of enzyme needed to digest 1 µg of λ DNA in 1 hour at 
37°C in a total reaction volume of 50 µL. Bioscript Moloney Murine Leukaemia 
Virus (MMLV). Reverse Transcriptase (10,000 units; BIO-27036) and is highly 
stable and sensitive for first-strand cDNA synthesis (Bioline, London).  
4.1.4.2 Other enzymes
          Trypsin/ethylenediaminetetra-acetic acid (EDTA) (cat. no. 4049), L-lactic 
dehydrogenase (cat. no. EC 1.1.1.27) and D-lactic dehydrogenase (EC 1.1.1.28) 
were purchased from Sigma-Aldrich. Trypsin-EDTA sterile-filtered solution was 
utilized in cell culture and comprised of 2.5 g porcine trypsin, 0.2 g EDTA-tetra 
sodium salt per litre of Hank’s Balanced Salt Solution with phenol red. L-Lactic 
dehydrogenase was from bovine heart, type III, and had an activity of ≥ 1000 
units/mg protein. D-Lactic dehydrogenase is lyophilised powder, purified from 
Staphylococcus epidermidis and had activity of ≥ 80 units/mg protein.  
4.1.4.3 Substrates and cofactors
          Methylglyoxal solution (40% w/w; cat. no. M0252-500ML), reduced L-
glutathione (G4251-10G), S-D-lactoylglutathione (cat. no. L7140-25MG), glyoxal 
(40% w/w; cat. no. L0625), aminoguanidine hydrochloride (cat. no. 396494), L-
lactic acid (cat. no. N7505-1G), D-lactic acid (cat. no. L0625), NAD+ (cat. no. 
N0632-1G) and NADPH (cat. no. N7505-1G) were obtained from Sigma-
Aldrich.  
4.1.5 Antibodies
          Monoclonal anti-Glo1 antibody produced in rat (cat. no. SAB4200193) and 
the anti-rat IgG antibody (cat. no. B7139) were purchased from Sigma-Aldrich 




          The primers and probe for β-actin and Glo1 were pre-designed from Life 
Technology Ltd (Paisley, Scotland). The primers that were utilized for the 
amplification of cDNA for GLO1 mRNA are summarised below in Figure 21.  
Figure 21: The primers used for cDNA amplification for GLO1 and β-actin. The 
mRNA expression of GLO1 was normalized to β-actin. 
4.1.7 Anticancer agents
           Doxorubicin (cat. no. D1515-10MG), vincristine (cat. no. V8879-1MG), 
cisplatin (cat. no. 479306-1G), paclitaxel (cat. no. T7191-1MG), etoposide (cat. 
no. E1383-25MG), methotrexate (cat. no. 06563-5MG), S-(+)-Camptothecin (cat. 
no. C9911-100MG) and mitomycin C (from Streptomyces caespitosus; cat. no.
M4287-2MG) were purchased from Sigma-Aldrich. Mechlorethamine (cat. no. 
C2942) were purchased from Cambridge Bioscience Ltd (Cambridge, 
UK).  SpBrBzGSHCp2 was available in-house by the host research team. It was 
prepared by acid-catalysed esterification of S-p-bromobenzylglutathione and 
purified by column chromatography as described (Thornalley et al., 1996).  
4.1.8 Other reagents
Ammonium persulphate (ACS reagent grade, cat. no. 248614), β-
mercaptoethanol (cat.no. M6250-10ML), 3',3'',5',5''-tetrabromophenol 
sulfonphthalein sodium salt (bromophenol blue, electrophoresis grade; cat. no. 
114405), diethylenetriaminepentaacetic acid (DETAPAC) (cat. no. D6518), Tween-
20 (cat. no. P2287), DMF (cat. no. D4551)), Bovine serum albumin (cat. no. A9418-
5G), Complete Lysis-M buffer (cat. No. 4719956001) , N,N,N’,N’-
tetramethylethylene-1,2-diamine (TEMED, ≥ 99% electrophoresis grade; cat. no. 
T9281-25ML), sodium phosphate monobasic (cat. no. 71505), hydrochloric acid 
(analytical grade, 1 N; HCl) (cat. no. H1758), trichloroacetic acid (TCA) (cat. no. 
T6399-5G) were purchased from Sigma-Aldrich. Filter paper, polyvinyl difluoride 
(PVDF) membrane were purchased from Bio-Rad (Hertfordshire, UK).   
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 Perchloric acid (cat. no. A2296-1LB), sodium chloride (cat. no. 7647-14-
5) and potassium bicarbonate (cat. no. 298-14-6), Tris(hydroxymethyl)-
aminomethane (Tris base) (cat. no. 77-86-1), Perchloric acid (cat. no. A2296-
1LB), sodium dodecyl sulphate (SDS) (cat. no. 28312B), SpectroTM multicolor 
broad range protein ladder 10-260 kDa, for 4 – 20% Tris-glycine SDS-PAGE (cat 
no. 26623), Glycine (cat. no. BP381-500) was purchased from Fisher Scientific 
(Loughborough, UK). Hydrazine hydrate (cat. no. 18412) was purchased from 
Fluka (Poole, Dorset, UK).  
                HyperLadder™ 1kb (cat. no. BIO-33053), agarose (cat. no. BIO-
41026), Oligo (dT)18 primer (cat. no. BIO-38029) is a single-stranded sequence of 
deoxythymine (dT) that was utilized to prime reactions catalysed by reverse 
transcriptase. dNTP mix set (cat. no. BIO-39044) contained dCTP, dTTP, dGTP 
and dATP. RiboSafe RNase Inhibitor (cat. no. BIO-65027) is a recombinant 
protein that inhibits a eukaryotic RNases, SensiMix™ SYBR® Low-ROX Kit 
(cat. no. QT625-05) were purchased from Bioline (London, UK).  
4.1.9 Analytical and preparative kits
          The glucose assay kit - hexokinase method (cat. no. GAHK20) - was 
purchased from Sigma-Aldrich. The RNAse mini kit (cat. no. 74106) was 
purchased from Qiagen (Manchester, UK). The Pierce BCA Protein Assay Kit 
(cat. no. 23227) was used to measure total protein concentration compared to 
protein standard at a wavelength of A562 nm was purchased from ThermoFisher. 
Enhanced chemiluminescence (ECL) reagent kit (cat. no. 34079) was purchased 




          All solvents were HPLC graded: acetonitrile (cat. no. 75058), 
tetrahydrofuran (THF) (cat. no. 109999) and methanol (cat. no. 67561), were 
purchased from Fischer Scientific (Loughborough, UK). Formic acid (≥ 98%; cat. 
no. F0507-500ML) and Trifluoroacetic acid (TFA, ≥ 99.0% HPLC grade; cat. no. 
302031). The column-BEH C18, 1.7 µm particle size column (100 x 2.1 mm) 
fitted with a (5 x 2.1 mm) pre-column was utilized for the dicarbonyl and 
glutathione assay and were purchased from Waters (Elstree, UK).   
4.1.10.2 Calibration of stock solutions of dicarbonyls
          High purity MG and 3-DG were prepared in-house by the host research 
team. MG was prepared by the method described by McLellan and Thornalley 
(McLellan and Thornalley, 1992a). 3-DG was prepared from glucose and 
toluidine by a combination of two methods described by Madson and Feather and 
Henle and Bachmann (Madson and Feather, 1981; Henle and Bachmann, 1996). 
Glyoxal (40% aqueous solution) was utilized without purification and was 
obtained from Sigma-Aldrich (Dorset, UK) was used without purification. The 
concentration of stock solutions of dicarbonyls was determined by the 
derivatization with aminoguanidine hydrochloride and measuring the absorbance 
at 320 nm spectrophotometrically of the 1,2,4-triazine derivatives. The 
concentration can then be deduced from the known molar extinction coefficient 
(Thornalley et al., 2000).  
4.1.11 Equipment 
          Corning clear 96 polystrene well plates (cat.no CLS9102), black 
polystyrene 96 well plates (cat. no. CLS3925), 100 mm x 20 mm dishes (cat.no 
P7612-360 EA), 6 well plate (cat. no. M9052-100EA), 12 well plate (cat. no. 
M9187-100EA) was obtained from Sigma Aldrich (Dorset, UK). Cryotube vials 
(1.8 ml; NUNC, cat. no. 363401) were purchased from Sigma-Aldrich (Dorset, 
UK). For real-time PCR, MicroAmp® optical adhesive film (cat. no. 4311971) 
and MicroAmp® optical 96-well reaction plate (cat. no. N8010560) were obtained 
from ThermoFisher Scientific. Special compressed gas mixture of 3% oxygen 
with nitrogen was purchased from CK Gas Products Ltd (Leicester, UK). HPLC 
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vials, caps, 200 μl glass inserts and plastic supports were purchased from Fisher 
Scientific (Loughborough, UK).  
4.1.12 Instrumentation
          For the quantification of protein assays, end-point absorbance assays and 
end-point fluorescence assay were performed using a FLUOstar OPTIMA 
microplate reader version 2.10 R2 was utilized from BMG Labtech (Ayelsbury, 
UK). The NanoDropTM UV/visible spectrophotometer ND-1000 was from 
LabTech International (Uckfield, UK) and was used for the estimation of sample 
DNA and RNA content. AccuSpin 3R centrifuge and Heraeus Pico 17 centrifuge 
were purchased from Fisher Scientific (Loughborough, UK). A UVICON UV/VIS 
spectrophotometer (Northstar Scientific Limited, Sandy, UK) was used to 
determine activities of Glo1, Glo2, MG reductase and MG dehydrogenase. The 
centrifugal evaporator was a Savant Instruments SpeedVac and Applied 
BiosystemsTM 7500 real-time PCR machine were from Thermo Fisher Scientific 
(Paisley, UK). Hypoxia chamber (cat. no. 27310) and single flow meter (cat. no. 
27311) were from Stemcell Technologies (Manchester, UK).  
          A Criterion™ Cell electrophoresis chamber (cat. no. 1656020), Mini Trans-
Blot Electrophoretic Transfer Cell (cat. no. 170-3930) and PowerPac™ Basic 
Power Supply (cat. no. 164-5050) were purchased from Bio-Rad (Hertfordshire, 
UK). Applied BiosystemsTM 7500 Real-time PCR machine was from Thermo 
Fisher (Paisley, UK). A gel imaging system for chemiluminescence, GeneGnome 
XRQ System was purchased from Syngene (Cambridge,UK).  
          Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis 
was conducted using two instruments from Waters (Manchester, U.K.): 
AcquityTM UPLC system with a Quattro Premier XE tandem mass spectrometer 
and an AcquityTM UPLC system with a Xevo-TQS tandem mass spectrometer.  
4.1.13 Software
          Masslynx 4.1 software (Waters, Manchester, UK) was used to integrate the 
data for the dicarbonyl and glutathione assays. The GC50 value was calculated 
from the non-linear regression analysis using the Enzfitter program from Biosoft 
(Cambridge, UK). Densitometry of bands on Western blots was performed using 
Image J software from the National Institute of Health and Image Quant software 
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from GE Healthcare Life Sciences. The statistical package SPSS (v10) was made 
by SPSS Inc. (Chicago, USA).  
4.2 Methodology
4.2.1 Culture of HEK-293 cells
          HEK-293 cells were delivered frozen on dry ice and were stored in liquid 
nitrogen until use. Each vial contained 2 x 106 cells in 1 ml cryopreservative 
medium. When required, the solution was rapidly thawed on a water bath (37oC) 
for 1 - 2 min. The cell suspension was transferred to a T-flask under aseptic 
conditions gently and mixed with 14 mL of pre-warmed culture DMEM medium 
containing high glucose (25 mM), L-glutamine (4 mM) and supplemented with 10 
% (v/v) FBS, 100 U/mL penicillin/0.1 mg/ml streptomycin. The cell suspension 
was incubated at 37 oC, 5 % CO2 and 100 % humidity and passed until cell 
fragments were removed and cell viability was >99%. 
4.2.2 Normal growth conditions
                HEK-293 cells were seeded at a density of 2 x 104 cells ml-1. Cells were 
cultured in T75 cm2 flasks to 80-90% confluence and routinely sub-cultured every 
three to four days. Cells were rinsed with 10 mL phosphate-buffered saline (PBS), 
2 ml pre-warmed trypsin-EDTA solution added for 3-4 min, trypsin inhibited by 
addition of 10 ml pre-warmed growth medium and cells collected by 
centrifugation (150g, 5 min, 18 oC). The supernatant was removed and the cell 
pellet re-suspended with 5 ml pre-warmed growth medium. Trypan blue solution 
was prepared (0.25 % trypan blue in PBS) and the cell viability assessed by the 
Trypan blue exclusion method (Strober, 2001). The viable cells were > 98% 
consistently throughout.  Aliquots of HEK-293 cells were prepared for 
cryostorage: 2 million cells in 1 mL of cryopreservative medium containing 60 % 
(v/v) FBS, 30 % complete growth medium and 10% DMSO.  
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4.2.3 Growth curve preparation
            HEK-293 cells (20,000 cells per cm2; 76000 cells per well in 12-well 
plates with 1 ml culture medium) were incubated for up to 4 days. Total cell 
number and viable cell number was counted every day for 4 days and a cell 
growth curve was constructed. 
4.2.4 Characterisation of glyoxalase system and dicarbonyl 
metabolism in HEK-293 cells cultured in vitro. 
           HEK-293 cells were cultured in 25 mM glucose in vitro for three days in 
triplicate. Cell extracts were analysed for the activity of enzymes involved in MG 
metabolism: Glo1, Glo2, MG reductase and MG dehydrogenase. Glo1 mRNA and 
Glo1 protein levels were also quantified. The levels of dicarbonyls and glutathione 
in HEK-293 cells were also determined. The media samples were analysed to 
determine D-lactate, L-lactate and D-glucose levels.   
          A growth curve and the measurement of Glo1 activity, mRNA, protein and 
the metabolic fluxes were also performed for the following experiments:  
 The effect of varying glucose concentration on HEK-293 cell growth  
in vitro.
 The effect of Glo1 overexpression on HEK-293 cell growth under  
      25 mM glucose conditions in vitro
 The effect of incubation with 7 µM Glo1 inhibitor, BBGD (2 x GC50),  
        on HEK-293 cell growth under 25 mM glucose conditions in vitro.  
 The effect of Glo1 silencing on HEK-293 cell growth under  
        25 mM glucose conditions in vitro.
 The effect of hypoxia on HEK-293 cell growth under 25 mM glucose   
        conditions in-vitro.   
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4.2.5 The effect of exogenous methylglyoxal on HEK-293 cell
growth – dose-response study
                Methylglyoxal was synthesised, purified and the concentration of 
aqueous stock solutions calibrated by McLellan and Thornalley (1992a). Sodium 
phosphate buffer (pH 7.4), 1 mM aminoguanidine hydrochloride with and without 
ca. 30 µM of the high purity methylglyoxal at 37 oC for 3 h in triplicate to 
derivatise MG by aminoguanidine to completion – Figure 22. The absorbance was 
recorded at 320 nm (Thornalley et al, 2000). The blank was corrected and the MG 
concentration was deduced in the stock solution.  The molar extinction coefficient 
is 2.41 mM-1cm-1.  
Figure 22: The derivatisation of high purity methylglyoxal solution. 
Aminoguanidine is a carbonyl scavenger and a prototype agent that prevents 
diabetic complications. It is pre-incubated with the physiological α-oxoaldehydes 
such as methylglyoxal to form isomeric 3-amino-1,2,4-triazine derivatives and 
prevent glycation by these agents in vivo and in vitro. The physiological 
conditions for this reaction are pH7.4 and 37oC. The rate kinetics of the reaction of 
aminoguanidine with methylglyoxal were the same with unhydrated and 
monohydrated forms but the concentration of the initial reactant influences the 
ratio of the triazine derivatives (Thornalley et al, 2000).  
               Methylglyoxal was sterile filtered by centrifugation (10,000g, 5 min, 4 
0C) at a concentration of 51.2 mM. HEK 293 cells (20,000 cells per cm2; 76000 
cells per well in 12-well plates with 1 ml culture medium) under high glucose (25 
mM) concentrations in vitro and were incubated overnight to adhere to the plate. 
The following day, 100, 200, 400 µM of methylglyoxal was added with a 1:1 ratio 
with PBS. Each concentration and untreated controls were studied in triplicate. 
The plates were incubated for 48 hours. Cells were gently washed with 1 mL PBS 
then detached by incubation with 250 µL trypsin-EDTA. The cells and the 
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medium containing methylglyoxal were removed from the plate. Cells were 
collected by centrifugation (250 x g, 5 min) and the supernatant medium removed. 
The cells were re-suspended in fresh culture medium and a diluted sample was 
counted using a Neubauer haemocytometer. Each cell suspension was counted 
thrice, the number of viable and non-viable cells per mL deduced.   
        Viable and non-viable cell numbers were recorded to produce an MG 
concentration-response curve. Data were fitted to the dose-response equation 
V=100 × (GC50)n / ((GC50)n + ([MG])n) where V is the viable cell number as a 
percentage of control cultures without the addition of MG, GC50 is the median 
growth inhibitory concentration value, [MG] is the concentration of MG and n is 
the logistic regression coefficient (also known as the Hill coefficient). 
Experimental data of V and [MG] were fitted by non-linear regression of V on 
[MG] using the programme EnzFitter programme (Biosoft, Cambridge, U.K.).   
            A time-course study on the effect of methylglyoxal on HEK-293 cell 
growth was also conducted. HEK-293 cells were cultured at a cell density of 
20,000 cells/cm2 in 12-well plates containing 25 mM glucose media in vitro; there 
were independent triplicates. One plate was for the addition of the GC50 value of 
methylglyoxal, whereas the other plate contained control incubations in triplicate. 
The number of viable and non-viable cells was counted every day for three day. 
4.2.6 Propagation of the glyoxalase 1 transfection vector
             Escherichia coli DH5α cell suspension from cryostorage was thawed 
rapidly and kept on ice. pIRES2-GLO1-EGFP plasmid solution (0.5 – 1 µL; 
286ng DNA per µL) was added and mixed gently with 0.1 mL competent E. coli
in a sterile Eppendorf tube on ice (Jackson et al., 1990; Jang et al., 1990; Cormack 
et al., 1996). A tube containing no DNA was also prepared as a control. The 
solution was incubated on ice 20 min followed by incubation at 42 oC for two min. 
This was subsequently incubated on ice again for 1-2 min. LB medium (1 mL) 
was added. This solution was incubated for 30 - 0 min at 37 oC. Aliquots (10 – 300 
µL) were pipetted onto an agar plate and gently smeared with sterile glass rod. 
Plates were then incubated overnight at 37 oC. 
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4.2.7 Bacterial transformation
            pIRES2-EGFP plasmid (100 ng), GLO1 cDNA (500 ng) and T4 DNA 
ligase (200 U) were incubated at 4 0C in ligation buffer (50 mM Tris-HCl, 10 mM 
MgCl2, 1 mM ATP, 10 mM DTT, pH 7.5) for four days. The products were 
transformed into DH5-α cells competent cells (heat shock method). An aliquot of 
the product (10-300 µL) were added to selective agar plates containing kanamycin 
30 µg mL-1. A few, well-formed, smooth-edged, isolated colonies from each plate 
were used to inoculate growth medium that also contained 30 µg mL-1 kanamycin. 
The restriction enzymes Bgl II and Pst I were used to obtain mini-preps and 
analytical digests by PCR method. These type II restriction endonuclease enzymes 
were chosen as studies have shown that the coding sequence of GLO1 can be 
easily obtained by digesting the vector with both enzymes. Plasmid DNA (1µg) 
and of Bgl II and Pst I (2.5 U) were incubated in 10X NEbuffer (100 mM NaCl, 
50mM Tris-HCl, 10mM MgCl2, 100μg/ml BSA pH 7.9 at 25°C to give a total 
volume of 20 µL. This was followed by incubation at 37oC overnight to yield the 
following fragment sizes: 1662 bp and 3646 bp that were viewed on 1% agarose 
gel to check the identity of the GLO1 gene. The fragment size for GLO1 is 
between 500-600 bp – Figure 23.  
             Mini-preps were used to re-transform competent XL1 B cells and 
midipreps were conducted to purify pIRES2-GLO1-EGFP plasmid containing 
GLO1. The DNA concentration was measured by the NanoDrop 
spectrophotometry for GLO1 plasmid 286.0 ng/µL and empty plasmid 215 ng/µL. 
The correct insertion of the GLO1 cDNA into the Pgem-T Easy was established 
and thus the plasmids were digested with the restriction enzymes.  
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Figure 23: Analytical digests of the GLO1 plasmid and empty plasmid by conventional 1% agarose gel electrophoresis.  
Lane 1: Empty plasmid; lane 2: empty plasmid; lane 4: GLO1 plasmid; GLO1 plasmid; lane 5: GLO1 plasmid; lane 6: GLO1 plasmid; lane 7: 
GLO1 plasmid; Lane 9: marker. The fragment sizes: 1662 bp and 3646 bp to check the identity of GLO1 gene. DNA Ladder utilized was 
GeneRuler 1 kb Plus DNA Ladder 75 – 20,000 bp.   
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4.2.8 Stable transfection of pIRES2-EGFP plasmid into  
        HEK-293 cells 
4.2.8.1 Preparation of transfected cells.
          Transfection was conducted using Lipofectamine 2000 according to the 
manufacturer’s instructions. Cells were seeded in 6-well plate at a density of 
300,000 cells in 2 mL Transfection medium (DMEM, 10% FBS, no antibiotic). 
Lipofectamine 2000 (1 µg µL-1; 2 µL) in a total volume of 100 µL OptiMEM 
serum-free medium was prepared. A separate solution of 1 µg plasmid DNA 
(GLO-1 plasmid 6.99 µl, Empty plasmid 9.30 µL) in 100 µl OptiMEM was also 
prepared. This was followed by incubation at room temperature for 5 min. The 
plasmid DNA solution and the Lipofectamine 2000 solution underwent fusion 
together to give a ratio for DNA: Lipofectamine 2000 as 1:4. This was followed 
by incubation for 20 min to allow transfection complexes to form between the two 
parties. An aliquot (200 µL) of OptiMEM-DNA-Lipofectamine 2000 solution was 
pipetted into each well of the 6 well plate drop-wise. Subsequently, the plate was 
mixed gently to provide a uniformed distribution of the mixture. The transfected 
cells were incubated at the following conditions: 37 oC, 5 % CO2 in air, 100% 
humidity for 24 hours for adherence to occur and increase confluency. Visual 
quantification of EGFP-containing transfected cells was conducted using a 
fluorescence microscope (excitation maximum, 488 nm; emission wavelength, 
507 nm).  
4.2.8.2 Attempts to generate stably transfected cell lines.
          After 48 h, cells were detached by trypsin and split to ~ 20% confluence 
and transfected cells were selected with sterile-filtered aminoglycoside antibiotic 
G-418 disulphate with fluorescence monitoring to detect transfected cells. 
Attempts were made to select transfected cells using the recommended dose 200-
500 µg/ml (405 µg/mg potency) changing the media every two days. However, 
there was interference with non-transfected cells growth despite plasmid contains 
the neomycin gene. This was found even when increasing the concentration of G-
418 to 2000 µg/mL (Sigma-Aldrich 405 µg/mg potency). Other methods to select 
the cell were via serial dilution using a 48 and 96 well plate, selecting colonies via 
the cycle and increasing the potency.   
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          G-418 disulphate from Fischer Scientific (705 µg/mg) was utilized and an 
antibiotic kill curve was constructed varying the concentration from (200 – 2000 
µg/ml) and were monitored daily for a period of 7 days – Figure 24. The purpose 
of the dose-response experiment is to define the minimum concentration of the 
selective antibiotic G-418 that can kill untransfected mammalian cells at a specific 
time to generate stable transfectant cell lines. Each cell line varies in their 
sensitivity to the antibiotic. The recommended doses provided by the supplier, 500 
(µg/mL) failed to work and the optimal dose was gained at 2000 (µg/mL) and 
were used for further experiments.  
            Further studies involved transfected cell colonies selected using a cloning 
disc (3.2 mm) and glass cylinder selector. Transfected cell colonies with uniform 
fluorescence were selected using a cloning glass cylinder (8 mm, 150 µL) and 
cultured further with G-418 disulphate (705 µg/mg; 2 mg/mL) containing 
medium. In subsequent sub-culturing, G-418 concentration was decreased to 1 
mg/mL. Glo1 activity and protein was assessed to determine the fold difference 
between Glo1 and empty stable transfectant cells. Colonies will be selected using 
a cloning disc (3.2 mm) and glass cylinder selector.   
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Figure 24: Microscopic images for the kill curve of G-418 antibiotic tested in HEK-293 cell lines. Qualitative analysis suggests that the 
viability of HEK-293 cells is in dependence of the concentration of the antibiotic monitored daily over the period of 8 days. The images reflect the 
adherent fraction of HEK-293 cells relative to confluency for Day 4, 6 and 8 after adding the G-418 antibiotic. The potency of the G-418 was 705 
µg/mg where it was diluted to the concentration range (200 – 2000 µg/mL) and was compared to control (0 µg/mL). Each group consisted of technical 
replicates for 3 biological replicates. The images were taken using the Nikon microscope (Magnification, 40X).   








4.2.9 Transient transfection of Glo1 siRNA into HEK-293 cells 
              Cells were transfected with 48 nM Accell Human GLO1 SMART siRNA 
pool and 48 nM Accell non-targeting Control siRNA pool (GE Healthcare 
Dharmacon Inc, Little Chalfont, Buckinghamshire, U.K) with Lipofectamine 
RNAiMAX Transfection Reagent (Thermo Fisher Scientific, Paisley, U.K.) based 
on the manufacture’s protocol for reverse transfection reaction. The complexes 
were prepared inside the well after which HEK-293 cells (1 x 105) in 12-well plate 
and 1 mL of DMEM containing high glucose (25 mM), L-glutamine (4 mM) and 
supplemented with 10 % (v/v) FBS, 100 U/ml penicillin/0.1 mg/ml streptomycin. 
Attempts were made to ensure Glo1 siRNA was knocked down by varying the 
concentrations from the recommended concentration (12 nM) given to extremely 
high concentrations (96 nM) to establish the dose that knocked down Glo1. This 
was confirmed by spectrophotometric measurement of Glo1 enzymatic activity, 
mRNA and protein levels to ensure >95% was decreased.  
4.2.10 Anti-cancer drug concentration-response curves
4.2.10.1 Glo1 overexpression studies in vitro
              Stock solutions of anti-cancer drugs were prepared in DMSO (100 mM), 
unless otherwise stated, and were sterile-filtered. Cisplatin stock solution was 
prepared in DMF. HEK 293 cells (20,000 cells per cm2; 76000 cells per well in 
12-well plates with 1 ml culture medium) were incubated overnight to adhere to 
the base of the plate. The following day, the culture medium was removed and 
replaced with medium containing the anti-cancer drug at the required 
concentration. Each concentration and untreated controls were studied in 
triplicate. The plates were incubated for 48 hours. Cells were gently washed with 
1 mL PBS then detached by incubation with 250 µL trypsin-EDTA. The cells and 
the medium containing anti-cancer drug were removed from the plate. Cells were 
collected by centrifugation (250 x g, 5 min) and the supernatant medium removed. 
The cells were re-suspended in fresh culture medium and a diluted sample was 
counted using a haemocytometer. Each cell suspension was counted twice, the 
number of viable and non-viable cells per mL deduced. The viable cell number 
was expressed as a percentage of untreated control. 
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4.2.10.2 Glo1 inhibitor studies in vitro
          The same procedure was conducted as described in Section 4.2.10.1. 
However, the constant GC50 value of Glo1 inhibitor 3.65 µM was added to each 
well containing varying concentrations of the anti-cancer drug. After 48 hours, the 
cell count was conducted via Trypan Blue exclusion assay. 
4.2.10.3 Glo1 silencing studies in vitro
          After 24 hours of transfection, the cells were incubated with and without the 
chemotherapeutic agent and were studied in triplicate. The stock solution of the 
chemotherapeutic agents was 50 mM in DMSO such that the maximum exposure 
to DMSO was 0.2 %. The plates were incubated for further 48 hours with the anti-
cancer drug. Cells were gently washed with 1 mL PBS then detached by 
incubation with 250 µL trypsin-EDTA. The cells and the medium containing anti-
cancer drug were removed from the plate. Cells were collected by centrifugation 
(250 x g, 5 min) and the supernatant medium removed. The cells were re-
suspended in fresh culture medium and a diluted sample was counted using a 
Neubauer haemocytometer. Each cell suspension was counted thrice, the number 
of viable and non-viable cells per mL deduced. The viable cell number was 
expressed as a percentage of untreated control.  
4.2.11 Hypoxia studies in vitro
Untransfected HEK-293 cells were seeded in a humidified atmospheric 
condition of 5% CO2 at 37oC to adhere overnight before being exposed to hypoxic 
conditions for 72h. The cells were then placed in a hypoxia chamber filled with 3% 
oxygen with nitrogen. The procedure corresponded with the manufacturer’s 
instructions (STEMCELL technologies, 2020). Excessive evaporation was prevented 
by placing two Petri dishes (100 mm x 20 mm) containing sterile water (10 – 20 mL) 
to the base of the chamber. A hermetical closure was performed by positioning the 
ring clamp. The gas tank was attached and the chamber was purged. The tank valve 
control was set at 8 – 10 psi clockwise whilst the flow meter was set at 20 L/min to 
remove oxygen for 4 minutes. The gas flow was subsequently turned off and the 
chamber was completely closed via the white clamps. A set of cell culture was 
placed in the conventional incubator as a control    
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 The method carried out to construct a growth curve to determine the 
effect of a hypoxic environment on the proliferation rate of HEK-293 cells and the 
routine procedures to characterise the glyoxalase system and the dicarbonyl 
metabolism that correspond to Section 4.3. The anti-tumour drug that produced 
the most resistance was also experimented to determine their effect under 
normoxic and hypoxic conditions in vitro.
4.3 Analytical methods
4.3.1 Cell lysate preparation
           Cell suspensions were centrifuged (250 x g, 5 min). The pellets (ca. 5 × 106
cells) were re-suspended in 300 µl PBS, pH 7.4, and centrifuged again. This was 
repeated 3 times to remove all extracellular protein. After the third wash, the 
pellets were stored at -80oC until further processing. Cell pellets were 
subsequently diluted in Lysis-M EDTA-free mammalian cell protein extraction 
reagent and the membranes were sedimented by centrifugation (14,000g, 20 min, 
4°C). The supernatant was removed and used as lysate in protein quantification 
and subsequent enzymatic activity assays.   
              Previous attempts have been made to establish the above optimized 
method to extract proteins and ensure a good protein recovery to conduct further 
experiments. For instance, varying the number of cells, sonication method and 
protein assay reagent where the concentration of protein in cells lysates was 
initially measured by Bradford protein assay but it was incompatible with the 
Lysis M buffer as the detergent consists of NP40 and % sodium deoxycholate and 
the Bradford method is compatible up to 0.25% (Bradford, 1976, Compton and 
Jones, 1985). This is the reason why the BCA protein assay was utilized.  
4.3.2 Total protein measurement
              Protein concentration in the cell lysate was determined by the 
bicinchoninic acid assay (BCA) method. 1% (10 mg/ml) of Bovine serum albumin 
(BSA) solution was calibrated by UV absorption spectrophotometry. The molar 
extinction coefficient of BSA is 6.9 cm-1 at 279 nm (Peters, 1962). The assay was 
calibrated (0 - 2000 μg/μl protein) using the bovine serum albumin to be used as 
the standard at an absorbance of 595 nm. The standards, blanks and the samples 
were in triplicate (25 µl per well) with 200 µl of the Working reagent in a 96 well 
164 
clear microplate. The plate was thoroughly mixed on a plate shaker for the 
duration of 30 seconds. This was followed covering the plate and an incubation of 
37°C for 30 minutes. The absorbance was then measured at 595 nm on plate 
reader. The protein concentration of the samples was obtained by the interpolation 
of the calibration curve. An example of a calibration curve is presented in Figure 
25.  
Figure 25: A calibration curve for determining the concentration of total protein 
using BSA as the protein reference standard. The albumin standard was 
formulated at 2 mg/mL in sterile water solution. 6 standards were utilized with 
varying concentrations within the range (0 – 2000 µg/ml). The X-axis is the 
protein concentration and the Y-axis is the absorbance measured at the 
wavelength 595 nm. Linear regression equation: Absorbance (arbitrary units) = 
(0.000800x + 0.275) x BSA standard (µg/ml); R2 = 0.993 (Data are mean ± SD; n 
= 3).  
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4.3.3 Characterisation of MG metabolism in HEK-293 cells.
4.3.3.1 Glo1 Activity
               The activity of Glo1 was determined by measuring the initial rate of 
formation of S-D-lactoylglutathione from the hemithioacetal formed non-
enzymatically from MG and GSH, followed spectrophotometrically at 240nm; 
Δε240 = 2.86 mM-1cm-1 – Figure 26 (Allen, et. al, 1993a).  
              Hemithioacetal was prepared by pre-incubation of MG (2 mM) with GSH 
(2 mM) at 37°C for 10 min in sodium phosphate buffer (500 µl, 100 mM, 37°C 
and pH 6.6). The cell extract (20 μl, prepared by lysing 5 x 106 cells in 100 μl lysis 
buffer and sedimenting cell membranes) was added and absorbance at 240 nm was 
monitored for 5 min. The activity of Glo1 is deduced from the initial increase in 
absorbance, corrected for homogenization buffer blank (Lysate M buffer). Glo1 
activity is given in units per mg protein (the latter determined by BCA assay) 
where one unit of Glo1 activity is the amount of enzyme which catalyses the 
formation of 1 μmol of S-D-lactoylglutathione per minute under assay conditions.  
                     Figure 26: The metabolism of methylglyoxal by Glyoxalase 1  
Glo1 catalyses the isomerization of the spontaneous reaction between the glutahionyl 
group of the tripeptide GSH and the aldehyde of MG to form hemithioacetal adduct: MG-
GSH. 
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4.3.3.2 Glo2 Activity 
               Glo2 activity is determined by measuring the initial rate of hydrolysis of 
S-D-lactoylglutathione to GSH and D-lactate - Figure 27. The reaction is followed 
spectrophotometrically by following the decrease in A240 for which the change in 
molar absorption coefficient is Δε240 = 3.10 mM−1 cm−1 (Clelland and Thornalley, 
1991). S-D-lactoylglutathione (0.3 mM, 100 μl, 4°C) was incubated in Tris-HCl 
buffer (100 mM, 500 µl, pH 7.4, 37°C) and water (37 °C, 380 µl). The cell lysate 
(20 μl, 5 x 106) was added and the absorbance was monitored for the duration of 5 
min at 37°C. Glo2 activity is given in units per mg of protein or per million cells 
where one unit is the amount of enzyme that catalyses the hydrolysis of 1 μmol of 
S-D-lactoylglutathione per min under assay conditions (Allen et al., 1993b). Other 
S-2-hydroxyacyl-glutathione derivatives are hydrolysed to GSH and the aldonic 
acid (Reeves and Thornalley, 1993).  
Figure 27: The hydrolysis of S-D-lactoylglutathione by Glyoxalase 2. 
Glyoxalase II catalyses the terminal step of the glyoxalase system whereby S-D-
lactoylglutathione is hydrolysed to reduced glutathione and the corresponding aldonic 
acid; D-Lactate.
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4.3.3.3 MG reductase activity
              NADPH-dependent aldoketo reductase is determined by measuring the 
initial rate of NADPH oxidation to NADP+ by cell lysates (5 x 106) in the presence 
of MG and NADPH – Figure 28.   This was followed spectrophotometrically at 
340 nm for which the change in extinction coefficient is Δε340 = - 6.20 mM-1cm-1. 
MG (20 mM in water, 50 µl) was incubated with NADPH (1 mM in water, 4°C, 
100 µl) in sodium phosphate buffer (100 mM, 500 µl, pH 7.4, 37°C) and water 
(330 µl, 37oC) for 10 min. Cell lysate or lysate buffer (20 μl) for blank, added to a 
final volume of 1 ml the solution was mixed by inversion and the absorbance at 
340 nm was measured for 5 min where the formation of hydroxyacetone (95%) 
and D-lactaldehyde is formed (Thornalley, 1994).  It is measured in units where 
one unit catalyses the reduction of 1 μmol of MG per min under assay conditions. 
NADPH + H+ + CH3COCHO → NADP+ + CH3COCH2OH + C3H6O2
                            Methylglyoxal                  Hydroxyacetone   lactoyladehyde 
Figure 28: The metabolism of methylglyoxal by MG reductase  
The 43 kDa enzyme has high specificity for methylglyoxal and is dependent upon 
NADPH that acts as an electron donor where it binds to its catalytic triad active site: Tyr-
Lys-Ser to form hydroxyacetone (95%) and lactoyladehyde.  
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4.3.3.4 MG dehydrogenase activity
            NAD+-dependent MG dehydrogenase activity is determined by measuring 
the initial rate of NAD+ reduction to NADH by cell lysates (5 x 106) in the 
presence of MG and NAD+ - Figure 29 (Murata et al. 1975). This was followed 
spectrophotometrically at 340 nm for which the change in extinction coefficient is 
Δε340 = 6.20 mM-1cm-1. MG (20 mM in water, 50 µl) was incubated with NAD+ (1 
mM in water, 4°C, 100 µl) in sodium phosphate buffer (100 mM, 500 µl, pH 7.4, 
37°C) and water (330 µl, 37oC) for 10 min. Cell lysate or lysate buffer (20 μl) for 
blank, added to a final volume of 1 ml the solution was mixed by inversion and 
the absorbance at 340 nm was measured for 5 min. The activity of MG reductase 
is measured in units where one unit catalyses the reduction of 1 μmol of MG per 
minute under assay conditions.   
NAD+ + CH3COCHO → NADH + CH3COCO2-
               Methylglyoxal                    Pyruvate  
Figure 29: The metabolism of methylglyoxal by MG dehydrogenase.  
Methylglyoxal dehydrogenase can detoxify MG into pyruvate which is then 
transferred into the tricarboxylic acid (TCA) via acetyl coA (Mostafa et al. 
2018).   
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4.3.4 Assay of D-lactate 
           D-Lactate can cross plasma membranes by three mechanisms: non-ionic 
passive diffusion, the specific lactate transporter and the inorganic anion exchange 
system. Formation of D-lactate in cultured cells may therefore be measured by 
assaying D-lactate in the culture medium. An end-point enzymatic fluorometric 
assay was used to measure the flux of formation of D-lactate by HEK-293 cells 
(McLellan et al., 1992). This can be determined by measuring the concentration of 
D-lactate in the culture medium at baseline and end of the culture period. An 
aliquot of ice-cold 0.6 M perchloric acid (PCA) (1 m L) was added to the media 
(500 µL) to deproteinise samples. The sample mixture was vortexed and left on 
ice for 10 minutes to enable the protein precipitation. To sediment the precipitate, 
samples were centrifuged (7000 x g, 4 0C, 5 min). An aliquot of the supernatant 
(700 µl) was neutralised to pH 7 by adding potassium bicarbonate (2 M, 200 µl).  
             Samples were vortexed before centrifugation (7000 x g, 4 0C, 10 min) 
again to sediment potassium perchlorate. The samples were saturated in carbon 
dioxide and this was removed by centrifugal evaporator at room temperature 
under reduced pressure (20 mmHg) for the duration of 5 min. An aliquot of 
supernatant or D-Lactate standard solution (100 µl) was added in duplicates to 
each well of a 96-well black microplate containing of glycine hydrazine buffer 
(100 µl, 1.2 M glycine, 0.5 M hydrazine hydrate, 2.5 m M DETAPAC, pH 9.2) 
and NAD+ (4 mM, 25 µl). The reaction was initiated on the addition of D-lactic 
dehydrogenase enzyme (25 µl, 250 units per ml). The microplate was wrapped by 
foil sheet and incubated at 37 0C in the dark for 2 hours. A control was performed 
without the enzyme for each sample and used as a blank. The fluorescence of 
NADH was monitored at excitation 340 and emission 460 nm. The calibration 
standard curve was in the range of 0 - 6 nmol D-lactate/well – Figure 30.  
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Figure 30: Calibration curve for D-lactate assay.  
D-lactate has an anhydrous enzymatic purity of > 90%. It is oxidized 
enzymatically by D-Lactate dehydrogenase to pyruvate generating a fluorescent 
signal at the excitation wavelength 340nm and emission 460 nm in the presence of 
NAD+. The amount of D-Lactate is proportional to the colorimetric product being 
formed. Linear regression equation: Fluorescence (arbitrary units) = (6685 ± 100) 
x D-lactate (nmol) + (3533 ± 217); R2 = 0.994 (n = 21).  
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4.3.5 Assay of L-lactate 
          An aliquot of ice-cold 0.6 M PCA (1 mL) was added to the media (500 µL) 
to deproteinise samples. The mixture was vortexed and left on ice for 10 minutes 
to enable the protein precipitation. To sediment the precipitate, samples were 
centrifuged (7000 x g, 4 0C, 5 min). An aliquot of the supernatant (700 µl) was 
neutralised to pH 7 by adding potassium bicarbonate (2 M, 200 µl). Samples were 
vortexed before centrifugation (7000 x g, 4 0C, 10 min) again to sediment 
potassium perchlorate. An aliquot of L-Lactate standard solution (100 µl) was 
added to each well of a 96-well black microplate containing of glycine hydrazine 
buffer (100 µl, 1.2 M glycine, 0.5 M hydrazine hydrate, 2.5 mM DETAPAC, pH 
9.2) and NAD+ (4 mM, 25 µl). For the supernatants, an aliquot of sample (10 µl) 
was added to each well, followed by an aliquot of deionized water (90 µl), glycine 
hydrazine buffer (100 µl) and NAD+ (25 µL). The media samples were diluted 10-
fold with water to ensure the values will be within the range of the standards. The 
reaction was started on the addition of L-lactic dehydrogenase enzyme (25 µl, 250 
units per ml). The microplate was wrapped by foil sheet and incubated at 37 0C in 
the dark for 2 hours. A control was performed without the enzyme and used as a 
blank. The fluorescence of NADH was monitored at excitation 340 and emission 
460 nm. Calibration standard curve was in the range of 0 -10 nmol L-lactate/well 
and is presented in Figure 31.  
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Figure 31: Calibration curve for the detection of L-lactate.  
L-lactate is oxidized to form the pyruvate intermediate that is detected by a fluorescent 
signal at an excitation wavelength of 340 nm and emission of 460 nm; this is directly 
proportional to amount of lactate. The standard curve was linear from 0 to 10 nmol for L-
lactate with a coefficient of determination of 0.988. Linear regression equation: 
Fluorescence = (3711 ± 88) x L-lactate (nmol) + (2905 ± 500); R2 = 0.998 (n = 21). 
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4.3.6 Assay of Glucose
              The glucose concentration in cultured media samples was detected using 
an end-point enzymatic absorbance assay. Glucose in the samples is converted to 
6-phosphogluconate via glucose-6-phosphate using the catalytic enzymes: 
hexokinase and glucose-6-phosphate dehydrogenase – Figure 32. Equimolar 
amounts of the phosphorylation of glucose are directly proportional to the yield 
and concentration of NADH formed from the reduction of NAD+.   
Figure 32: The detection of glucose via an enzymatic absorbance assay.   
This coupled enzymatic reaction is catalysed by hexokinase and Glucose-6-phosphate 
dehydrogenase. At first, hexokinase catalyses the formation of D-glucose and ATP to 
produce Glucose-6-phosphate which is the initial substrate in a number of metabolic 
reactions: aerobic glycolysis, hexose monophosphate shunt pathway and the biosynthetic 
pathways: starch and glycogen. The concentration of Glucose-6-phosphate may reflection 
pathophysiological mechanisms in diabetes, cancer, oscillations and the depressive status 
of catabolites. Following the phosphorylation reaction, Glucose-6-phosphate is then 
catalysed by Glucose-6-phosphate dehydrogenase in the presence of NAD+ to form 6-
phosphogluconate and this is quantified at 340 nm. During the oxidation reaction, NAD+
is reduced to NADH.   
          The samples were diluted to ensure the measured concentrations were 
within the standard curve range. Samples from low glucose were diluted 5-fold 
whereas samples in high glucose were diluted 20-fold with water. 2% of PCA 
(100 μl) to an aliquot of diluted culture medium (100 μl). The mixture was 
vortexed and left on ice for 10 minutes to enable the protein precipitation. Keep 
on ice for 10 min for the protein precipitate to develop fully. To sediment the 
precipitate, samples were centrifuged (6000 x g, 4 0C, 10 min). An aliquot of the 
supernatant (180 µl) was neutralised to pH 7 by adding potassium bicarbonate (1 
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M, 33 µl) ca. 7 with pH paper. Samples were vortexed before centrifugation (6000 
x g, 4 0C, 10 min) again to sediment potassium perchlorate and remove the 
supernatant. The supernatant is then utilized in the glucose assay.  
           An aliquot of standard or diluted sample (25 μl) was added to each well of 
a microplate then the assay reagent (225 μl) was added. The assay mixture found 
in the commercial kit comprised of 1 mM ATP, 1.5 mM NAD+, 1 unit.ml 
hexokinase (HK) and 1 unit/ml glucose-6-phosphate (G-6-P) dehydrogenase 
(Sigma Aldrich). The plate was incubated at room temperature for 15 minutes for 
the NADH to form in the reaction mixture before the absorbance at 340 nm was 
read using the microplate reader. The standard curve was constructed between 0 – 
1.5 mM D-glucose – Figure 33. The concentration of D-glucose in the sample was 
deduced from the equation of the line whereas the consumption of D-glucose was 
calculated by deducting the experimental measurements at the end of the culture 
period from the baseline media. The results were expressed in µmol/day/106 cells.  
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Figure 33: Calibration curve for the detection of D-glucose via enzymatic 
absorbance assay. The measured absorbance at the wavelength 340 nm after 15 
minutes incubation was plotted against the concentration of glucose (mM). An 
increase in absorbance is positively correlated with the concentration of glucose. 
Linear regression equation: A340 (A.U.) = (0.509 ± 0.007) x D-glucose (mM) + 
(0.2622 ± 0.01); R2 = 0.995 (n = 21).  
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4.3.7 Western blotting
Western blotting is used to detect specific proteins in a sample extract. A 
10% polyacrylamide gel was prepared and removed from the gel cassette from the 
casting stand and placed into the electrode assembly into the clamping frame with 
the shorter plate facing forward. 1-fold dilution of prepared 10 x Electrophoretic 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) was poured into the 
Criterion electrophoresis cell (Bio-Rad Laboratories, 2018). Cytosolic extracts of 
HEK-293 cells (20 µg) were mixed in a one to one ratio with 4 X Laemmli buffer 
and were heated at 100 oC for 5 minutes to hydrolyse proteins and disulphide 
bonds (Laemmli, 1970). Once cooled, the sample mixture was loaded into the well 
and an aliquot of the pre-stained protein Spectra Multicolor Broad Range Protein 
Ladder (10 to 260kDa, 8 µl) was also added to a well to separate the samples by 
SDS-PAGE. The samples were electrophoresed at 120 V for 1 hour – Figure 34. 
Figure 34: SDS-PAGE band profile of Spectra Multi-colour Broad Range Protein 
Ladder (ThermoFisher Scientific, 2020).   
The protein ladder consists of 4 coloured chromophores: pink, blue, orange and green that 
can be bounded to the 10 pre-stained proteins with a molecular mass in the range of 10 to 
260 kDa. This can be added directly for loading samples in gel electrophoresis and 
western blotting. The lot-to-lot variation is approximately 5% and is stored in (62.5 mM 
Tris phosphate at pH 7.5, 25 oC, 2 % (w/v) SDS, 33 % (v/v) glycerol 1 mM EDTA, 1 mM 
NaN3 and 10 mM DTT.  
             The separated proteins were transferred from the gel to PVDF membrane 
by the wet transfer method (Towbin, et al., 1979). A wet transfer was performed 
at high intensity settings, 100 V for 1 hour to allow a limited time for transfer. It 
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involves using a cassette that consists of foam pads, polyacrylamide gel, PVDF 
membrane in the anode site and filter paper as shown in Figure 35 to ensure the 
proteins are transferring in the right manner. The sandwich is then submerged in 
transfer buffer (25 mM Tris, 192 mM Glycine, 10% Methanol (v/v), pH 8.3) 
(Towbin et al., 1979). The formulated buffer increases the buffering capacity, 
protein binding to the PVDF membrane particularly methanol to improve transfer 
efficiency.  
                The transfer membrane was then blocked with 5% (w/v) dried milk 
protein in Tris-buffered saline with Tween-20 (TBS-T buffer; 150 mM NaCl, 10 
mM Tris/HCl pH 7.6 and 0.05% Tween-20). The membrane was then probed 
using anti Glo1 primary antibody produced from rat at an optimized concentration 
of 1 in 5,000 overnight at cold temperature 4oC on a plate shaker at a steady speed 
if one intends to divide the procedure in two days.   
               However, if one has planned to do it in one day, the incubation period of 
the primary antibody is 1 hour on a plate shaker at a steady speed. Following the 
blotting with the primary Glo1 antibody, the membrane was washed three times 
with TBSTA buffer for 10 – 15 minutes. The membrane was then probed with the 
secondary antibody After blotting with the primary antibody, the membrane was 
washed three times with TBS-T buffer for 10 min. The blot was then divided into 
two where the HRP antibody of β-actin (1/8000) was added to the side that 
contains the molecular weight of β-actin. The other half containing the target Glo1 
at a molecular weight of 21 kDa was probed with secondary antibody (anti-rat, 
1/10000) on the plate shaker at a steady speed at room temperature for 1 hour. 
This followed by rinsing the blot several times with TBST. The blot was then 
developed with the ECL reagent. An image of the blot was taken from the 
imaging system for chemiluminescence; GeneGenome XRQ System (Syngene). 
The intensity of the Glo1 protein band was normalised to β-actin which is a 
protein loading control). Membranes were then quantified with ImageJ software 
where Glo1 blotting results were normalised to β-actin (protein loading control).   
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Figure 35: Layout of the western blot transfer setup (Adapted from Leinco 
Technologies, 2018). This step is key in transferring separated proteins from the gel to 
a solide support matrix to enable detection of specified proteins using antibodies. The 
gel is equilibrated in transfer buffer before placing into the sandwich that is pressed 
together in cassette that support the structure. The cassette is place into the tank 
vertically filled with transfer buffer.  
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4.3.8 Real-Time PCR quantitation
          The relative copy number of GLO1 gene mRNA in HEK-293 cells was 
measured by real-time quantitative PCR. The procedure includes the extraction of 
mRNA, purification and reverse transcription to cDNA. The cDNA was quantified 
by measuring SYBR green dye as fluorescence in a PCR reaction. The SYBR 
green dye has high fluorescence when bound to double-stranded DNA and can 
cause intercalation between DNA bases.  
4.3.8.1 Primer design 
The primers and probe for Glo1 and ACTB were pre-designed primers probe 
mixture from Life Technology Ltd (Paisley, Scotland). The gene expression level 
was evaluated using 2(-ddCt) with ACTB as a reference gene for normalization 
for relative expression level. Dissociation plots otherwise known as melt curves 
were constructed for each assay plate to ensure the primers were working 
constantly – Figure 36.   
                     Figure 36: The melt curves for Beta-actin and Glo1. 
(A) Beta-actin and (B) Glo1. The X-axis represents the temperature change whereas the Y 
axis presents the derivative of relative fluorescence divided by the derivative of 




          HEK-293 cells were cultured in 25 mM glucose in vitro (1 x 105) in 12-well 
plate. Cells were transfected with 48 nM Accell Human GLO1 SMART siRNA 
pool or an Accell non-targeting Control siRNA pool (GE Healthcare Dharmacon 
Inc, Little Chalfont, Buckinghamshire, U.K) with Lipofectamine RNAiMAX
Transfection Reagent (Thermo Fisher Scientific, Paisley, U.K.) based on the 
manufacture’s protocol. After 72-hour incubation, the cells were collected and 
RNA extracts of the cells were prepared.  
4.3.8.3 RNA extraction and purification
          The Total RNA of HEK-293 cells (wildtype, GLO1 siRNA and scrambled 
siRNA) were extracted using the Qiagen RNeasy mini kit according to the 
manufacturer’s instructions. HEK-293 cells under normoxic and hypoxic 
conditions were also conducted utilizing the same method as follows using the 
QIAGEN RNeasy mini kit according to the manufacturer’s instructions. The 
samples were lysed by the addition of RLT lysis buffer (350 µL) containing β-
mercaptoethanol and pipetting the suspension around 10 times. There is a high 
concentration of guanidine-thiocyanate present in the lysis buffer that acts as a 
chaotropic agent promoting cell lysis.   
             The lysed samples were then mixed with 70 % (v/v) ethanol to promote 
the binding conditions with RNA to the silica-based spin-column. To efficiently 
remove the impurities and contaminants present in the samples, they were washed 
thrice with multiple buffers: RW1, RPE with centrifugation. The procedure was 
then finalized by the addition of RNAse-free water. The quality and the 
concentration of RNA were measured using the NanoDrop 1000 
spectrophotometer. 2 µL of the RNA sample was utilized and pure RNA were 
expected to give a ratio of 1.9 - 2.1 at A260 and A280. The samples were diluted to 




           Reverse transcriptase reaction was performed in 20 µL total volume with 
100 ng total RNA extracts of HEK-293 (wildtype, Glo1 siRNA and scrambled 
siRNA) using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems™) and run using an Eppendorf Mastercycler gradient. The priming 
pre-mix was prepared in RNase-free reaction tube: a total of 0.1 µg of RNA from 
cells were annealed with 10 µM oligo (dT)18 (1 µL), 10 mM dNTP mix (1 µL) and 
RNase free water (10 µL) at 70oC for 5 min before incubation on ice for 1 min. 
The reaction pre-mix was prepared by the addition of 10U/µL RNase inhibitor (1 
µL), 5 X Bioscript reaction buffer (4 µL) and 200 U/µL Bioscript reverse 
transcriptase (1 µL) in RNAse-free water. 10 µL of the reaction premix was added 
to the priming premix and mixed gently by pipetting. Samples were heated at 42 
0C for 30 min. The reaction was terminated by incubating at 850C for 5 min and 
samples were chilled on ice. The synthesized cDNA was diluted 4-fold and were 
stored at -20 0C and repeated-thawing was avoided before analysis.  
4.3.8.5 Analysis of gene mRNA expression by SYBR green
          The method was utilized to measure the expression of mRNA of GLO1 
gene and normalized to the housekeeping gene; Beta-actin. The synthesized 
cDNA was used to produce the standards and for samples.  
4.3.8.6 Preparation of the standards for PCR
          From each independent replicate (n=3) of HEK-293 cells (wildtype, empty 
vector and GLO1 overexpressed cells), 1 µg was combined together to one 
RNase-free reaction tube as standard curve stock. A 10-fold serial dilution was 
then constructed to custom standards over the range 0 – 1000,000 pg.  
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4.3.8.7 Preparation of the samples 
The reverse transcription product cDNA was diluted 4-fold and were used for 
qRT-PCR to detect the expression level of the target gene; GLO1. In a 20 µL 
reaction volume, (2 µL) was added in a clear MicroAmp Optical 96 well reaction 
plate (Applied Biosystems™) in triplicate. The standards of the serially diluted 
cDNA values were run alongside the samples and were used for quantification 
using the β-actin as a reference gene. SensiMixTM SYBR Low-ROX Mastermix 
(10 µL), primer (0.5 µL) and nuclease free water (7.5 µL) was added to the well. 
The plate was sealed using a MicroAmp Optical adhesive film (Applied 
Biosystems™) and were centrifuged for several seconds. The mRNA expression 
of GLO1 was measured using the SYBR green technique on ABI 7500 real time 
PCR system. The initial reaction was at 95 °C for 10 min to stimulate the hot-start 
DNA polymerase, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The 
standard curve is shown in Figure 37.  
                           Figure 37: The calibration curve of real-time PCR.  
The semi-log regression line point of the x axis that presents the log copies of 
mRNA per ml and the the y axis is the Ct value for each calibration standard. The 
slope (-3.05) is the estimation of the efficiency of the PCR amplification. The 
Linear regression equation: Threshold cycle = (-3.05 ± 34.9) x log input amount 
of mRNA + (34.4 ± 2.4); R2 = 0.994 (n=21).  
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4.3.8.8 Data analysis
          Following the completion of the PCR reaction, the cycle threshold (Ct) data 
was obtained for the control and the samples. Ct is defined as the number in which 
fluorescence crosses the threshold value. Delta Ct (dCt) is the difference between 
the target gene’s Ct (Ct(t)) i.e GLO1 and the Beta-actin control (Ct(t)). The fold 
change was compared between samples and the linear equation in gene expression  
dCt = Ct(t) - Ct(end)  
ddCt = dCt(exp) - dCt(cal)  
Fold change =2(-ddCt)  
4.3.9 Assay of dicarbonyls by stable isotopic dilution analysis 
         LC-MS/MS
          The amount of 3-DG, glyoxal and MG in the culture medium and HEK-293 
cells incubated with and without the anti-cancer drugs were determined by utilizing 
1,2-diaminobenzene for the derivatisation and quantification of the subsequent 
quinoxaline compounds by stable isotopic dilution analysis LC-MS/MS – Figure 
38 (Rabbani and Thornalley, 2014d; McLellan et al., 1993).  
Figure 38: Derivatisation utilized in the dicarbonyl assay.  
1,2-Diaminobenzene reacts with the dicarbonyl, this eliminates water and forms the 
Quinoxaline adduct, 6, 7-dimethoxy-2-methylquinoxaline. The derivatisation involves solid-
phase extraction with HPLC under acidic conditions to prevent the synthesis of MG via triose 
phosphates (Rabbani and Thornalley, 2014d).  
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4.3.9.1 Sample preparation
          Non-transfected HEK-293 cells (ca. 1 x 106 cells) were seeded overnight and 
the following day they were treated for three hours with two-fold the GC50 value of 
the following anti-tumour drugs that had high Glo1-linked MDR from the dose 
response studies: paclitaxel, mechlorethamine, doxorubicin, mitomycin c and 
methotrexate. These were compared with non-transfected cells and two amongst 
the anti-cancer drugs that had low Glo1-linked MDR. The cellular samples were 
washed with PBS at a minimal residue to eradicate any remaining media. They 
were centrifuged  (250 x g, 5 min) to sediment detached cells. The supernatant was 
collected to be used for immediate analysis.  
          The cell pellets were de-proteinised by the addition of trichloroacetic acid 
(TCA)- saline solution (20% TCA, 0.9% sodium chloride (NaCl), 10 µl). The 
samples were vortexed well. An aliquot of water (40 µl) was added followed by 
3% sodium azide in water (5 µl) to inhibit peroxidase activity (Rabbani and 
Thornalley, 2014d). Isotopic standard cocktail (5 µl; 2 pmol stable isotopic 
dicarbonyl) [13C3]MG, [13C2]glyoxal and [13C6]3DG were added to each sample. The 
samples were vortex mixed and centrifuged (6,000 g, 10 min, 4 °C) to sediment 
membranes. The supernatant (45 µl) was removed and added to 10 µl 
derivatisation agent solution (0.5 mM diaminobenzene in 200 mM HCl containing 
0.5 mM DETAPAC). Samples and standards (2 – 20 pmol) were incubated in the 
dark at room temperature for 4 hours in order for the derivatisation to take place so 
the quinoxaline adducts will be analysed by LC-MS/MS and the calibration of the 
analyte/internal standard response ratio can be established. 
4.3.9.2 Preparation of calibration standards
          Calibration standards were prepared and derivatized concurrently containing 
2 pmol isotopic standards at 400 nM [13C3]MG, [13C2]glyoxal and [13C6]3DG and 0 – 
20 pmol methylglyoxal – Tables 6 and 7 (Rabbani and Thornalley, 2014). The 
cocktails of dicarbonyls were at a concentration of 800 nM. The calibration curves 
of the dicarbonyls are presented in Figure 54 where the peak area ratio of the 
analyte/isotopic standard (y-axis) against the analyte concentration (x-axis).  
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Table 4: Calibration standards for dicarbonyls 
There were 6 calibration standards. The stable isotope that comprised of glyoxal, 






 (pmol)  
MG  
(pmol)  
IS (GSS2) Stable 
Isotope substituted G, 
MG and 3DG  
1 1 1 1 2 
2 2 2 2 2 
3 4 4 4 2 
4 6 6 6 2 
5 8 8 8 2 
6 10 10 10 2 
Table 5: Preparation of calibration standards from stock solution 
Standards were treated with ice-cold TCA-saline (10 μl) and were vortexed. An addition of 
water (25.0 - 0 μl), 3% sodium azide (5 μl) was added and the mixture was vortexed. 800 nM 
of MG standard was added 0 – 25.0 μl. A constant amount of the [13C]Dicarbonyls stock (5 
μl) was subsequently added and the solution was mixed. The samples underwent 
centrifugation at 6000g and 4 oC for 10 min. 0.5 mM of DB in HCl-DETAPAC (10 μl) was 






 Water  
(µl)  
3%  Sodium 
azide   
(µl)  
 800 nM MG 
standard 
(µl)  
 400 nM 
IS (µl)  
 0.5 mM 
DB (µl)  
0 10 25.0 5.0 0.0 5.0 10.0
1 10 22.5 5.0 2.5 5.0 10.0
2 10 20.0 5.0 5.0 5.0 10.0
3 10 15.0 5.0 10.0 5.0 10.0
4 10 10.0 5.0 15.0 5.0 10.0
5 10 5.0 5.0 20.0 5.0 10.0
6 10 0.0 5.0 25.0 5.0 10.0
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Figure 39: Standard curve for dicarbonyls.  
The validated method was applied to determine the concentration of methylglyoxal, glyoxal and 3-DG and was established by the calibration solution 
of the derivatives of α -dicarbonyl. There was good linearity over the concentration range (0 – 20 pmol). (A) Methylglyoxal. Regression equation: 
Peak area ratio = ((0.267 ± 0.008) x MG [pmol]) + (1.58 ± 0.09); R² = 0.996 (n = 7). (B) Glyoxal. Regression equation: Peak area ratio = ((0.062 ± 
0.002)x glyoxal [pmol]) + (0.062 ± 0.017); R² = 0.997 (n = 7). (C) 3-DG. Regression equation: Peak area ratio = ((0.169 ± 0.005)x 3-DG [pmol]) + 
(0.052 ± 0.056); R²= 0.996 (n = 7).  
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4.3.9.3 LC-MS/MS conditions
          Liquid chromatography was performed by utilizing a reverse phase 
octadecylsilica (ODS) BEH C18, 1.7 µm particle size column (100 x 2.1 mm) 
fitted with a 5 x 2.1 mm pre-column. The temperature of the column was 30 °C. 
The two solvents utilized in the dicarbonyl assay were: 0.1% TFA in water 
(solvent A) and 0.1% TFA in 50:50 acetonitrile (MeCN) in water (solvent B). The 
gradient used is displayed in Table 6 below. 
Table 6: Chromatographic elution profile in the MG assay. 
There are two mobile phases: 0.1% TFA in water (Solvent A) and 0.1% in 50% 
acetonitrile (Solvent B). The analytical columns need to be conditioned with the mobile 
phase prior to use and equilibrated between each injection to avoid irreproducible 
retention times. Isocratic is when the composition of the mobile phase does not alter and 
remains consistent. 
Method phase 
Time Flow rate Solvent A Solvent B  
Curve (min) (ml/min) (%) (%) 
Analysis 0 0.2 100 0 0 
10 0.2 0 100 Linear 
Column wash 15 0.2 0 100 Isocratic 
Re-equilibration 15 0.2 100 0 Immediate change
30 0.2 100 0 Isocratic 
         The instrument utilized in the analysis was AcquityTM UPLC system with 
eluate directed into the electrospray source of a Quattro Premier XE tandem mass 
spectrometer. The optimised settings were: capillary voltage was 0.6 kV, ion 
source temperature 120 °C, desolvation gas temperature 350 °C, the cone gas flow 
140 l/h and the desolvation gas flows 140 and 900 l/h respectively. Table 7 shows 
the optimised multiple reaction monitoring (MRM) conditions used in mass 
spectrometric detection. 
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Table 7: Optimised MRMs used to detect and monitor dicarbonyls
The internal standards and the analyte adducts were detected by multiple reaction monitoring (MRM) using LC/MS-MS with a Waters Acquity ODS 
column (2 x 100 mm). 













MG 7.8 145.1 77.1 24 24 
[13C3]MG 7.8 148.1 77.1 24 24 
Glyoxal 7.1 131.0 77.1 24 23 
[13C2]Glyoxal 7.1 133.0 77.1 24 23 
3-DG 5.6 235.2 199.0 21 15 
[13C6]3DG 5.6 241.2 205.0 21 15 
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4.3.10. The assay of glutathione metabolites by LC-MS/MS 
The amount of GSH, GSSG and S-D-lactoylglutathione in cultured HEK-293 cells 
for the detection and quantification of GSH, GSSG and S-D-lactoylglutathione, as 
previously described (Xue et al., 2016).
4.3.10.1 Sample preparation 
          HEK-293 cells were cultured in 25 mM glucose and treated with and 
without two-fold the median inhibitory concentration of Mitomycin C and 
Mechlorethamine for 45 min, 1.5 h and 3 h to determine whether there is an 
increase in GSH depletion. After the incubation period, media was removed and 
HEK-293 cells were trypsinised by the routine trypsinisation procedure and were 
counted by Trypan Blue exclusion assay. HEK-293 cells (ca. 0.5 - 1 x 106) were 
sedimented by centrifugation (150 g, 5 min). The medium was removed without 
disturbing the cell pellet and was re-suspended in 40 µl of a precipitating solution 
of 10% TCA, 0.15% NaCl and 0.25% sodium azide in water to facilitate the 
precipitation of proteins and to prevent the enzymatic activities of peroxidases. 
Samples were then centrifuged (20,000 g, 30 min, 4 oC) and aliquots of the 
supernatant (10 µl) was mixed with internal standard/isotopic standard cocktail 
(10 µl), made up to 50 µl by the addition of 0.1% TFA (aq) and were transferred 
to vials and analysed by LC-MS/MS for detection of each analyte. 
          The limit of detection (LoD) was 0.92 pmol, 1.46 pmol and 0.54 pmol for 
GSH, GSSG and S-D-lactoylglutathione respectively.  Analytical recoveries were: 
GSH, 97.1 ± 1.6%; GSSG, 92.7 ± 5.7%; and S-D-lactoylglutathione, 99.3 ± 
14.1%.  Intra-batch coefficient of variation was determined by analysis of 
replicate samples.  Intra-batch coefficient of variation was: GSH, 8.8% for GSH 
(n = 6); and GSSG, 10.9% (n = 6).  
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4.3.10.2 Preparation of standards      
Stable isotopic GSSG was prepared in-house. Stable labelled [glycine-
13C215N1]GSH was oxidised using diamide (Kosower, et al., 1969) as shown in 
Figure 40 to obtain stable labelled [13C415N2]GSSG to be used in the LCMS/MS 
method to quantify cellular GSSG.  An aliquot of [13C215N1]GSH solution (3.2 
mM, 100 µL) and 10 mM diamide in methanol (30 µL) were added to 100 µL of 
10 mM sodium phosphate buffer, pH 7.4 (100 µL) and were incubated at 37°C for 
30 minutes.  The reaction mixture was purified by elution via a 500 mg strong 
anion-exchange solid-phase extraction (SAX SPE) cartridge in the formate form.  
[13C415N2]GSSG was remained on the SAX-SPE cartridge and the cartridge was 
washed with 10 mL water to remove the reduced form of diamide. 
[13C415N2]GSSG was collected by elution with 100 mM formic acid (5 mL) and 
underwent lyophilised to dryness. It was then reconstituted in water (1mL) and 
filtered through a 0.2 µm nylon filter.  The concentration of [13C415N2]GSSG was 
determined by the isotopic dilution analysis of known amounts of GSSG.  The 
synthesis yield was 28%.  
Figure 40: The formation of GSSG from GSH 
Tetramethylazodicarboxamide otherwise known as diamide has two amide groups and 
acts as a thiol-oxidizing agent to oxidize reduced glutathione γ-L-glutamyl-L-cysteinyl-
glycine to disulfide (GSSG) stoichiometrically.
191 
Stock solutions (1 mg/ml) of GSH hydrochloride, GSSG and S-D-
lactoylglutathione were prepared in water and were filtered. Further dilutions of 
these stocks were prepared using 0.1% TFA (solvent A) in water.  Standards were 
prepared as shown in Table 8 and 9. S-D-lactoylglutathione was not routinely 
included in calibration standards since the quantities in test samples were below 
the limit of detection for the assay.  Calibration curves were constructed plotting 
peak area ratio of analyte/isotopic standard against analyte concentration as shown 
in Figure 41.  The amount of GSH, GSSG and SLG was calculated by utilizing 
the peak area ratio, calibration curve, cell count and dilution factors involved.  
Table 8.  Calibration range for glutathione analysis: reduced, oxidized and S-D-
lactoyglutathione. Calibration standards were prepared for sample analysis over the 














0 0 0 0 100 20 
1 200 1 10 100 20 
2 400 2 20 100 20 
3 800 4 40 100 20 
4 1200 6 60 100 20 
5 1600 8 80 100 20 
6 2000 10 100 100 20 
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                      Table 9. Preparation of glutathione standards  
The normal standard solution is GSH (100 µM), SLG (0.5 μM) and 5 μM GSSG 
 (5 μM). 
Calibration 
solution 













0 - 20 20 10
1 2 18 20 10 
2 4 16 20 10 
3 8 12 20 10 
4 12 8 20 10 
5 16 4 20 10 
6 20 - 20 10 
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                                               Figure 41. Typical calibration curves of glutathione by LC-MS/MS.   
They were constructed utilized unlabelled analyte for GSH (0 – 2000 pmol); GSSG (0 – 100 pmol) and S-D-lactoylglutathione (0 – 10 pmol) and a 
constant aliquote of isotopically-labelled internal standard of 10 µL. The linearity of the data and the goodness of fit was established by linear 
regression and the coefficient of determination (R2).  A: Standard curve for GSH.  Regression of Peak area ratio on amount of GSH (pmol) gave: Peak 
area ratio = ((0.0145 ± 0.002) x GSH (pmol)) ± 0.180; r2 = 0.999; n = 7.  B: Standard curve for GSSG.  Regression of Peak area ratio on amount of 
GSSG (pmol) gave: Peak area ratio = (0.1072 ± 0.0027) x GSSG (pmol)) ± 0.124; r2 = 0.998; n = 6.  C: Standard curve for S-D-lactoylglutathione.  
Regression of Peak area ratio on amount of S-D-lactoylglutathione (pmol) gave: Peak area ratio = ((0.1711 ± 0.0032) x S-D-lactoylglutathione (pmol)) 
± 0.167; r2 = 0.998; n = 7.   
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4.3.10.3 LC-MS/MS 
The glutathione assay was conducted using the AcquityTM UPLC-Premier 
XE tandem mass spectrometer system. The capillary voltage was 3.4 kV. The 
source ionisation temperature was 120 
o
C. The desolvation gas flow was 549 l/h 
and cone gas flow was 146 l/h. The optimised MRMs used for glutathione analysis 
and their fragmentation analysis are given in Table 10 and Figure 42. The elution 
profile for glutathione analysis is presented in Table 11.  
















GSH 308.2 179.1 11.7 30 13 
[13C215N1]GSH 311.2 182.1 11.7 30 13 
GSSG 613.2 483.7 14.4 52 18 
[13C415N2]GSSG 619.2 489.7 14.4 52 18 
S-D-
lactoylglutathione 
380.2 76.2 13.1 32 35 
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Figure 42. Fragmentation of glutathione.





Table 11: Gradient used for glutathione assay on LC-MS/MS 
4.3.11 Assay of GSH conjugates of Mechlorethamine 
         This assay was conducted to detect and quantify GSH metabolites and GSH 
conjugates of Mechlorethamine via stable isotopic dilution analysis. The fragmentation of 
GSH conjugates can be divided into: benzylic, disulfide, aromatic, aliphatic and thioester 
where they can be determined by high resolution mass spectrometry with specified 
collision energies (Xie et al. 2013). 
4.3.11.1 Preparation of samples 
           Untreated HEK-293 cell pellets (1 x 106 cells) were resuspended in 40 µl solution 
containing 10% TCA, 0.15% NaCl and 0.25% sodium azide in water.  This solution 
precipitates proteins and acts as a preservative by inhibiting peroxidase activity in the 
sample; residual peroxidase activity otherwise remains in TCA extracts.  Samples were 
centrifuged at 20,000 g for 30 min at 4 °C and aliquots of supernatant (10 µl) transferred 
to vials for LC-MS/MS analysis with the addition of 10 µl isotopic standard cocktail. 













Initial 0.2 100 0 - 
1 0.2 100 0 - Isocratic 
15 0.2 40 60 - Linear 
16 0.2 40 60 - Isocratic 
Post-run 
Initial    0.4 0 - 100 
10 0.4 0 - 100 Isocratic 
25 0.4 100 - 0 Immediate 
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4.3.11.2 Preparation for the Mechlorethamine-GSH adduct 
        0.5 mM Mechlorethamine with 1 mM GSH was incubated in 10 mM 
phosphate buffer, pH 7.4, at 37 oC for 4 hours in a sealed cryovial and is frozen at 
– 20 oC. 
4.3.11.3 Preparation on standards 
         The standards and mass spectrometric conditions utilized in Section 4 for the 
glutathione assay was utilized for this assay. However, there is an addition of 
optimized MRMs for glutathione the GSH conjugates of Mechlorethamine – Table 
12 and 13 respectively. The reactions for the optimized MRMs are illustrated in 
Figure 43. 
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Neutral fragment loss 
GSH Identifier 308.2 84.2 9.74 30 26 Cys-Gly 
Identifier 308.2 162.1 30 17 Glu, NH3
Quantifier 308.2 179.1 30 13 Glu 
[13C215N1]GSH Identifier 311.2 84.2 9.74 30 26 [13C215N1]Cys-Gly 
Identifier 311.2 165.1 30 13 Glu, NH3
Quantifier 311.2 182.1 30 13 Glu 
S-D-lactoylglutathione Identifier 380.2 76.2 10.4 32 35 Glu-S-D-lactoyl-Cys 
Identifier 380.2 148.2 32 22 Glu, Gly, H2CO2
Quantifier 380.2 234.2 32 16 Glu, NH3
GSSG Quantifier 613.2 355.5 10.92 52 25 2 Glu 
Identifier 613.2 483.7 52 18 Glu 
[13C415N2]GSSG Quantifier 619.2 361.5 10.92 52 25 2 Glu 
Identifier 619.2 489.7 52 18 Glu 
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Molecular ion  
(Da) 








Neutral fragment loss 
MEC-GSH-OH Identifier 409.3 84.2 9.28 34 43 MEC-OH-Cys Gly 
Quantifier 409.3 280.3 34 15 Glu 














698.7 84.2 9.50 49 40 
MEC-GSH-Cys-Gly 













         MCE-GSH-OH










  (M+1 = 280.3)
H2N O
Fragment ion 2
(M+1 = 84.2 Da) 
- MCE-OH Cys-Gly,













                     MCE-GSH








     Fragment ion 1
(M+1 = 298.3 & 300.3)
H2N O
Fragment ion 2 
(M+1 = 84.2 Da) 
- MCE Cys-Gly,

































                MCE-GSH2
(Molecular ion M+1 = 698.7)
Fragment ion 1
 (M+1 = 440.4)
H2N O
 Fragment ion 2 
(M+1 = 84.2 Da) 
- MCE GSH-Cys-Gly,
       -H2CO2
Figure 43 Optimised MRMs for Mechlorethamine glutathione conjugate analysis.  
A. Fragmentation of hydrolysed Mechlorethamine-GSH conjugate, MCE-GSH-OH. B. Fragmentation of Mechlorethamine-GSH conjugate, 




4.4 Data analysis  
          For the concentration-response curves of anti-cancer drugs, viable cell 
number (percent of untreated control) V was plotted against drug concentration D 
and fitted by nonlinear regression to the concentration response equation:  V = 
100 x (GC50n)/(GC50n + [D]n) where GC50 is the median growth inhibitor 
concentration of the drug and n the logistic regression. Non-linear regression was 
performed using ENZFITTER programme (Biosoft, Cambridge, U.K.). Mass 
Lynx software was utilized to analyse the data for glutathione, dicarbonyl and 
GSH conjugate assays. The data was parametric and there is a normal distribution 
between the two groups. Thus, significant difference between experimental 
groups was assessed by Student’s t-test to predict the form of variance whether 
equal or unequal variance. Significance was defined as p ≤0.05. Non-parametric 
analysis were utilized for Glo1 mRNA analysis for three groups.  
5.0 RESULTS 
5.1 Characterisation of the glyoxalase system and dicarbonyl 
metabolism in HEK-293 cells in vitro. 
5.1.1 Growth and viability HEK-293 cell growth in medium 
containing 25 mM glucose in vitro. 
            HEK-293 cells were cultured in a serum-supplemented basal medium, 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10 % (v/v) FBS and 
25 mM glucose, under aseptic conditions in vitro. From the growth curve, HEK-
293 cells were in exponential growth up to day 3 of culture and thereafter the rate 
of cell growth decreased – Figure 44. After 4 days, the cell number had increased 
to ca.1.61 x 106 cells per well. In subsequent experiments, HEK-293 cells were 
sub-cultured and incubated three days in 25 mM glucose conditions in vitro. The 
mean population doubling time was 0.715 ± 0.08 days (n = 3). This suggests that 
it has a high proliferation rate which is a characteristic of tumours. The 
micrographic images are shown in Figure 45. 
202 
Figure 44: Growth curve of HEK 293 cells in 25 mM glucose in vitro.  
HEK-293 cells (20,000 cells/cm2) were incubated in DMEM media with 10% FBS and 25 mM 
glucose concentrations in 12-well plates that have a diameter of 3.8 cm. This was at 37oC, 5% 
CO2 atmospheric conditions. The viable and non-viable cell number were counted using 
Trypan blue exclusion method every 24 h to construct the growth curve. Data are mean ± SD 
(n = 3). The log proliferation phase was between 1 – 3 days with a maximal cell number at day 
4 of ca.1.61 x 106 cells per well. 
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Figure 45: Micrographic images of HEK-293 cells during growth in DMEM medium with 10% FBS. 
HEK-293 cells (20,000 cells/cm2) grown in DMEM medium with 10% FBS at 37oC, 5% CO2 atmospheric conditions. Images were taken every 24 
h at 20X magnification and presented the epithelial morphology of HEK-293 cells and how their viable cell number and proliferation rate 
increased over the period of 4 days.  
Day 4Day 1 Day 2 Day 3Day 0
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5.1.2 Activity of Glo1, Glo2, MG reductase and MG 
dehydrogenase in HEK-293 cells in 25 mM glucose in vitro. 
               The activity of Glo1, Glo2, MG reductase and MG dehydrogenase was 
measured in HEK-293 cell extracts incubated in 25 mM glucose using the 
protocols described in Section 4.3.3 and the results are presented in Table 14. The 
enzymatic activity of Glo1 and Glo2 is 3639 ± 21 and 32.0 ± 0.6 mU/mg protein 
respectively. The MG reductase activity is 1.84 ± 0.10 mU/mg protein and the 
levels of MG dehydrogenase were undetectable. This reflects the minor role of 
MG reductase and MG dehydrogenase in the metabolism of MG in HEK-293 cells 
and emphasises that the major metabolic pathway of MG metabolism is by Glo1 
of the glyoxalase pathway. 
Table 14: Activity of enzymes of methylglyoxal metabolism in HEK-293 cells in 
vitro. The data presented is the mean ± SD (n = 3). L.O.D, limit of detection. 
Glo1 activity (mU/mg protein) 3639 ± 21 
Glo2 activity (mU/mg protein) 32.0 ± 0.6 
MG reductase activity (mU/mg protein) 1.84 ± 0.10 
MG Dehydrogenase (mU/mg protein) <LOD (0.6) 
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5.1.3 Glyoxalase 1 protein and mRNA contents of HEK-293 cells 
incubated in high glucose concentration in vitro 
The level of the Glo1 protein and mRNA in HEK-293 cells cultured in 25 mM 
glucose in vitro for three days was determined by Western blotting and real-time 
PCR respectively to provide a molecular and cellular characterization of Glo1 – 
Figure 46. The Glo1 protein level in HEK-293 cells is 0.683 ± 0.141 whereas the 
relative GLO1 mRNA expression is 0.904 ± 0.008 normalized to β-actin.  
Figure 46: A representation of the relative levels of Glyoxalase 1 protein and 
mRNA in HEK-293 cells plated at 2 x 104 cells/mL incubated in high glucose (25 
mM) conditions for three days in vitro.  
(A) HEK-293 whole cell lysates (20 μg) were analysed by Western blot to detect Glo1 
protein using the anti-Glo1 antibody. The Glo1 was detected to be ~ 23 kDa and was 
stripped and re-probed with the antibody against anti-Beta-actin. Beta-actin was detected 
to be ~ 43 kDa and was used as a loading control due to its abundance in cells to normalize 
the relative expression of the protein of interest: Glo1 and ensure the blot is working 
within detection range to avoid signal saturation and variation. The western blot is 
representative of three independent replicates Data are mean ± SD (n = 3). (B) Glo1 
mRNA expression by real-time PCR in HEK-293 cells normalized to Beta-actin. Data are 
mean ± SD (n = 3). 
A B 
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5.1.4 The level of dicarbonyl metabolites in HEK-293 cells   
         incubated in high glucose concentration in vitro 
5.1.4.1 The flux of net L-lactate and D-lactate formation in  
             HEK-293  cells in vitro
          The flux of D-Lactate formation and the net of L-Lactate formation was 
determined over three days incubation of HEK-293 cells cultured in high glucose 
(25 mM) conditions in vitro. The media samples were collected on baseline and 
Day 3 where the flux of D-lactate was calculated by deducting the increase of D-
lactate at Day 3 from baseline, normalized to cell number and the number of days 
of incubation. Thus, it was presented as D-Lactate formation as nmol per million 
cells per day as shown in Table 15. The net L-lactate formation was determined 
similar to that of D-Lactate formation; however, it was presented as µmol per 
million cells per day. HEK-293 cells exhibit characteristics of various tumours 
where there is high flux of MG formation and elevated Glo1 activity – conditions 
that are susceptible to toxicity of Glo1 inhibitors (Distler and Palmer, 2012). D-
Lactate is a surrogate measure of flux of MG formation and is progressively 
metabolised by HEK-293 cells. 
Table 15: Values of the flux of net L-lactate and D-lactate formation in HEK-293 
cells incubated in media containing 25 mM glucose in vitro. Data are mean ± SD 
(n = 3). 
Mean metabolic flux 25 mM glucose  
Net L-lactate formation (µmol/day/106 cells) 6.72 ± 0.24 
D-Lactate formation (nmol/day/106 cells) 118 ± 10 
207 
5.1.4.2 The metabolism of D-lactate in HEK-293 cells in vitro 
          The rate of metabolism of D-lactate by HEK-293 cells was determined by 
measuring the amount of D-Lactate in the culture medium of HEK-293 cells with 
and without the addition of exogenous D-lactate (10 µM) at baseline and after 
incubation for 2 days. This is presented in Table 16. The incremental increase in 
the rate of D-lactate metabolism on addition of 10 µM D-lactate was 22.7 
nmol/day/106 cells. The concentration of D-lactate in control cultures at baseline 
is ca. 1 µM, originating from fetal calf serum in the medium. Assuming the rate of 
D-lactate metabolism is directly proportional to D-lactate concentration, this 
suggests that the rate of D-lactate metabolism in control cultures is ca. 2.3 
nmol/million cells/day or 2.5% of the observed rate of D-lactate increase in 
control cultures. This indicates that the observed rate of  increase in amount of D-
lactate in HEK293 cultures is approximately equal to the rate of D-lactate 
formation and hence flux of methylglyoxal formation.  
Table 16: D-lactate formation in HEK-293 cells with and without the addition of 
exogenous D-lactate (10 µM) incubated in media containing 25 mM glucose for 
48 hours in vitro. Data are mean ± SD (n = 3). 
Culture conditions Rate of increase in D-Lactate formation 
(nmol/day/106 cells) 
Control 89.6 ± 8.3 
+ Exogenous D-Lactate (10 µM)  112.3 ± 2.9 (P<0.05) 
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5.1.4.3 The flux of glucose consumption in HEK-293 cells in vitro
         The amount of net glucose consumption by HEK-293 cells can be 
determined by measuring the culture medium containing 25 mM glucose at 
baseline and after 3 days – Table 17. This increases the rate of glycolysis and 
cell survival. 
Table 17: The net glucose consumption by HEK-293 cells incubated in media 
containing high glucose conditions for 3 days in vitro. Data are mean ± SD (n = 
3). 
                                               HEK-293 cells in vitro
Glucose consumption  
(µmol/day/106 cells) 
        45.2 ± 6.0 
5.1.4.4 The concentration of methylglyoxal in HEK-293 cells in vitro 
            The cellular concentration of the main dicarbonyl of MG in HEK-293 
cells following three days cultured in medium containing 25 mM glucose in vitro
was assessed – Figure 47. The concentration was 4.34 ± 1.47 pmol/106 cells and 
the high level suggests that HEK-293 cells have increased dicarbonyl stress 
under high glucose conditions to increase protein glycation.  
Figure 47: The methylglyoxal concentration in HEK-293 cells in medium 
containing 25 mM glucose in vitro. HEK-293 cells were cultured in DMEM 
medium containing 25 mM glucose for three days. Data are mean ± SD, (n = 3). 
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5.1.4.5 The levels of glutathione in HEK-293 cells in vitro 
          The cellular contents of GSH, GSSG and S-D-lactoylglutathione in HEK-
293 cells (1 x 106) following three days culture supplemented with high glucose 
concentrations in vitro – Table 18. To calculate the levels of total glutathione it is: 
Total GSH = GSH + (2 x GSSG).  
Table 18 The levels of glutathione in HEK-293 cells in vitro. 
HEK-293 cells were cultured in medium containing 25 mM glucose for three days 
in vitro to determine the levels of glutathione to three independent replicates. Data 
are mean ± SD, (n = 3). 
                                                            HEK-293 cells in vitro
 GSH (nmol/106 cells) 4.40 ± 0.28 
GSSG (nmol/106 cells) 0.00706 ± 0.00428 
Total GSH (nmol/106 cells) 4.41 ± 0.28 
GSH (% Total GSH)  99.9  
GSSG (% Total GSH)   0.122  
Cellular S-D-lactoylglutathione (pmol/106 cells)  < 1.5 (L.O.D) 
210 
5.2 The effect of glucose concentration on HEK293 cells  
      in vitro
         The concentration of glucose was measured to determine its effect on the 
HEK-293 cell growth on the glyoxalase system and dicarbonyl metabolism. The 
hormetic potential of methylglyoxal and its role in causing dicarbonyl stress can 
then be deduced. The standard protocol for culture of HEK-293 cells used herein 
has initial glucose concentration of 25 mM. This was compared to incubation with 
a low glucose concentration of 5 mM under aseptic conditions in vitro.  
    5.2.1 Characterisation of the glyoxalase system of HEK-293  
             cells incubated in high and low glucose concentration  
             conditions in vitro
5.2.1.1 Assessment of HEK-293 cell growth in medium containing   
            5 mM and 25 mM glucose in vitro.
           HEK-293 cells were cultured with cell density of 20,000 cells per cm², 
76,000 cells per well, using a 12 well plate for 4 days. The growth and cell 
viability of HEK 293 cells was determined via Trypan blue exclusion assay where 
> 99% in the three independent replicates were viable. From the growth curve, the 
growth of HEK-293 was exponential to day 3 of culture and thereafter the rate of 
cell growth decreased.  After 4 days, the cell number had increased to ca. 1.61 x 
106 cells per well in 25 mM glucose and 0.82 x 106 cells per well in 5 mM glucose 
in vitro. 25 mM glucose was used in MDR studies (supplier recommended 
conditions) – Figure 48. This is ca. 49.0 % decrease in cell growth and suggests 
that high glucose concentration is a growth advantage for HEK-293 cells and low 
glucose (5 mM glucose) can decrease cell survival and is reflected on the viable 
cell number of HEK-293 cells at the stationary phase.
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Figure 48: Growth curve of HEK 293 cells in 5 mM and 25 mM glucose for 4 
days in vitro.  
HEK-293 cells (20,000 cells/cm2) were incubated in DMEM media with 10% FBS and 5 
mM 25 mM glucose concentrations indicated for 4 days. Data are mean ± SD (n = 3). 
Key: low glucose   ; high glucose  
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5.2.1.2 The activity of glyoxalase 1 of HEK-293 cells in low and high 
glucose conditions in vitro
          The enzymatic activity of Glo1 in HEK-293 cells incubated with low D-
glucose (5 mM) and high D-glucose (25 mM) conditions for three days was 3350 
± 317 and 2951 ± 106 mU per mg protein respectively. This is ca. 11.9% decrease 
and reflects the metabolic role of high glucose concentration and the increased 
formation of methylglyoxal as a driver of dicarbonyl stress – Figure 49. An 
increase in the Glo1 activity is required to protect the proteome of tumours against 
the high flux of MG formation. 
Figure 49: The effect of glucose concentration on the Glo1 activity in HEK-293 
cells in vitro.  
HEK-293 cells were cultured in medium containing low glucose concentration (5 mM) 
and high glucose concentration (25 mM) for 3 days. Data are mean ± SD (n = 3). Key: 
low glucose (5mM) ; high glucose (25 mM)  
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5.2.1.3 Flux of glucose consumption, net L-lactate and D-lactate 
formation in HEK-293 cells cultured in low and high glucose conditions 
in vitro.
   Tumour cells require high glycolytic rate and convert most of glucose to 
lactate in order to grow and proliferate even other oxygenated states; this is 
known as the Warburg effect (Vander Heiden et al., 2009; Vander Heiden, 2011). 
Therefore, following the Glo1 activity measurement, the effect of glucose 
concentration on D-Lactate, L-lactate and D-glucose was determined to 
characterise the energetic metabolism in HEK-293 cells incubated with 5 mM and 
25 mM glucose concentrations for three days.  
            The flux of D-lactate formation was determined in media samples at 
baseline and after three days and the flux of D-Lactate formation deduced. The 
flux of D-Lactate formation in HEK-293 cells under low D-glucose concentration 
conditions was 510 ± 51 nmol/day/106 cells whereas under high D-glucose 
concentration conditions it was 305 ± 18 nmol/day/106 cells. This is ca. 40.2 % 
decrease in D-lactate production in high glucose conditions in comparison to low 
glucose conditions (p < 0.01) in vitro - Table 19. 
            Similarly, there was a significant difference in the net formation of L-
lactate in HEK-293 cells where under low glucose conditions, the concentration of 
L-lactate was (70.6 ± 7.5 µmol/day/106 cells) (p < 0.0001) in vitro whereas under 
high glucose conditions it was (4.82 ± 0.21 µmol/day/106), this is ca. -93.2% 
increase in L-lactate formation. The flux of L-Lactate formation was markedly 
higher regardless of the glucose concentration than the flux of D-Lactate 
formation. This highlights the concentration of both physiological enantiomers of 
lactate in HEK-293 cells. 
            Moreover, there was -41.8 % increase in glucose consumption in HEK-
293 cells cultured under low glucose concentration (48.8 ± 3.8 µmol/day/106 
cells) in comparison to high glucose (28.4 ± 6.1 µmol/day/106 cells) (p <0.01). 
This suggests that HEK-293 cells have higher glucose consumption via anaerobic 
glycolysis that inhibits pyruvate from entering Krebs cycle and increases the 
conversion of pyruvate to lactate. Increased anaerobic glycolysis also increases 
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the flux of formation of triose phosphates, DHAP and G3P which in turn increases 
the flux of MG formation.  
               To investigate whether the flux of glucotriose degradation to 
methylglyoxal has occurred in high glucose conditions in vitro, the percentage of 
flux of glucotriose was calculated by dividing the flux of D-Lactate formation of 
HEK-293 cells by twice the flux of glucose consumption (Hooper et al., 1988). 
This was followed by multiplying the value by 100 to establish the percentage of 
flux of glucotriose. There was 5.35% increase in the percentage of flux of 
glucotriose in HEK-293 cells under low glucose conditions 0.523 ± 0.021 in 
comparison to high glucose conditions (0.551 ± 0.096) in vitro. This indicates that 
glucose has been consumed in the Embden-Meyerhof pathway primarily than 
other pathway mechanisms such as pentose phosphate pathway in high glucose 
conditions in vitro.  
Table 19: The varied analytical assays determining the metabolic fluxes of HEK-
293 cells under high and low glucose conditions in vitro.  
HEK-293 cells were cultured in medium containing low glucose concentration (5 mM) 
and high glucose concentration (25 mM) for 3 days. Data are mean ± S.D. for 
independent samples (n = 3). Significance **, p < 0.01, **** p ≤ 0.0001  (t test, two-
tailed, equal variance) with respect to low glucose (control).  
                                               HEK-293 cells in vitro 
Metabolic variable 5 mM glucose  25 mM glucose  
Net L-lactate formation 
(µmol/day/106 cells) 
70.6 ± 7.5 4.82 ± 0.21 **** 
D-Lactate formation 
(nmol/day/106 cells) 
510 ± 51 305 ± 18.5     ** 
D-glucose consumption 
(µmol/day/106 cells) 
48.8 ± 3.8 28.4 ± 6.1      ** 
D-Lactate flux 
(% Glucotriose) 
0.523 ± 0.021 0.551 ± 0.096 ** 
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5.2.2 The effect of exogenous methylglyoxal on the growth and 
viability of HEK-293 cells in vitro
To characterize the response of HEK-293 cells to dicarbonyl stress, HEK-
293 cells was treated for 48 h with increasing concentration of exogenous 
methylglyoxal to evaluate its effect on cell viability and growth. Concentration-
cell growth response curves were constructed from 6 different drug concentrations 
(100 – 2000 µM) and data fitted to deduce 50% of maximal inhibitory 
concentration (GC50) and logistic regression coefficient (n). Low concentrations 
of methylglyoxal were insufficient to induce a response. At ≥ 100 μM of 
methylglyoxal there was a decrease in viable cell number in HEK-293 cells in 
vitro. As the concentration of exogenous methylglyoxal increases, cell growth 
arrest increases - Figure 50. The dose of methylglyoxal (X-axis) and drug 
response (Y-axis) was plotted on a logarithmic scale. The resulting methylglyoxal 
concentration-response curve is inverse sigmoidal. The GC50 value for 
methylglyoxal is 887 ± 40 µM and the logistic regression coefficient was 0.565 ± 
0.024. 
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Figure 50: Methylglyoxal concentration-response curve for HEK-293 cell growth 
incubated under high glucose (25 mM) conditions in vitro.  
Data are mean ± SEM, n = 3 for Methylglyoxal concentrations 100, 150, 200, 500, 750 
and 1000 and 2000 μM. Repeated measurements were conducted to establish the 
pharmacological profile of methylglyoxal. MG concentration-viable cell number (% of 
control) were fitted to the dose-response equation = 100 × 8870.565/(8870.565 + 
[Methylglyoxal]0.565). GC50 (887 ± 40 μM) and the logistic regression coefficient (0.565 ± 
0.024; n = 21) 
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5.2.2.1 The effect of 887 µM methylglyoxal on the growth of HEK-293   
cells in DMEM medium containing 25 mM glucose   
             concentration  in vitro
          To study time course of effect of MG on HEK-293 cell growth, a growth 
curve of HEK-293 cells was constructed form incubations with and without 887 
µM methylglyoxal under high glucose conditions – Figure 51. For the control, the 
growth of HEK-293 cells was exponential to Day 3 of culture. After 3 days, the 
cell number had increased to ca. 0.982 x 106 cells per well. The addition of 887 
µM methylglyoxal decreased cell growth of HEK-293 cells in vitro and after 3 
days, the cell number had decreased to ca. 0.536 x 106 cells per well. This is ca.
45% decrease which validates the GC50 value obtained from the dose-response 
study. Paradoxically, this illustrates how highly proliferating cells such as HEK-
293 cells under high glucose conditions presents a resistant phenotype towards 
treatment with exogenous methylglyoxal and may reflect the level of Glo1 
activity and accumulation of MG-derived protein adducts. 
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Figure 51: Time-course study of the effect of 887 µM methylglyoxal on the 
growth of HEK-293 cells under high glucose conditions (25 mM) for three days in 
vitro. Data are mean ± SD (n = 3). Key: Untreated (control);  887 µM 
methylglyoxal 
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5.3 Stable transfection of HEK-293 cells for overexpression 
of glyoxalase 1 
5.3.1 Comparative analysis of transfected versus non-transfected 
HEK-293 cells on Glo1 activity.
HEK-293 cells were transfected with vector expressing human Glo1 (pIRES2-
GLO1-EGFP) using Lipofectamine 2000 in OptiMEM media. Empty plasmid 
(pIRES2-EGFP) was used as control. Transfected cells were selected with G-418 
disulphate; transfected cell colonies were selected using cloning glass cylinder 
and cultured further with 2 mg/ml G-418 disulphate in high glucose (25 mM) 
conditions in vitro. The efficiency of the transfection was assessed by visual 
quantification of EGFP-expressing cells using fluorescence microscopy 
(excitation maximum, 488 nm; emission wavelength, 507 nm). This is followed 
by the measurement of Glo1 activity by spectrophotometry and Glo1 protein by 
western blotting using cytosolic cell extracts. Cell lysates (5 x 106) of cells 
transfected with pIRES2-GLO1-EGFP plasmid, pIRES2-EGFP plasmid and wild 
type cells were analysed for Glo1 activity and protein levels. GLO1-
overexpressed transfectant cell line had 4 – 5-fold (>90%) increased Glo1 
activity, with respect to empty vector stable transfectant control over the ten 
passages studied – Figure 52. 
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Figure 52: Glyoxalase 1 enzymatic activity of stable transfectant HEK293-
derived cell lines for overexpression of Glo1 and empty vector control in vitro.
HEK-293 cells were cultured in medium containing high glucose (25 mM) 
conditions in vitro for 3 days. Data are mean ± SD (n = 3). Significance testing for 
paired data were assessed by two-tailed Student t-test for two study groups with 
equal variance (homoscedastic): Glo1 overexpression with respect to empty 
vector control ***, P<0.001. Key: wild-type      ; Glo1-overexpressed     ; Empty 







5.3.2 Glyoxalase 1 protein content of stable transfectant HEK293-
derived cell lines for overexpression of Glo1 and empty vector 
control incubated in high glucose (25 mM) conditions in vitro
          The level of the Glo1 protein of HEK-293 cells of wild-type and HEK-293 
cells transfected with vector expressing human Glo1 (pIRES2-GLO1-EGFP) and 
empty plasmid (pIRES2-EGFP) cultured in medium containing 25 mM glucose in 
vitro was determined by Western blotting. GLO1-overexpressed transfectant cell 
line had 4 – 5 fold (>90%) increased Glo1 protein, with respect to empty vector 
stable transfectant control over the ten passages studied – Figure 53.   
Figure 53: Glyoxalase 1 protein content of wild-type and stable transfectant 
HEK293-derived cell lines in vitro. HEK-293 cells were cultured in medium 
containing 25 mM glucose in vitro for 3 days. (A) Glo1 protein blot, (B) Glo1 protein 
blot quantitative analysis. Each lane contained 20 µg protein. Beta-actin 1:8000 dilution 
and the anti-rat Glo1 antibody was used at a 1:10000 dilution. The mean values are 
plotted and the error bars represent the standard of the mean. Data are mean ± SD of three 
independent experiments (n = 3). Statistical significance was determined by two-tailed 
Student’s t-test for Glo1 overexpression: ***, P<0.001 with respect to empty vector 
control. Key: W, wild-type     ; G, Glo1-overexpressed pIRES2-GLO1-EGFP)    ; E, 








5.3.3 Assessment of HEK-293 cell growth in wildtype and stable 
transfectant HEK-293-derived cell lines in vitro.
           HEK-293 cells were cultured with cell density of 20,000 cells per cm², 
76,000 cells per well, using a 12 well plate in medium containing 25 mM glucose 
in vitro. From the growth curve, HEK-293 wild type cells were exponential to day 
3 of culture and thereafter the rate of cell growth decreased.  pIRES2-GLO1-
EGFP and pIRES2-EGFP stable transfectant cells lines had slightly lower cell 
growth rate than untransfected control – Figure 54. After 4 days, the cell number 
for wild type, pIRES2-GLO1-EGFP and pIRES2-EGFP had increased to ca.1.5, 
0.977 and 0.868 x 106 cells per well respectively. The micrographic images of the 
three forms of cell lines subjected to fluorescence microscopy are shown in Figure 
55. There is green fluorescence in the Glo1 overexpressed and Empty vector 
stable transfected cells whereas no GFP protein is indicated in the wild-type HEK-
293 cells. The morphology of HEK-293 cells has altered from an epithelial-like 
phenotype in wild-type cells to round cell phenotype in Glo1 overexpressed HEK-
293 cell. The cellular defect is due to the toxicity following the introduction of 
highly efficient plasmid DNA in which the target protein, Glo1 is overexpressed 
under a cytomegalovirus promoter despite a concentration of 1 µg of DNA was 
used (Mori et al., 2020).  
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Figure 54: Growth curve of stable transfectant HEK293-derived cell lines for 
overexpression of Glo1 and empty vector control under high glucose conditions in 
vitro. Data are mean ± SD (n = 3). There was an effect of genotype x time (P = 
0.007; ANOVA repeated measures).Key: wild-type  ; Glo1-overexpressed 
pIRES2-GLO1-EGFP) ; Empty vector (pIRES2-EGFP)       
Figure 55: Micrographic images of HEK-293 cells during growth in DMEM medium 
with 10% FBS under 25 mM glucose conditions in vitro: wild-type, GLO1 
overexpressing pIRES2-GLO1-EGFP and empty plasmid pIRES2-EGF utilizing 
phase-contrast bright field and fluorescence microscopy. A 20x objective lens was 
used and the total magnification was 400x.  
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5.3.4 The flux of metabolites in wild-type and stable transfectant 
HEK293-derived cell lines in vitro
       The flux of glucose consumption and flux of D-lactate formation was 
measured in HEK-293 cells: wild type and stable transfectant Glo1 
overexpressing pIRES2-GLO1-EGFP cells and empty vector control pIRES2-
EGFP cells – Table 20. Glucose consumption was decreased 27% in pIRES2-
GLO1-EGFP cells and unchanged in pIRES2-EGFP cells, with respect to wild 
type control. Glucose consumption was decreased in pIRES2-GLO1-EGFP cells 
by 28%, compared to pIRES2-EGFP cells.  
        The formation of D-lactate was decreased 58% and 37% in pIRES2-
GLO1-EGFP and pIRES2-EGFP cells, respectively, with respect to wild type 
control. The formation of D-lactate was decreased in pIRES2-GLO1-EGFP cells 
by 33%, compared to pIRES2-EGFP cells. The formation of D-lactate expressed 
as a percentage of glucose metabolism is a measure of percentage of glucose 
metabolism forming methylglyoxal. This was decreased 41% and 38% in 
pIRES2-GLO1-EGFP and pIRES2-EGFP cells, respectively, with respect to wild 
type control but unchanged in pIRES2-GLO1-EGFP cells with respective to 
pIRES2-EGFP cells. This suggests that the Glo1 overexpressing transfection cells 
line has decreased glucose consumption and proportionate decreased flux of MG 
formation, compared to empty vector transfectant control. Stable transfection 
tended to decrease the proportion of glucose leading to MG formation in both 
stable transfectants with and without Glo1 overexpression.   
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Table 20: Glucose consumption and formation of D-lactate by wild type and stable transfectant HEK293-derived cell lines cultured in 
medium containing 25 mM glucose for three days in vitro.  
Metabolic variable Wild-type Glo1-overexpressed 
(pIRES2-GLO1-EGFP) 
Empty vector (pIRES2-EGFP) 
D-Glucose consumption 
(µmol/day/million cells) 
39.4 ± 1.2 28.6 ± 1.3 ***,ooo 40 ± 1 
Flux of formation of D-
lactate (nmol/106/day) 
89.7 ± 12.3 38.1 ± 4.6 **,o 56.6 ± 10.2 * 
Flux of formation of D-
lactate (% glucotriose) 
0.114 ± 0.017 0.067 ± 0.007 * 0.071 ± 0.009 * 
Data are mean ± SD, n = 3. Significance *, ** and ***, P<0.05, P<0.01 and ***, P< 0.001 with respect to wild-type control; o and ooo, 
P<0.05 and P<0.001 with respect to empty vector transfectant control. 
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5.4 Effect of anti-cancer drugs on HEK-293 cell growth
5.4.1 Dose-response for the effect of anticancer drugs on HEK-293 
cell growth in vitro.
         Wild-type, empty vector (empty) and Glo1 overexpressing (Glo1+) stable 
transfectant lines of HEK-293 cells were incubated with and without anti-tumour 
drugs for 48 h with six different drug concentrations. Viable and non-viable cell 
number was assessed by Trypan blue exclusion assay. Data was fitted in 
concentration-response curves to deduce GC50 and n values – Figure 56 for 
topoisomerase inhibitors, 57 for alkylating agents and 58 for other anti-tumour 
drugs and the experimental anti-tumour drug cell-permeable Glo1 inhibitor. The 
GC50 values for the anti-cancer drugs are given in Table 21. The anti-cancer drugs 
that had most resistance was Doxorubicin, Mechlorethamine, mitomycin c, 
paclitaxel and methotrexate. Cisplatin is attracted to cells overexpressed with 
pIRES2-EGFP-GLOI plasmid. Vincristine, Camptothecin and Glo1 inhibitor had 
the least resistance.  
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Table 21: Effect of anti-cancer drugs on the growth of HEK-293 cells (Wild-type, 












2.42 ± 0.36 1.90 ± 0.11 12.70 ± 0.90 7 
Mitomycin C 
(nM) 
158 ± 54 174 ± 29 2541 ± 360 15 
Cisplatin (µM) 4.17 ± 0.18 3.17 ± 0.35 0.73 ± 0.05 0.2 
Methotrexate 
(nM) 
3.83 ± 0.36 4.02 ± 0.35 28.5 ± 0.9 7 
Camptothecin 
(nM) 
18.5 ± 0.6 21.8 ± 2.2 37.6 ± 3.3 2 
Doxorubicin 
(nM) 
2.99 ± 0.34 3.54 ± 0.28 55.9 ± 3.4 16 
Etoposide (nM) 161 ± 11 500 ± 32 1170 ± 169 2 
Taxol (nM) 10.5 ± 1.2 6.8 ± 1.0 56.4 ± 7.2 8 
Vincristine (nM) 35.2 ± 1.5 63.4 ± 5.2 83.7 ± 3.3 1.3 
Glo1 inhibitor 
BBGD (µM) 
3.68 ± 0.20 4.78 ± 0.18 7.37 ± 0.30           1.54 
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Figure 56: Inhibition of growth of wildtype and stable transfectant HEK-293 cell lines by topoisomerase inhibitors.
 A. Doxorubicin B. Etoposide C. Camptothecin.  Data were fitted to dose response equation and were solved for GC50 and n by non-linear regression 




Figure 57: Inhibition of growth of wildtype and stable transfectant HEK-293 cell lines by the alkylating agents. A. Mechlorethamine B. 
Cisplatin. C. Mitomycin C Data were fitted to dose response equation and were solved for GC50 and n by non-linear regression (n = 18) which relates 
to 6 concentrations in triplicates. Wildtype,  ,empty vector      , Glo1 overexpressed  
A. B. C. 
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Figure 58: Inhibition of growth of wildtype and stable transfectant HEK-293 cell lines by 
other anti-tumour drugs. A.Glo1 inhibitor. B. Paclitaxel C. Vincristine. D. Methotrexate 
Data were fitted to dose response equation and were solved for GC50 and n by non-linear 
regression (n = 18) which relates to 6 concentrations in triplicates. Wildtype,     ,empty vector     
, Glo1 overexpressed  
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5.4.2 Time-course studies on HEK-293 cells incubated with the 
anti-cancer drugs that caused high Glo1-MDR.
          To investigate the time dependence of the growth inhibitory effects of anti-
cancer drugs on HEK-293 cells, time course studies were conducted on wild-type 
HEK-293 cells in vitro incubated with and without mechlorethamine, mitomycin 
C, methotrexate and paclitaxel at the GC50 concentration where as Doxorubicin 
was conducted at two-fold the GC50 – Figure 59. There was minimal cell death 
after 24 h in drug-treated cells whereas on the second day of incubation there was 
ca. 55% decrease cell death and was significantly decreased on the third day of 
incubation ca. 67% decrease in most cases. HEK-293 cells treated with 
Methotrexate and Mitomycin C had ca. 38% decrease in the third day of 
incubation. This correlates with the micrographic images in Figure 60 where it 
presents the time course of changes in cell morphology and growth of HEK-293 
cells with and without 5.98 nM Doxorubicin. The drug-treated cells had a round 
cell phenotype whereas the control maintained its epithelial-like phenotype. This 
suggests how the anti-tumour drugs that mediated MDR can decrease cell 
proliferation and induce changes to the morphology of HEK-293 cells. 
